Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations
Spring 1-2017

An Ethical Framework for Global Governance for Health Research
Kiarash Aramesh

Follow this and additional works at: https://dsc.duq.edu/etd

Recommended Citation
Aramesh, K. (2017). An Ethical Framework for Global Governance for Health Research (Doctoral
dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/121

This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne
Scholarship Collection.

Duquesne University

Duquesne Scholarship Collection
Electronic Theses and Dissertations

Spring 1-2017

An Ethical Framework for Global Governance for
Health Research
Kiarash Aramesh

Follow this and additional works at: https://dsc.duq.edu/etd
Recommended Citation
Aramesh, K. (2017). An Ethical Framework for Global Governance for Health Research (Doctoral dissertation, Duquesne
University). Retrieved from https://dsc.duq.edu/etd/121

This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection.

AN ETHICAL FRAMEWORK FOR GLOBAL GOVERNANCE FOR HEALTH
RESEARCH

A Dissertation
Submitted to the McAnulty College and Graduate School of Liberal Arts

Duquesne University

In partial fulfillment of the requirements for
the degree of Doctor of Philosophy

By
Kiarash Aramesh

May 2017

Copyright by
Kiarash Aramesh

2017

AN ETHICAL FRAMEWORK FOR GLOBAL GOVERNANCE FOR HEALTH
RESEARCH

By
Kiarash Aramesh
Approved April 15, 2017

________________________
Henk ten Have, MD, PhD
Director, Center for Healthcare Ethics
Professor of Healthcare Ethics
(Dissertation Director)

________________________
Gerard Magill, PhD
Vernon F. Gallagher Chair for
Integration of Science, Theology,
Philosophy and Law
Professor of Healthcare Ethics
(Committee Member)

________________________
Joris Gielen, PhD
McAnulty College and Graduate
School of Liberal Arts
Assistant Professor of Healthcare Ethics
(Committee Member)

_____________________
Henk ten Have, MD, PhD
Director, Center for Healthcare Ethics
Professor of Healthcare Ethics
( Center Director)

________________________

James Swindal, PhD
Dean, McAnulty College and
Graduate School of Liberal Arts
(Dean)

iii

ABSTRACT

AN ETHICAL FRAMEWORK FOR GLOBAL GOVERNANCE FOR HEALTH
RESEARCH

By
Kiarash Aramesh
May 2017

Dissertation supervised by Professor Henk ten Have, MD, PhD
Global Governance is the way by which various affairs of human social life at the
global scale are governed in the absence of a global governance. This field is composed
of complex networks of role players. Global Health Governance is a branch of Global
Governance that governs the health-related affairs. An important branch of this huge
complex of networks that has not been analyzed sufficiently in the scholarly literature yet
is Global Governance for Health Research. Global health research, although it is a part of
global health affairs, has its own features and conditions that bring about its specific
issues and challenges at the global scale. Therefore, Global Governance for Health
Research, although is generally a part of Global Health Governance, has major
differences (along with similarities and overlaps) with it in different aspect, including the
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major role-players, ethical authorities and institutions, and the main issues and
challenges.
This dissertation classifies the major role players of Global Governance for Health
Research into the state and non-state role players. The major state role-players of Global
Health Governance are intergovernmental organizations such as the World Health
Organization (WHO), the World Bank, and UNESCO. The non-state organizations
include the World Medical Association (WMA) and numerous other civil society and
philanthropic organizations and corporations. The WHO and the World Bank, although
important in the realm of global research, have not been the most influential role-payers
in Global Governance for Health Research. Since the Global Governance for Health
Research has mainly been materialized through internationally recognized frameworks
and guidelines, the organizations that created, adopted, and promulgated these
instruments have been the most influential role-players in the realm of Global
Governance for Health Research, among them being the UNESCO, WMA, and CIOMS.
Global Governance for Health Research has its own challenges that are discussed in
chapter 3 and studied through cases in chapter 4 of this dissertation. Challenges such as
exploitation and helicopter research, double standards, bilateralism, the impact of biopolitics, ethical imperialism and colonialism, and the problem of data sharing and big
data. The framework of gaps is also relevant to this field and the knowledge, normative,
policy, institutional, and compliance gaps show themselves in Global Governance for
Health Research. The cases discussed in this dissertation include the Zika Pandemic, the
Research integrity in Iran, HIV/AIDS Research in Africa, Sending Biological Specimens
Abroad (the problem of Bio-piracy), Research on Pre-Implantation Human Embryo, and
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Local and International Alternative Medicines. Each of these cases portrays a specific set
of challenges and gaps in the current situation of Global Governance for Health Research.
In addition, it has been shown that most of the challenges in this area are of ethical
nature. Therefore, there is a need to a systematic and comprehensive ethical framework in
this arena.
This dissertation suggests an ethical framework for Global Governance for Health
Research that is composed of three main elements. A virtue-based element/layer that
encompasses three moral virtues of empathy, compassion, and care. These virtues are the
most basic moral attributes of physicians/health researchers and underlie their ethical
behavior and their compliance to the principles. A two-layered principle-based element
that encompasses a layer of fundamental principles, i.e. Human Dignity, Human Rights,
and Non-Exploitation and a layer of more specific or practical principles that mostly
adopted from the UNESCO Declaration of Bioethics and Human Rights to have a
comprehensive and universal approach and from the NIH framework to have a researchoriented systematic approach. And the last element of the suggested framework is
inspired by particularism or situation ethics that demands establishing, empowering, and
strengthening networks of oversight and review committees/boards to guarantee the
continual and comprehensive case-by-case ethical review and oversight and monitoring
all over the gigantic networks involved in global health research enterprise.
Despite the existing challenging trends such as neoliberalism, isolationism, and
protectionism in the Western countries and fundamentalism in some developing countries
it seems that the suggested framework can be helpful in shedding ethical light on the
challenges of Global Governance for Health Research and in filling its various gaps. This
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study is a small step in filling the knowledge gap. The suggested framework can fill part
of the normative gap, this framework can be an ethical basis for policies that may fill the
policy gap, the situation-ethics element of the framework is concerning the necessity and
the ethical way for filling the institutional gap and finally, removing or alleviating the
moral barriers is one of the ways for filling the compliance gap. Filling these gaps is not a
one-time mission, instead, the process of developing and filling these gaps is continuous
and will continue as long as the Global Governance for Health research is a reality on the
global scene. In the final part of this dissertation, a number of practical and research
recommendations and suggestions are provided.
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Chapter One - Definition, Conceptual Analysis, and History
The first step for understanding and analyzing the situation, challenges, and ethical
aspects of global governance for health research is understanding its key related concepts.
These concepts are involved in shaping the main conceptual frameworks within them all
the discussions and arguments develop and proceed. Therefore, in this beginning chapter
of this dissertation, providing a comprehensive conceptual analysis of the involved key
concepts seems to be not only helpful but necessary. Having a clarified set of concepts at
the beginning of a theoretical endeavor helps the participants to grasp a more vivid
understanding of the content and the flow of arguments and prevents the unnecessary
ambiguities and misunderstandings that are just the results of uncertainty and
disagreement on the exact meaning of the concepts.
The main concepts that are described in this chapter include Governance, Global
Governance, Global Health Governance, and Global Governance of Research. These
main concepts are used in shaping the theoretical frameworks of the discussions and
arguments throughout this dissertation. Many other concepts are used in other parts of
this dissertation, such as research integrity, civil society, evidence-based medicine, etc.
each of them defined in the respective parts. On the other hand, there are other concepts
that are very important and crucial, but are not defined here or anywhere else in this
dissertation just because their definitions are considered consensual and a part of
common knowledge. These “common knowledge” terms and concepts include (but are
not limited to) research, biomedicine, health, government, state, organization, politics,
society, etc. Therefore, just four above-mentioned main and essential concepts are
defined and discussed in this chapter and neither described within the next parts of this
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dissertation, nor are obvious, consensual, well-defined, and self-evident (or so are
considered here).
In addition to the conceptual analysis, a brief history of the theoretical development
of each one of the above-mentioned concepts has been provided under each respective
title, along with a conceptual definition. As well, in the last part of this chapter, a brief
history of the international/global research enterprise and its main developments and
historical milestones is depicted. A specific part, research integrity, has been explored in
more details because it provides a more explicit example and has also been separately
discussed in the next parts of this dissertation (in chapter three as a case study).
This historical perspective is needed for acquiring a better comprehension of the
nature and importance of the existing challenges and their ethical nature, dimensions, and
possible solutions. Exploring the historical perspectives is an integral part of any
theoretical work (at least in the field of health humanities) since the best way for finding
a comprehensive and realistic picture of the conceptual challenges is looking at them in
the mirror of their emergence, developments, variations, and transformations through the
courses of their histories.
i. Governance
Governance, in its traditional sense, can be simply defined as “the process of
governing.” It is important, however, to notice that this term not only refers to the process
of governing by governments but also to the process of governance in the absence of a
specific government. The latter denotes the more dynamic, sophisticated, and sometimes
subtle processes of governing by various interacting role players in the social/collective
human life. Therefore, governance can be defined as the sum of a wide variety of means
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and processes used by various individuals and institutions to manage their various affairs
in the collective human life.1
Before proceeding in defining governance, four different notions need to be defined
in more details: institution, organization, state, and nation. Although the terms institution
and organization and the terms nation and state can be (and frequently have been) used
interchangeably, as in some instances in this dissertation they are so, in a closer look they
have different extent of meanings and connotations:
(1) Institutions are “social conventions” or “rules of the game”, therefore, marriage,
market, church, and democracy are examples of institutions. (2) Organizations, however,
are “material entities” having physical locations (or seats), and other organs such as
office, employees, equipment, and budget.” Therefore, entities such as the World Health
Organization and National Institutes of Health are among the examples of organizations
(although in the name of National Institutes of Health one can readily see the
interchangeability of institution and organization). (3) states are “governmental-territorial
entities”. A governmental-territorial entity means a specific territory defined and
confined by its borders that is formally under sovereign governance of a government.
This definition is equal to the formal definition of nation-state (this is the reason behind
this fact that the terms nation and state are commonly being used interchangeably). The
examples of states are clear and abundant: The United States of America, the United
Kingdom, Russia, China, Iran, and other members of the United Nations are among the
states. (4) Nations, however, can be defined as “communities with share identities”, or in
other words, “groups of persons professing solidarity based on and around of their
respective unifying items, such as language, religion, ethnicity, history, or other bonding
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elements.”2 Although nations and states usually coincide, they are not identical. There are
nations such as Kurds or Palestinians who are not represented by a single state, and there
are states, such as Switzerland and former Yugoslavia, that contain (or contained)
different nations. In addition, some nations are (or have been) divided between separate
states, such as former East and West Germany, South and North Korea, and South and
North Sudan.3
The role players in governance include (but are not limited to) corporations,
organizations, professions, religious bodies, media, pressure groups, lobbyists, coalitions,
civil society actors, activists, and other formal and non-formal role players. In this sense,
governance encompasses all the processes of social organization and social coordination.
This function is provided not only by governments (or intergovernmental institutions
such as organizations, coalitions, treaties, etc.), but also by other social institutions and
civil arrangements that work in the forms of markets or networks. Therefore, in one
sense, the forms of governance can be broadly categorized into hierarchies (including
states), markets, and networks, the last one being the most sophisticated form that shapes
the main platform of global governance.4
Governance, in various forms, exists in different fields of collective human life,
including organizations, activities, and outcomes; and in any level of it, including family,
team, tribe, community, nation-state, and globe. Therefore, there are countless types of
governance mentioned and described in the literature, for example, public governance,
organizational governance, corporate governance, global governance, non-profit
governance, project governance, environmental governance, health governance, and
information technology governance.5
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The origin of the word governance is the Greek word κυβερνάω (kubernáo) that
means to steer. Governance with the meaning of the process of governing has been used
in different English texts such as the book titled The Governance of England by Charles
Plummer that was published in 1885. The meaning of governance had always been linked
with the functions of governments until the last decades of the twentieth century. In those
decades, a conceptual shift occurred and this world became a fashionable term in the
academic and political discourse that equated almost solely with the concept of
governance without a government or beyond single government(s).6 In other words, the
term, governance, with its current definition has become popular and viral in political,
social, economic, and ethical discourses and in the academic literature, since not sooner
than the early 1990s (see below).
The newly-emerging ubiquity of the term of governance in the scholarly and
political literature is an obvious phenomenon at the beginning of the twenty first century.
This ubiquity is especially noticeable in the field of global affairs. Two main trends have
led to this abundant reliance on the concept of governance (governing without a
government) for describing and understanding the current state of global affair:
First, the ever-increasing complexity of human collective life and emergence of
new patterns of social interactions and social life that had brought up new challenges and
problems (e.g. global warming, pandemics, cybersecurity) that cannot be solved or
managed within the borders of single sovereign states. In other words, in the absence of a
single government or a single hierarchical order in the global scene, a system of
governance without government is (or in some cases should be) in place to deal with such
supranational and transnational challenges and issues.
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Second, the emergence of numerous non-state and non-governmental and nonintergovernmental role-players on the scene has changed the scene of global affairs from
the one once dominated by Intergovernmental Organizations to the current one that is
mostly governed by other role payers, such as non-governmental organizations,
transnational enterprises, and civil society organizations (see chapter 2).7 In other words,
in the absence of a single global government, the sophisticated and intertwined network
of various role players are in charge of managing different transnational and global
affairs. This system is best described by “governing without a government” or
governance.
The concept of governance, in general, had almost always been accompanied by
questions about the criteria of good governance, or on the other words, this very question
that what makes a form of governance a good one. Historically speaking, however, a
newly-emerged emphasis on the concept of good governance and its theoretical and
practical components, have arisen over the last decades of the twentieth century through
the processes originated in the World Bank and International Monetary Fund. They
developed criteria for good governance to guide the process of financial support for
developing countries.
Mark Bevir in his book titled Governance: A Very Short Introduction, holds that
governance plans deal with issues of efficiency, development, capacity, accountability,
and legitimacy. They try to combine practical effectiveness with ethical values. This
obviously shows that the adjective good is a strongly value-ridden one. The values
overarching these plans have been mainly inspired by liberal democratic theories, that
means that they aimed to develop representative, accountable, transparent, responsible,
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and at the same time, stable and sustainable forms of governance,8 although they have
also been accused of imposing the Western liberal values (or neoliberal values) to other
countries and lack of respect for cultural diversity and sovereignty of the low and middle
income societies and countries. Later in this dissertation these accusations are described
and explored in more details.
The collapse of the Soviet Union and many other dictatorships in the developing
countries in the final years of 1980s and over the 1990s, led to the appearance of
numerous new democracies on the global sense with a common feature that was their
desperate need for financial support for reconstructing their infrastructures and for
developing modern political, social, and economical systems. This need resulted an
upsurge of new demands for financial support from international organizations such as
the World Bank and the International Monetary Fund. These financial organizations, in
turn, needed to make sure that their financial support would produce their
desired/anticipated developments and changes in the recipient countries.
The need to ensure the efficiency of their lending activities (compatible with their
accounts of development), led the international funding bodies to create a set of criteria
for good governance as the prerequisites of their financial support.9 They clearly
understood that without a desired governance in place, all the financial supports would
vanish very fast in a web of corrupted politicians and swamp of ineffective systems.
Therefore, these intergovernmental financial institutions began to put an emphasis on
exploring the pitfalls and strengthening the institution of governance in the receiving
countries. For example, a report published by the world bank in 1989, titled Sub-Saharan
Africa: From Crisis to Sustainable Growth, argued that the “crisis of governance” is a
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major obstacle for development of African countries. Consequently, the World Bank
started to add the term “good governance” to its technical vocabulary dealing with
technical issues and civil society and aiming to improve the functions of governance in
the receiving low and middle income countries.10
As mentioned above, the criteria set by intergovernmental organizations for good
governance - because of their inevitable value-ridden nature - have raised concerns on
and accusations of imposing liberal or neoliberal ideas and ideals to the developing
countries.11 Although in the historical experience, setting neoliberal prerequisites and
requirements for financial support has failed in producing sustainable development in the
developing countries, this question on what entails a good governance still exists. In the
following chapters of this dissertation, the role of bioethics in dealing with this quest is
discussed.
Because of the bioethical nature of many of the supranational and transnational
problems and their trajectories, trends, implications, and solutions, especially in the
global health sector (including health-related research enterprise), bioethics is of a special
relevance to global governance.12 In this sense, two topics of “governance through
bioethics” and “governance of bioethics” can be separately discussed. The former topic
covers the discussions about the role of bioethics in global governance for health and the
latter one covers the governance of theoretical developments of bioethics itself on the
global scene.13
As a matter of fact, the current state of global health and global bioethics, and their
theoretical and practical specifics, developments, and challenges, cannot be
comprehensively understood and analyzed without taking the concept of global
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governance into serious theoretical consideration. On the other hand, global bioethics is
the field or platform in which an ethical framework for setting global criteria for good
governance is to be sought.
ii. Global governance
Global governance can be defined as the way in which different role-players in the
regional or global spheres exert different sorts of power to manage various affairs at the
international level.14 In is also defined as:
“…the sum of the informal and formal values, norms, procedures, and institutions
that help all actors – states, intergovernmental organizations […], civil society,
transnational corporations […], and individuals – to identify, understand, and address
trans-boundary problems.15”
This is obvious that power-relation is a central concept in global governance.16 In
other words, one can say that global governance, as a concept and as a subject of study,
provides the overall picture of a sophisticated network of different kinds of power
relations that play role in creating or managing supranational and transnational affairs in
the contemporary globalized world.
In a historic perspective, the concept of global governance had two predecessors:
(1) international relations and (2) the world order. A theoretical and historical
review of these two preceding concepts can shed light on the current standing and
characteristics of the concept of global governance.
1- International Relations: Collaboration among nation-states in the modern world
has been the subject of international relations studies. The broad range of the forms with
which the relations among nation-states are being materialized (intergovernmental
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organizations, bilateral or multilateral coalitions and treaties, international soft or hard
laws, etc.) has been the subject of this interdisciplinary field of study. The key point has
been (1) the centrality of sovereign nation states as the supreme role players on the global
scene and (2) dealing with supranational issues (such as global trade, pandemics, war and
peace, environmental issues, and humanitarian aids or interventions) through the
international organizations, treaties, coalitions, or other kinds of collaboration between
nation states.17
2- The World Order: After the end of the cold war, in many of the scholarly works
on global affairs, the concept of international relations was replaced by the concept of
world order.18 The central element of this notion has been the centrality of a hierarchical
order of power and affluence on the global scene that defines the role and influence of
each role player, at the top being the United States and Western industrialized
democracies. The theories that relied on this concept tried to provide a realistic portray of
the realities of the way global affairs were being approached and managed. The concept
of world order, however, was criticized as being top-down and static. Therefore, the
concept of world order was soon substituted by the more dynamic and describing concept
of global governance.19
The above concepts were gradually replaced by the concept of global governance
through the last decade of the twentieth century and the first decade of the twenty first
century. The reasons behind the emergence of the concept of global governance were as
follow:
1- The ever-increasing occurrence of some problems with a global nature that
could not be solved without a globally coordinated operation. For example, the
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phenomenon of climate change is not limited to any geographic area or national borders
and cannot be dealt with effectively in the absence of globally coordinated action plans.
As another instance, pandemics and outbreaks, such as the recent outburst of Ebola virus
disease in West Africa, demand highly coordinated global reactions. The local
governments usually are not able to implement effective measures in a timely manner.
International organizations and foreign aid providers need to be coordinated to act
effectively and with abidance to a well-planed road map. Coordinating all these resources
and reactions is done through global governance.20
2- The above-mentioned increasing appearance of global problems has been
coupled with the exponential increase of non-state role players who are influential in
dealing with such problems, in some times, even more than intergovernmental
organizations who are formally considered in charge of them. In other words, the
emergence of non-governmental role-players and their influential input in governing
global affairs, in addition to the relative shortcoming and stumbling of formal
international organizations in the same areas(see below), led to the emergence of a new
understanding of the way by which the global affairs are being governed(Also see above,
under the topic of governance).21
3- The state role players started to act beyond of and apart from the previously
established intergovernmental organizations. Instead of originating their actions through
the programs formulated and conducted within the established intergovernmental
organizations, they started to launch unilateral or bilateral programs acting in parallel
with the intergovernmental organizations. The health sector, especially in the cases of

11

pandemics such as HIV/AIDS, is a well-discussed example of such an increased
emergence of bilateralism instead of multilateral organizations.22
4- At the same time, at least in some serious world problems, such as the recent
Ebola outbreak, the formal intergovernmental organizations proved weak and lagged
behind the other role-players.23 The important role of non-state actors (and the stateoriginated interventions beyond the intergovernmental organizations) in managing such
crises showed that instead of intergovernmental (international) organizations, there is a
sophisticated form of global governance in place, with various actors and numerous ways
of action, that shapes the global approach to such crises and global emergencies.24
In sum, through the past decades, as a result of (1) the fundamental changes in the
composition of global role-players in addition of (2) the drastic changes in the nature and
extend of global issues, and (3) the need for developing and adopting a concept without a
top-down and unwanted hierarchical nature in the related scholarly and political
discourse, the concepts of “international relations” and “world order” have gradually
been replaced by the concept of “global governance”.25 This new concept achieved
acceptance and ubiquity in the relevant literature very fast, in a way that nowadays seems
to be an essential conceptual tool for understanding, describing, analyzing, and discussion
the issues, problems, and phenomena that have transnational, supranational, or crossnational nature or element(s).
As mentioned above, in the emergence of the concept of global governance and
replacing the previously ruling concepts such as international relations and world order,
the health sector and the health-related issues have not been the exceptions. The
transnational and supranational nature, extend, and solutions of many of health issues
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(e.g. pandemics, health implications of global trends such as climate change, global
collaborations in the areas of healthcare and health research, etc.) in addition to the
development of unilateral and bilateral health-related programs beyond the
intergovernmental organizations, and the abundance of newly-emerged non-state role
players on the global scene has led to the appearance and prominence of the notion of
global health governance (also called global governance for health) that is discussed in
the following part of this chapter.
iii. Global health governance
The newly shaped conceptual and practical profile of global governance is
impeccably mirrored and exemplified in global health governance. As historically and
theoretically depicted above, global governance entails collective efforts of various rolepayers and has been practiced in numerous ways.26 The health sector has never been an
exception. The same scene of numerous role players and numerous ways of role playing
exist in the health sector. These role players and their actions along with the existing
problems and challenges, take shape to what we know as the global health governance or
global governance for health.
The various means and models of realization of global health governance in the
contemporary globalized world include (but are not limited to): Promulgating health or
healthcare ethics-related international instruments, including binding and non-binding
guidelines, decelerations, resolutions, rules, and regulations; forming bilateral or
multilateral coalitions and collaborations on heath affairs; establishing and running
international health-related organizations, including regional and global ones; funding
health-related program in other countries; conducting international biomedical research;
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and providing healthcare or emergency interventions in crises in other
countries/regions.27
Each of the main categories of actors in global health governance (states, IOs and
NGOs) encompasses a various array of role players.28 Sometimes, an international
organization, officially takes the leading role in one of the global affairs, for example, the
WHO is the organization in charge of global health issues.29 Such international
organizations, including the WHO, work based on consensus among almost all the
member states. Although managing everything according to broad consensus seems to be
the most democratic way of managing global affairs, there are some instances where
more powerful or wealthy members of such international organizations decide to play
unilateral roles.30
When a nation state decides to play a role beyond its borders and intervene in the
international sphere, that nation state is playing a role in global governance. For instance,
launching health related initiatives and programs in other countries for fighting outbreaks
or preventing diseases in an international level is part of global health governance.31
These efforts raise the problem of bilateralism that sometimes is considered as a threat to
multilateral global health governance.
Many countries, mostly in the developing world, cannot afford the healthcare
needed by their people. In the case of disasters, like outbreaks, famine, or drought, this
gap becomes wider.32 These countries usually depend on international sources, like the
helps provided by wealthier countries to provide even basic healthcare for their people.
According to the WHO’s estimate, 23 countries of the world receive more than 30
percent of their health budgets from sources outside their borders.33 This monetary aid
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usually comes with price tags, least of them is the power bestowed to the wealthier
countries to govern health affairs in developing help-receiving countries. Having
financial leverage, either in international organizations or in bilateral relations with other
countries, makes it possible for richer and more powerful countries to play their own role
in global health governance.34
Historically speaking, the international coalitions for global health governance,
however, are dated back to the 19th century. The pandemics and epidemics of various
infectious diseases, like cholera, yellow fever, smallpox, and typhus, parallel with
revolutionary scientific discoveries like the germ theory of disease, ended up to some
international meetings aimed to establish international institutions and guidelines for
preventing the spread of such diseases35.
The first international conference on health was held in Paris in 1851, with
participation of 12 European countries. Establishing uniform procedures and regulations
for quarantine and founding an international sanitary board to oversee maritime activities
were the main subjects of discussions. Although historical in being the first international
meeting on health, this conference ended up as a failure in the terms of application,
international cooperation, and implementation. Although the conference produced a
convention with 11 articles and 137 regulations covering major disease with adverse
influence on trade, such as cholera, plague, and yellow fever, only three governments
eventually ratified the convention, two of them, later retracted their ratification. 36
Two main reasons for this failure were as follow:
First, different participant countries, depending on their geographical locations
and other factors, had different and conflicting interests in tightening or softening the
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quarantine measures, for example, while nations with significant trading interests showed
resistance against tough quarantine measures, countries bordering the Mediterranean Sea
sought more strict quarantine measures.37
Second, there were no consensus on the cause of communicable diseases like
cholera, plague, and yellow fever. Some delegates (e.g. British officials) attributed
cholera to environmental factors and bad air, therefore, they insisted on establishing
sanitary measures instead of quarantine. Others attributed cholera to an infectious agent.
These countries, like Spain, Greece, and Russia were in favor of quarantine. Although in
these countries, sometimes the quarantine measures were used to isolate certain social
groups like Jews or foreigners. The third theory, for example maintained by Austria, was
the supernatural theory that attributed such diseases to the displeasure of God and
considered them as divine punishment, therefore, they insisted on religious measures as
the only way to contain cholera and other outbreaks.38
The next five conferences held between 1859 and 1885 (1- Second Sanitary
Conference in Paris, 1859; 2- Third Sanitary Conference in Istanbul, 1866; 3-Fourth
Sanitary conference in Vienna; 4- Fifth Sanitary Conference in Washington, 1881; 5Sixth Sanitary Conference in Rome, 1885). These conferences, also, did not generate any
substantive agreement.
It was after Robert Koch’s work on cholera -which established a scientific
consensus on the cause and treatment of cholera-that the first international agreement was
successfully created at 1892’s International Sanitary Conference in Venice. This
agreement was titled the International Sanitary Convention (ISC) and allowed for very
limited quarantine practices for ships passing through the Suez Canal carrying pilgrims to
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and from Mecca. Although of limited scope, it was the first successful international
effort for global health governance.39
Over the next 58 years and through the next conferences (e.g. Eighth Sanitary
Conference in Dresden, 1893; Ninth Sanitary Conference in Paris, 1894; Tenth Sanitary
Conference in Venice, 1897; Liquor Traffic in Africa in Brussels, 1906; Opium in
Shanghai, 1909; Twelfth Sanitary Conference in Paris, 1911; Opium in The Hague, 1911;
and (15) Opium in The Hague in 191340), the ISC was revised and expanded in various
terms including the number of diseases it covered. This is noteworthy that the main
purpose of the ISC was not establishing new quarantine measures; instead, it was mainly
aimed at removing the unnecessary and burdensome practices and limit the allowable
quarantine practice under the international law to the effective ones without unnecessary
impeding or obstructing the flow of commerce and travelers across the borders. 41
The ISC needed an organizational structure to coordinate the efforts of different
states and facilitate the communications and surveillance. For this purpose, the first
international health organizations were founded in the first decade of the twentieth
century. These organizations were the International Sanitary Bureau (ISB) that later
changed its name to the Pan American Sanitary Bureau and then to the Pan American
Health Organization; and the Office International d’Hygiene Publique (OIHP). 42
The trend of establishing organizations for global heath governance consequently
continued by appearance of other major role players in the scene. Organizations such as
the International Health Division (IHD) of the Rockefeller Foundation (RF), founded in
1913, and the Health Organization of the League of Nations (HOLN), created in 1922.43
The importance of the IHD was partly in this fact that it was the first noteworthy
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appearance of a philanthropic organization belonging to the private sector in global health
governance.
After the WWII and establishment of the United Nation, the World Health
Organization was founded as the most prominent international organization in the global
health governance.44 Around the time of establishment of WHO as the United Nations
(UN) specialized agency for health, other international organizations contributing to
health were as follow: The UN Relief and Rehabilitation Administration (UNRRA)
established in 1943; UN International Children’s Emergency Fund (UNICEF) founded in
1946; and UN High Commissioner for Refugees (UNHCR) founded in 194945.
However, in the second half of the 20th century, WHO remained the most important
institution and focal point of global health governance46. Now it is obvious that it is
losing its leading role in the global health governance and needs reforms to regain and
preserve its leading role47.
In sum, global health governance can be understood as a merging point of two
major trends: (1) the trend of the change in the composition of global role players in a
way that international relations gradually transformed into global governance, and (2) the
trend of globalization in health sector, e.g. pandemics, migration of healthcare
professionals, need for global surveillance systems, the global distribution of
pharmaceutical products, and the effects of global patterns such and the climate change
and global inequality on health. The health research enterprise has not been an exception
for any of these two major trends. The following part of this chapter takes a closer look at
the convergence of globalization and health-related research, that has taken shape to
global governance for health research.
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iv. Global Governance for Health Research
Health research enterprise encompasses all research activities that are related to
human health, including biomedical, epidemiological, and ecological research. Research,
as described in details below in this chapter, has developed into a global and cross border
enterprise with various role players from states to corporates and from intergovernmental
organizations to non-for-benefit ones. Therefore, research activities with transnational
and supranational nature are subject to global health governance. This branch of global
health governance, although has not been studies like the branches dealing with
pandemics or disasters, play an influential role in the health and welfare of human
societies all over the globe.
Taking a historical look reveals that the distinct separation between research and
therapeutic clinical practice in health sciences, is a recent phenomenon, dates back to the
first decades of the twentieth century. Before that time, for centuries, experimenting new
treatments or interventions was considered as a part of the routine practice of physicians
and was supposed to be aimed at providing the best health for the patient. It was in the
twenties century that health-related research enterprise experienced an exponential
growth, was recognized as separated from clinical therapeutic practice, and in the second
half of that century international and multicenter research projects began to sprout and
grow.48
Just like other global enterprises, the international health-related research
established its own system of global governance.49 The global governance for healthrelated research has mainly been established in the following ways: First, the
international declarations, codes, and guidelines developed for setting global ethical

19

standards for health-related research; second, the national rules and regulations made by
the countries that host the main funding bodies and institutions on international research;
and third, the internal regulations, standards, and guidelines of the various sorts of
organizations that fund international research.50 Therefore, for sketching a realistic
portrait of the history of global governance for biomedical research, the best way is
taking a look at the developments in the above-mentioned means of implementing global
governance for biomedical research and its main concepts and theories.51
The recent programs funded by Fogarty International Center (FIC) to establish
research ethics capacity in developing countries is a noteworthy example.52 This program
is aimed to transfer the research oversight and review capacity to the low and middle
income countries. It has been accused to trying to impose Western values to developing
countries. The FIC tried to nullify these accusations by emphasis on including local moral
teachings in the curricula and planning for transferring the capacity (both educational and
oversight) to the local participant institutions over the period of the programs.
In an attempt for analyzing the theoretical aspects of global governance for health
research, Wahlberg et al. introduced four spheres (or layers) of ethical governance for
health research as follow: deliberation, regulation, oversight, and interaction . Some
countries have established organized processes for national ethical deliberations. This
national debate can produce ethical awareness and help to develop a democratic process
of problem-solving in the ethical governance of biomedical research enterprise. In
addition, ethical regulations at both national and global levels have been developed and
shaped another layer of ethical governance for health research. The regulations pave the
way for the next sphere or layer that is ethical oversight. As it is discussed in the
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following chapters, establishing independent oversight for health research has been one
of the major achievements and at the same time challenges of governance for health
research. The last sphere or layer is interaction among the role players in research
including researchers and research participants. 53 This four-layer model although seems
helpful in portraying the existing models of governance for health research, does not shed
light on the specific ethical challenges ahead of global governance for heath and cannot
contribute in providing new answers and solutions for the existing problems.
v. A Historical Perspective
The historical developments of the above-mentioned concepts have been depicted
under each topic. The history of conceptual development of the modern notion of
governance partly dates back to the 1970s when Michel Foucault transformed this
concept.54 Concepts such as governmentality and biopolitics that were coined or
redefined by this French philosopher have been influential in the academic and
intellectual discourse on governance. His intellectual role and its critical assessment have
been provided in chapter three under the topic of biopolitics vs. bioethics. In this part, the
developments of global research enterprise have been portrayed (see below).
In the very beginning of the twentieth century, for the first time in a research that
can be called an international research in some senses, American researcher Walter Reed,
obtained written informed consent for healthy volunteers in his yellow fever experiment
in Cuba.55 At that time, obtaining informed consent had not been established as a
standard of practice in clinical research. However, international reflections on the
unethical behaviors in research began from the same years. For example, at an 1898
medical meeting, William Osler, one of the giants in the history of medicine, condemned
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the experiment presented by an Italian researcher. That researcher, who worked on
yellow fever in 1897, declared that he had injected a bacillus to five people and produced
yellow fever in them. William Osler’s reflection was frankly that to deliberately inject a
poison like that into human subjects of research without their previous consent is
criminal.56
The first known regulations governing research with human subjects were
publicized in the first year of the twentieth century. These Prussian regulations were
followed by a code in German in 1931 issued by the Reich Minister of the Interior.57 In
the later decades of that century, the increasing awareness toward biomedical ethics and
disclosure of some infamous instances of violation against human dignity and human
rights in research projects, led to national, and then international endeavors aimed at
establishing a set of ethical standards for health-related research.58
The first international code on health-related research ethics was developed and
announced in the wake of WWII and in the response to disclosure of unethical behaviors
of Nazi doctors on their human subjects during their experiments through the world war
II.59 The most well-known and internationally embraced instrument in the field of healthrelated research ethics, however, is the declaration of Helsinki. First adopted by the
World Medical Association (WMA) in 1964, this declaration was subject to several
revisions and amendments. These revisions and amendments kept this instrument updated
and reliable until now.60 The declaration of Helsinki is a brilliant example of using soft
law in the global governance .
In addition to the international instruments, some scholarly works and national
laws, guidelines, and codes have had great influence on the global governance for
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biomedical research ethics. The development of four principles of biomedical ethics by
Beauchamp and Childress and the Belmont Report, both in the 1970s, were mammoth
steps in establishing the ethical frameworks for global governance for biomedical
research.61
As said above, the first known national regulations for governance of research
enterprise have been developed in Germany in early 1900s, however, what happened in
Germany in the following decades proved that just having well-written regulations is not
enough to prevent unethical behaviors. As a matter of fact, the same story was repeated in
other countries who hosted an established research sector. The most well-known stories
happened in the United States. The ones that proved the crucial role of whistleblowers
and the need to establish independent ethical oversight for research.
In June 1966, Henry K. Beecher published an article titled Ethics and Clinical
Research in New England Journal of Medicine. He introduced 22 cases of unethical
clinical research on human subjects Drawn from the immediate postwar period from 1948
to 1965 protocols from leading investigators in leading institutions, working on some of
the most important questions in medicine, and published in the most reputable medical
journals. Examples included purposeful infection with hepatitis of residents at the
Willowbrook State School for the Retarded; injection of cancer cells into elderly and
senile patients in which the subjects were merely told they would be receiving some cells;
and insertion of a special needle through a bronchus into the left atrium of the heart of
patients and healthy subjects. And suturing a mercury-filled resistance gauge to the
surfaces of the left ventricles of the subjects. Beecher’s revelations caused a shift from
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Researcher Paternalism to Regulatory Protection; Utilitarianism to Principlism; and
Relying on researcher judgment to IRB review and informed consent.62
Ezekiel J. Emanuel and Christine Grady, in their article and then book chapter,
titled Four Paradigms of Clinical Research and Research Oversight explained four
distinct paradigms that the research enterprise and research oversight has passed through
during the last eight decades in the United States of America, namely: Researcher
Paternalism, Regulatory Protectionism, Participant Access, and Community
Partnership.63 Some other studies show the comparable historical trends occurring in the
biomedical research enterprise in other countries.64
According to Emanuel and Grady, in the late 1980s and early 1990s, a paradigm
change from regulatory protectionism to participant access occurred in the United States.
Before that time, the conception of clinical trial participant was a vulnerable patient that
needs protection provided by oversight/regulatory bodies and institutions such as the
Institutional Review Board (IRB) reviews and informed consent. This
perspective/paradigm was based on a historical experience of abused and exploitation of
research subjects of researchers that were exposed and led to establishment of oversight
legislations and institutions.65
However, in the late 1980s and early 1990s some events triggered a paradigm
change. Two important ones among them were the AIDS epidemics and the breast cancer
movement. In these cases, the patients advocate groups demanded earlier access of dying
patients to experimental drugs.66 This was a dramatic change. The patients/research
subjects had no longer been considered as vulnerable persons to be protected against
unnecessary enrolment in clinical trials, instead, the protection was against unfair access
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to the clinical trials as the only hope for survival in front of patients who had no other
curative or therapeutic choice.67
Therefore, through a paradigm change, (1) the key protection changed from IRB
review and individual informed consent to individual autonomy; (2) the conception of
clinical trial participant changed from a vulnerable patient to an informed consumer, (3)
the role of research and healthcare changed from research priorities being seen as threat
to clinical care to clinical trials being viewed as best, cutting-edge clinical care; (4) the
underlying philosophy of research oversight changed from principlism to individual
rights-based theories ; and (5) the highlighted ethical principle changed from independent
review to informed consent.68
The demand of HIV/AIDS patient for informal access to experimental drugs also
was mirrored in the laws and regulations. The informal access to experimental drugs was
made possible through legislations that passed in 1987 and was revised in 2009 (see
below for details).69
Similar changes occurred on the global scene. A prominent example of demanding
compassionate use of experimental drugs occurred during the Ebola outbreak in West
Africa. Although Ebola infection has no proven curative treatment, some experimental
medicines have been used hoping to save patients who otherwise would be likely to die.
The long process of approving experimental drugs for using in standard clinical practice
has always been a subject to criticism. During the HIV/AIDS epidemics, sometimes there
were competitions among potential participants (patients/infected people) for entering the
clinical trials because they looked those clinical trials as the last resort and beacon of
hope for receiving an effective treatment. In the case of Ebola infection, however, the
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clinical trials were being conducted thousands of miles away from the foci of outbreak.
Delivery of experimental drugs to those patients was not part of any research study or
clinical trial. As a matter of fact, considering the especial context of chaos and shortage
of healthcare workers and facilities, it was impossible to conducts sufficiently well
designed and well-conducted clinical trial in those areas. Providing experimental drugs
for those patients hoping to be effective in relieving their suffering and even saving their
lives was an act out of compassion/philanthropy.70
The most important development in the realm of global governance for research
ethics occurred in the past two decades. These developments are as follow:
1- The rapid growth of research enterprise in the Low and Middle Income
Countries (LMICs) that made the health-related research and research ethics a global
subject to concern and debate.71
2- The significant increase in the number and size of international and multicenter research projects that also brought global attention and international concerns into
the health-related research enterprise.72 The issues raised by these multi-center research
collaborations can be classified into two major categories:
2.1. The issues raised by the collaborations between centers from developed
countries with centers from developing (low and middle income) countries. The power
and knowledge imbalance in these collaborations have raised concerns on the exploitative
nature of them or imposing ethical standards by the powerful counterparts. Examples of
the issues that can be located within this category are double standards in clinical trials
and the lack of benefit sharing in research activities funded by developed countries and
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executed in the low and middle income countries. These concerns have been discussed in
details in chapter three.
2.2. The issues raised by the collaboration in which all the counterparts belong to
the developed countries and no power imbalance exists. Even in these kinds of
collaborations, emergence of new sources of ethical concern has been proved to be
unenviable. Working on big data, large scale biobanks, and the relation between research
sector and medical tourism are among the examples of this category. These concerns, as
well, have been discussed in more details in chapter three.
The ethical issues related to health research can be classified into several categories.
Each category of health research ethics or each part of health research enterprise has its
own history of developing a national and then global oversight or network of governance.
The historical overview is not complete without a brief discussion on at least one of the
examples that shows how ethical debates proceed in each of these categories or parts. For
this purpose, research integrity can be a suitable choice. Research integrity, as a topic
discussed in more detail later in this dissertation, also has its own history that can be
depicted in more details and serve as an example on the above-mentioned historical
courses and backgrounds:
Some aspects of research integrity, such as avoiding plagiarism, are as old as the
written history, itself. However, the notion of research integrity in its current dimensions
and characteristics is a relatively new notion. For example, in the United States, research
integrity became a public issue in 1981. In that year, a congressman named Albert Gore,
Jr. who was the chairman of the Investigations and Oversight Subcommittee of the House
Science and Technology Committee, held the first hearing that was provoked by the

27

public disclosure of certain research misconduct cases. Those cases had occurred at four
major research centers in the previous year. About twelve cases of research misconduct
were revealed in the US between 1974 and 1981. The attention of the US Congress to the
issues related to research integrity was continued throughout the 1980s because of some
added accusations of research misconduct and reports that the NIH, universities, and
other research institutions were unsatisfactorily reacting to those accusations.73
In 1985, the Congress of the United States passed the Health Research Extension
Act. This Act required the Secretary of Health and Human Services to issue a regulation
requiring applicant or awardee institutions to establish "an administrative process to
review reports of scientific fraud" and "report to the Secretary any investigation of
alleged scientific fraud, which appears substantial."74
In March 1989, the PHS created the Office of Scientific Integrity (OSI) in the
Office of the Director, NIH, and the Office of Scientific Integrity Review (OSIR) in the
Office of the Assistant Secretary for Health (OASH). The reason behind foundation of
these offices was to deal with research misconduct.
The establishment of OSIR also began the course of detaching responsibility for
research misconduct from the funding organizations. In May 1992, OSI and OSIR were
combined into the Office of Research Integrity (ORI) in the OASH.
As the prominent examples of its activities, ORI published the ORI Introduction to
the Responsible Conduct of Research in 2004 and began the RCR Program for Graduate
Schools in collaboration with the Council of Graduate Schools to institutionalize RCR
education in graduate training.75
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The above examples show the process of legislative and regulatory attention to the
issues of research integrity and research misconduct in other countries and in the global
scene: First, some cases of violation of research integrity gain public attention, then
gradually the related rules and regulations are passed in the legislative bodies and
executive offices take shape to enforce those rules and regulations. The global
governance for research needs the same process to take shape at the global scale to deal
with the issues of research misconduct and research integrity through global governance
for research ethics.
In sum, the concept of global governance for research has two parallel lines of
history: First, the history of the concepts of governance, global governance, and global
governance for heath, as depicted under their respective titles above in this chapter. An
overall look at this history shows that globalization along with the dramatic changes in
the composition of role players on the global scene has resulted the development of these
conceptual tools to be used in analyzing and solving the issues with global nature. The
course of development of the concepts and their emergence out of their predecessors (e.g.
international relations and world order) shows the significance and influence of values
(i.e. moral theories and value systems) in their theoretical make and nature. These
concepts have always emerged, used, and developed within ethical frameworks.
Therefore, any scholarly and analytic discussion on them is deeply value-ridden and
proceeds within specific ethical frameworks. As shown in the next chapters of this
dissertation, the existing challenges and issues, also, are mainly of significant ethical
nature or have major ethical components. And the best way to approaching them is seeing
them within the respective ethical frameworks. Before taking a deeper look at the existing
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issues, it is necessary to examine the exact composition of these role players in more
details. This detailed examination can be found in the following chapter.
Second, the history of health research itself. The other line of history that collides
with the history of global health governance and takes shape to the concept of global
governance for health research, is the history of health research. As a modern enterprise,
as depicted above, health research is young, aging less than 100 years. However, over its
relatively short lifespan, this enterprise has changed the way human beings give birth,
live, die, and perceive themselves. Like any other intentional deed of human being, health
research is a subject of ethical analyze and assessment. It is also true about the part of this
enterprise that goes beyond and across the national borders and take shape to another
facet of what is called globalization. Health research on the global scene has been an
enormous source of ethical challenges and debates. Dealing with these challenges on the
global scene and at the global level needs the respective ethical framework, that the next
chapters of this dissertation are aimed to provide.
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Chapter Two - Situation Analysis
This chapter explores the existing situation and portrays the map of Global
Governance for Health Research in the contemporary world. For this purpose, this
chapter firstly provides a detailed description of the major role players, including
institutions and instruments, and secondly, depicts a scheme of the global network
through with the Global Governance for Health Research operates.
The role players on the scene of Global Health Governance have generally been
classified into two major categories: (1) States and Intergovernmental Organizations, and
(2) Non-State actors.76 The same classification seems to work for classifying the roleplayers of Global Governance for Health Research, although as it looks obvious through
this chapter, there are two major differences: (1) major role players on the scene of
Global Governance for Research are not the same as the ones in Global Health
governance, and (2) The more important part of Global Governance for Health Research
is the international soft law rather that the existing organizations.
As discussed in chapter one, the terms nation and state and the terms institution and
organization can be used interchangeably. However, they also bear different meanings
and connotations (see above). In this chapter, the term “international organizations” have
been used with its current connotation in the political discourse that equates with
intergovernmental organizations, however encompasses some significant exceptions,
including the World Medical Association (WMA) that is an international, but not
intergovernmental organization. A more detailed description can be found later in this
chapter.
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An important fact reveals itself through examining different role players in this
chapter. This fact is that the most significant part of Global Governance for Research in
the contemporary world is the body of the existing soft international laws. This body has
been created by the involved organizations and has gradually found its place in the
international discourse. The process through which the soft law gains popularity and
acceptance and becomes hard law, such as what occurred for the Universal Declaration of
Human Rights, is beyond the scope of this chapter, although it provides a good example
by introducing the bioethical documents that have gone through the same process.
Although there is no overseeing and governing organization for global research, the
standards, values, principles, and guidelines that are developed, and delineated through
the aforementioned instruments have been used as the normative and theoretical grounds
and educational resources for local and regional governing bodies to develop their own
systems of research regulation and oversight. Therefore, a significant part of the situation
analysis of Global Governance for Health Research consists of examining the codes,
declarations, and guidelines and their exceptional role in shaping the current situation and
their potential to be used in developing a comprehensive and consensual ethical
framework for Global Governance for Health Research. The same endeavor has been
previously done by Emmanuel and Grady for creating an ethical framework for clinical
research.77
After describing the role players within each of the aforementioned two main
categories, this chapter discusses the characteristics and mechanisms of the global
network through with the Global Governance for Health Research operates. This part
connotes the interrelated, sophisticated, and, in some senses, convoluted nature of this
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network. The truth is that there is not such a thing as a defined and coherent network to
oversee the Global Governance for Research. Instead, different parties with different
scopes, agendas, interests, and extends of influence take part in governing the existing
asymmetrical collection of activities that can be considered international research projects
throughout the world. At the end of this part, an example of creating a comprehensive
and systematic ethical framework with reliance on the extant guidance is provided. This
example sheds light on the way ahead of normative scholarly work in the field and its
general characteristics.
The situation analysis and map in this chapter also provides a basis for portraying the
most relevant challenges and obstacles in the field that are discussed in the following
chapters of this dissertation. Having a good knowledge of the situation and its main
challenges lead this dissertation to its next chapters to discuss the ethical framework for
good governance in this field.
i. States and Intergovernmental Organizations
In this part, three major intergovernmental organizations involved in Global
Governance for Research Ethics are discussed: The World Health Organization (WHO),
the World Bank, and the United Nation’s Educational Scientific and Cultural
Organization (UNESCO). Then, other forms of the involvement of states in the global
governance for research are discussed that include the role of the United States and the
Council of Europe.
This part shows that the significance and influence of these role players in Global
Governance for Health Research is different from their significance and influence on
Global Health Governance. While WHO is formally supposed to adopt the leading and
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central role in Global Health Governance, it seems that its role in Global Governance for
Health Research is more peripheral and tangential. On the other hand, UNESCO has
played a more significant role in shaping the ethical frameworks for biomedical research
and its governance at the global scale. In sum, while WHO has been mostly involved in
the technical aspects of health promotion and Global Health Governance and the World
Bank has exerted its impact in funding global projects and developing the concept of
Good Governance at the political level, UNESCO has developed the most comprehensive
and cultural-sensitive ethical instruments to be used in shaping an ethical framework for
Global Governance for Health Research.
WHO: In some cases in the scene of global governance after the WWII, an
international organization, officially takes the leading role in one of the global affairs.78
For example, the World Health Organization (WHO) is the organization in charge for
global health issues.79 Such international organizations, including the WHO, work based
on consensus among almost all the member states.80 In addition to WHO, the World
Bank plays a major role in Global Health Governance (see below). Also, there are other
United Nations agencies focusing on the international health issues. However, WHO is
still, at least formally, the United Nation’s major body in dealing with Global Health
Governance.81
To act as the leading organization in international health-related affairs, the WHO
was founded in the wake of the World War II in 1948.82 Its constitutional ratification
meeting was held in New York City in 1946 and the first meeting of the body was held in
Geneva in 1948.83 WHO has been the most important institution and focal point of global
health governance in the 20th century.84
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The highest decision-making body for WHO is the World Health Assembly. In the
World Health Assembly, delegations of the 194 member states convene each year,
generally in Geneva, Switzerland. The World Health Assembly appoints the Director
General, governs the budgetary and financial affairs, and decides on its missions and
main directions. The Executive Board, consisting of 34 members who are experts in
health is in charge of giving effect to the decisions and policies of the World Health
Assembly and provide it’s needed expertise and technical support and advice.85 The
secretariat, the main administrative and technical part of WHO, operates as the third
element of the governance of this organization. Finally, the picture of the governing
bodies of WHO becomes completed by adding it’s six regional offices that enjoy degrees
of autonomy and perform much of the programmatic work of this organization. These
regions include: Africa, the Americas, the Eastern Mediterranean, Europe, South-East
Asia, and the Western Pacific.86
Although WHO was originally founded to take a leading role in global health
governance, its leadership has always been a subject of fluctuations and criticism. This
leadership or lack of leadership, however, have usually been pertaining to the public
health issues. The role of WHO in governing the ethical aspects of the health research
enterprise has mostly been tangential and not substantive. Research is relevant to the
WHO’s constitutional roles, functions, and objectives in two ways:
1- Research is essential for WHO to perform its health-related roles and functions and
achieve its constitutional main objective that is “the attainment by all people of the
highest possible level of health.” The health-related policies and practices should be in
accordance and resulted from valid and reliable scientific knowledge which, in turn, is
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only achievable through well-designed and well-conducted health research. WHO has a
good grasp of this mandate. For example, at the Ministerial Summit on Health that was
held in 2004 in Mexico City, the participants (including the health ministers) asserted that
health policy, public health, and health service delivery should be grounded in reliable
evidence derived from high quality research.87
2- The WHO’s constitution specified a research function of this organization: “to
promote and conduct research in the field of research”. Therefore, WHO established its
first Advisory Committee on Medical Research in 1959 (renamed to the Advisory
Committee on Health Research in 1986) and afterwards the regional advisory committees
were founded. In addition, the Sixty-Third World Health Assembly (held in May 2010)
approved WHO’s strategy on research for health. This strategy was approved by the 193
Member States of WHO. 88 One of the six core functions of WHO, as listed in The
Eleventh General Program of Work is “shaping the research agenda and stimulating the
generation, translation, and dissemination of valuable Knowledge.” Research in WHO,
however, focuses mainly on “secondary and commissioned research” with a focus on
health systems, health policy, and health advocacy. 89
Therefore, WHO pays attention to conducting and promoting research as the basis for
evidence-based for healthcare (encompassing all its elements from prevention to
treatment and rehabilitation) and for policy making for health (for example, in its 2013
report, WHO emphasized on the crucial role of research for universal health coverage).90
Consequently, observing the ethical standards in research is important to WHO, although
it was usually limited to the research inside or under direct supervision of WHO and has
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not made this organization a world leader in shaping ethical frameworks for health
research.
The WHO Strategy on Research for Health lists three main principles as the guiding
principles for the type of research it supports: (1) Quality: WHO holds a commitment to
high-quality research. High-quality research means being “ethical, expertly reviewed,
efficient, effective, accessible to all, and carefully monitored and evaluated.91” (2)
Impact: This principle implies that WHO prioritize research based on its potential
consequences and achievements for health. (3) Inclusiveness: Adopting a multisectoral
approach and collaborating with communities and civil society and collaboration among
state members and stakeholders consist the meaning of inclusiveness to WHO.92
In 2011, WHO published the Standards and Operational Guidance for Ethics Review
of Health-Related Research with Human Participants. This document is aimed at
providing guidance for Research Ethics Committees for reviewing the health-related
research projects with human subjects. However, this document does not include
guidance on how to approach and resolve ethical challenges in research ethics and is not
intended to substitute ethical guidelines.93
WHO has also published the International Ethical Guidelines for Biomedical Research
Involving Human Subjects and the International Ethical Guidelines for Epidemiological
Studies in collaboration with the Council for International Organizations of Medical
Sciences (CIOMS) that are discussed below in the part dedicated to discussing the role of
CIOMS.
The World Bank: The World Bank has started funding global health-related
programs from a few decades ago and became a major role-player in global health

37

governance.94 Since the 1980s the World Bank has become the largest financial supporter
of global heath projects.95 Although the main role of the WHO and World Bank is in
providing healthcare for in-need societies and dealing with global public health issues
such as outbreaks and pandemics, they both fund health-related research projects and
develop ethical guidelines for research activities.96
Formally established in December 1945, this organization is based in Washington
DC. The World Bank works like a cooperative and has 189 member countries. The
highest policymakers at the World Bank are the representatives of the member states who
convene at the Board of Governors that convenes once a year (Annual Meetings). The
Executive Directors (appointed by the five largest stakeholders of the bank) who work at
the Bank receive their specific duties from the Board of Governors. The World Bank
Group President (selected by the Board of Directors for 5-year periods) chairs the
meetings of the Board of Directors.97 The highest official of the World Bank is the
president who has always been a US-citizen. This is among the facts that shows the high
influence of the United States in this intergovernmental organization.
The World Bank Group consists of five major financial organizations as follow: (1)
International Bank for Reconstruction and Development (IBRD), (2) International
Development Association (IDA), (3) International Finance Corporation (IFC), (4)
Multilateral Investment Guarantee Agency (MIGA) (5) International Centre for the
Settlement of Investment Disputes (ICSID).98
The World Bank has been among the main sponsors of some impactful health-related
research projects, one of the most well-known among them being the project of Global
Burden of Diseases. This project has invented a health economics unit for measuring
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utility in health, named Disability-Adjusted Life Years (DALYs). This project, although
it has gained vast acceptance in the world and has been useful in providing more reliable
assessments of the burden of diseases (for example, providing a single measure for
calculating premature deaths and disabilities), has also been criticized for many aspects
of it such as putting economic value on human life, entailing sex or age discrimination,
and not being cross-cultural.99 These ethical debates show the numerous ethical concerns
that exist in the way of creating measures for health measurement in different
communities and providing fair estimates of the health needs and priorities and
comparing them between different counties and communities.
The World Bank has taken some steps in developing a guideline for research,
however, no guidelines have been announced or adopted yet.100 Therefore, this
organization, although very influential in Global Health governance and in raising ethical
debates, has not contributed in Global Governance for Research Ethics by taking part in
shaping the existing body of the related soft law.
UNESCO: The United Nation’s Educational Scientific and Cultural Organization
(UNESCO) though not considered directly related to the technical aspects of health
issues, has had a noteworthy contribution in developing ethical standards and norms for
global bioethics and healthcare ethics and accordingly, UNESCO has made a major
contribution in global governance for biomedical research. The most prominent step
taken by UNESCO for this purpose, has been developing, adopting, and disseminating
the UNESCO Universal Declaration of Bioethics and Human Rights .101 The General
Conference of UNESCO in its 33rd meeting on 19 October 2005, unanimously adopted
this declaration.102
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As one of the UN organizations, UNESCO is in charge of coordinating international
collaborations in education, science, culture, and communication.103 The constitution of
UNESCO ratified in November 1945 at the end of United Nations Conference aimed at
stablishing an educational and cultural organization convened to create an organization to
promote a culture of peace and intellectual and moral solidarity among human beings.
Consequently, the first General Conference of UNESCO convened in Paris in November
and December, 1946 with representations from 30 countries.104
The governing bodies of UNESCO include the General Conference that consists of
the representatives of the State Members (with participation of Member States, Associate
Members, and observers from Non-Member States and intergovernmental and nongovernmental organizations) and meets every two years. The General Conference is the
supreme governing body of UNESCO that determines its policies and missions, set its
programs and budget, and elect its Director General and members of the Executive
Board.105
UNESCO operates through five major programs: education, natural
sciences, social/human sciences, culture, and communication/information. As the
specialized UN organization with a mission on science, including the life sciences,
UNESCO has always focused on ethics in science and technology, including bioethics.
Accordingly, since 1993, it has been hosting the International Bioethics Committee (IBC)
and has dedicated part of its budget to pursuing specific objectives in the field of ethics in
science and technology. In 1998, UNESCO established the World Commission on the
Ethics of Scientific Knowledge and Technology to cover other areas of applied ethics and
the Intergovernmental Bioethics Committee (IGBC) to fulfil the respect for cultural
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diversity and geographic representation in its bioethical operations. As an international
organization affiliated to the UN, part of the objectives that UNESCO defined for itself in
the field of bioethics has been setting globally consensual standards. In the General
Conference, held in 2001, ethics of science and technology was included among the five
top priorities of UNESCO, confirming the organization’s leading role in bioethics. The
same meeting of the General Conference invited the Director-General to examine the
possibility of setting and adopting universal norms on bioethics. This was the practical
starting point of a series of endeavors that ended to creating and adopting the UNESCO
Universal Declaration of Bioethics and Human Rights in 2005.106
The UNESCO Universal Declaration of Bioethics and Human Rights consists of an
introduction and 28 articles organized under the following titles and subtitles:(1) Scope;
(2) Aims; (3) Principles: Human Dignity and Human Rights; Benefit and Harm;
Autonomy and Individual Responsibility; Consent; Persons without the Capacity to
Consent; Respect for Human Vulnerability and Personal Integrity; Privacy and
Confidentiality; Equity, Justice, and Equity; Non-Discrimination and NonStigmatization; Respect for Cultural Diversity and Pluralism; Solidarity and Cooperation;
Social Responsibility and Health; Sharing of Benefits; Protecting Future Generations;
Protection of the Environment, the Biosphere, and Biodiversity; (4) Application of the
Principles: Decision-Making and Addressing Bioethical Issues; Ethics Committees; Risk
Assessment and Management; Transnational Practices; (5) Promotion of the Declaration:
Role of States; Bioethics Education, Training, and Information; International
Cooperation; Follow-up Action by UNESCO; (6) Final Provisions: Interrelation and
Complementarity of the Principles; Limitations on the Application of the Principles;
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Denial of Acts Contrary to Human Rights, Fundamental Freedoms, and Human
Dignity.107
Some of the characteristics of this declaration that are relevant to global governance
for health research are as follow:
(1) This declaration provides the first and only universally and consensually created
set of norms and principles for governing bioethics, including research ethics. The
unanimous approval of all the members of UNESCO is one of the important features of
this declaration. Therefore, this declaration provides another great example (like what
was said about the Declaration of Helsinki) of the role of soft law in global governance,
at all, and in global governance for health research, in particular.108
(2) All the principles of the classic set created and adopted by the Belmont report and
the Beauchamp and Childress’s four principles of biomedical ethics, which are the
columns of principlism in bioethics, are included among the principles of this declaration.
However, other principles are added to make it more comprehensive, inclusive, and
global. Adding these principles expands the scope and view of these principles from a
Western-oriented one to a globally and transculturally recognized set of principles.
Therefore, these principles can also be called a part of the common intellectual heritage
of mankind.109
(3) UNESCO is one of the UN organizations, therefore, in creating ethical
instruments, it should observe and consider the norms and principles once promulgated
through The Declaration of Human Rights. The UNESCO Universal Declaration of
Bioethics and Human Rights has been successful in keeping the necessary abidance to
this great predecessor, and at the same time, encompass and observe other important
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values such as cultural diversity, with this important caveat that no principle (including
respect for cultural diversity) should be interpreted in a way that is contrary with human
rights and fundamental freedoms.110
In sum, one of the features that differentiate global governance for health research
from global health governance is its strong relation with bioethics and medical
humanities. Therefore, the relevance of UNESCO to global governance for health
research seems to be even stronger that WHO’s, even if WHO is the main international
organization in charge of global health governance, formally speaking. In the next
chapters of this dissertation, the principles introduced and adopted by the UNESCO
Universal Declaration of Bioethics and Human Rights are used for developing an ethical
framework for the global governance for biomedical research.
The United States of America: The contribution of the United States of America
(USA) in Global Governance for Health Research actualize in three main ways: (1)
developing theories and domestic guidelines and legislations that are pioneer,
groundbreaking, standard-setting, and serve as prototypes and models for other countries
and institutions; (2) influential participation and playing a unique role in international
organizations and coalitions; (3) hosting the most prominent funding bodies for
international health research both in the governmental and private sectors. Below, brief
discussions on each of these roles are provided:
1.Over the past decades, the US has always hosted the pioneer institutions and
scholars in the field of biomedical ethics, including research ethics. One of the major
developments, was the whistleblower article of Henry Beecher that showed that in health
research it is not enough to rely on the personal virtues, respected characters, and good
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intentions of researchers and their hosting institutions, because even in the most
prestigious institutions and under supervision and leadership of the most reputable
physician/researchers this is quite possible that extreme violations of the rights of human
subjects take place. 111 Therefore, independent oversight backed by legislations grounded
in solid principles and values are necessary for governance of health research
enterprise.112
In 1974, the National Research Act was passed and the National Commission for the
Protection of Human Subjects in Biomedical and Behavioral Research was established.
Consequently, according to the act and within the framework of the principles of the
Belmont Report (see below), the federal regulations for protection of human subjects
were developed and adopted by the Department of Health, Education, and Welfare. This
name of this department was later change to its current name, the Department of Health
and Human Services. These regulations are process-oriented; therefore, they look less
relevant to the subject of developing an ethical framework for Global Governance for
Health Research.113
In 1978, the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research published a short but influential document
delineating the moral principles for biomedical research that is called after its birthplace,
the Belmont Report. It was in the Belmont Report that for the first time, a framework of
general principles for biomedical research ethics (also known as the Belmont Principles)
were introduced. These principles include: Respect for Person (applies to informed
consent), Beneficence (applies to risk-benefit assessment, and Justice (applies to selection
of research participants). Displaying such a close and obvious relevance between the
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abstract moral principles and the practical ethical aspects of research ethics is one of the
main features of Belmont Report. The principles of Belmont Report were not developed
by referring to certain philosophical works or schools, but they were included in the
report based on their widely acceptance in the cultural tradition or in other words, based
on Social morality. 114
Consequently, in 1978, Beauchamp and Childress introduced their four principle of
biomedical ethics as follow: Respect for Autonomy, Beneficence, Non-Maleficence, and
Justice. The differences between these two frameworks, although trivial, were grounded
on some criticisms on the Belmont Report. For example: Respect for Person implies
respect for all the persons, regardless of their possession or lack of autonomy, while the
informed consent is developed to protect the subjects who are autonomous and for the
subjects with reduced autonomy, the principles of beneficence and non-maleficence look
more relevant. As another example, the concerns about using utilitarian justifications to
endanger the human subjects of research (like what had occurred in a group or scandalous
research projects revealed by Beecher) led Beauchamp and Childress in include NonMaleficence as a separate principle in their framework. 115 These principles were
consequently included in the more comprehensive and global framework provided in The
UNESCO Universal Declaration of Bioethics and Human Right.116
2.The USA is an important member of almost all international organizations with
noteworthy role in the Global Health Governance and Global Governance for Health
Research (including intergovernmental organizations such as WHO and international
nongovernmental organizations such as WMA). In addition, the USA has not limited its
participation in Global Health Management to its role in international organizations.
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Instead, this country has initiated a number of large unilateral and bilateral programs to
promote global health that have been accused of weakening multilateralism in Global
Health Governance.
3.The USA is the most important state-funder of health research, including
international health research in the world. This funding occurs in two major ways: (1)
through for-profit organizations such as corporates, or non-profit organizations such as
philanthropic institutions, that is discussed elsewhere in this dissertation; and (2) through
the federal budget by government in the for of the projects funded by the National
Institutes of Health (NIH). Therefore, the regulations overseeing the practice of US-based
parties in these research projects are important parts of Global Governance for Health
Research. Since these regulation are mostly grounded in the Belmont principles (see
above), there is no need to examine them in more details in this part of this dissertation.
The Council of Europe
The Council of Europe had been a major role-player in Global Governance for Health
Research in the past decades by its role in shaping the soft law. This organization should
not be confused with the European Union although all the members of the European
Union are also members of the Council of Europe. The Council of Europe was founded in
1949 and is an intergovernmental organization having 46 members. One of more than
200 multilateral conventions created by the Council of Europe over its history is The
Convention on Human Rights and Biomedicine. 117
The Convention on Human Rights and Biomedicine (its full title being: The
Convention for the Protection of Human Rights and Dignity of Human Being with regard
to the Application of Biology and Medicine) is the first international agreement created
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regarding the newly emerged biomedical technologies. This convention is the first
legally-binding international biomedical law and ethics document that
considers human dignity a central concept and creates a legal framework for communities
with various cultural and normative backgrounds.118
This convention is a good example of international hard law that contains values such
as human dignity that do not belong to a specific cultural or philosophical context, but
belong to the common heritage of mankind.119 Another example that is made by this
convention is the methodology through which a group of countries join a convention and
then, the group expands by joining other members and adopting it as their on legallybinding law. Although the recent trends of isolationism and protectionism augmented by
political phenomena such as Brexit and the recent election of Donald Trump as the
president of the United States might shadow the efforts toward globalization in
international law, the need to strengthen global governance in areas of research and the
will of human kind to preserve and prevail its common moral heritage, such and human
rights and human dignity, will finally overcome these temporary retreats and shape the
future of global governance.
ii. Non-State Role Players
Civil society and private sector organizations are among the most important role
players in the scene of global governance for biomedical research and in protecting the
vulnerable groups in research.120 Their contribution can be divided into three main
categories: philanthropic organizations, civil society, and for-profit organizations. In sum,
the non-state role players participate in Global Governance for Health Research in two
ways: First, by supporting, conduction, and promoting international research all over the
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world. Second, by taking part in ethical regulation and oversight for research. Some
international organizations that belong to civil society has taken important parts in this
realm, e.g. the World Medical Association (WMA) that crated the Declaration of
Helsinki and The Council for International Organizations of Medical Sciences (CIOMS)
with the International Ethical Guidelines for Biomedical Research Involving Human
Subjects. The Non-State organizations show that how globalization has changed the scene
of global power relations in a way that the states are not the only major role players, but
in some areas, they even lag behind the non-state role players in the governance of global
affairs.
1- Philanthropic organizations: This category includes all the organizations
established to serve the public in the field of global health.121 These organizations either
provide health-related support for in need societies around the globe or support activities
that are in service of common good. The constitution of the WHO explicitly recognizes
the potential contribution of civil society organizations in global health affairs. Part of the
mission of these organizations is protecting vulnerable populations both inside and
outside of research. Bill & Melinda Gates Foundation is an example of this category of
organizations.
Among the private organizations, the Bill & Melinda Gates Foundation is a
noteworthy example. This foundation has been a major contributor to global health with
profound influence on international health policy and the design of global health
programs and initiatives. Although the foundation’s contribution to global health is a
publicly recognized fact, its grant-making program may be less known even by the
professionals. Between January 1998, and December 2007 the total value of these grants
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was US$8. 95 billion. A wide range of global health organizations, such as WHO, the
World Bank, the Global Fund to Fight AIDS, Tuberculosis and Malaria, prominent
universities, and non-governmental organizations received grants. The share of
supranational organizations was $3·62 billion (40% of all funding). Just the share
allocated to research and development (mainly for vaccines and microbicides) or to basic
science research was over a third ($3·27 billions) of funding.122
This should be mentioned that a major part of global health governance is conducted
through partnership between public and private sectors . Among the most prominent
examples of such collaborations are the Albendazole Donation Program, Medicine for
Malaria Venture, and International AIDS Vaccine Initiative. These partnerships are
effective in protecting vulnerable groups and are sometimes more efficient that the more
bureaucratic international organizations.123 It has been claimed that the concept of
building collaborative partnerships with business is a central view of the United Nations
(UN) organizations on the governance of globalization.124
Private philanthropies have always been subject of criticisms. For instance, Bill &
Melinda Gates Foundation is criticized because of its global agenda. The critiques argue
that this foundation is too focused on technology and disease that shapes the vertical
approaches that are easily quantifiable, while does not pay enough attention to horizontal
approaches that focus on improving health systems.125
2- Civil Society: Civil society that encompasses Non-Governmental Organizations,
community movements, and other institutions that arise in the communities and act as
non-governmental actors, are among the major role players in Global Health
Governance.126 Professional associations are among the civil society actors. In the field of
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global health research ethics, the World Medical Association (WMA) and the Council for
International Organizations of Medical Sciences (CIOMS) have been one of the most
influential role players in the past decades. This importance has mostly been because of
the Declaration of Helsinki and the International Ethical Guidelines for Health-related
Research involving Humans.
The WMA: World Medical Association is a confederation of medical professional
associations with members from 112 countries. Professional associations typically are
independent institutions and are not part of or subordinate to any governments. Therefore,
the WMA is an international organization, but not an intergovernmental one. The mission
of the WMA, as stated on its website, is: “…to serve humanity by endeavoring to achieve
the highest international standards in Medical Education, Medical Science, Medical Art
and Medical Ethics, and Health Care for all people in the world.”127
The first General Assembly of the WMA was held in Paris, September 1947.128 Being
established in the wake of WWII and the shocking revelation of the violations against
human rights occurred during the research experiments of Nazi physicians, the WMA
was founded with a deep concern about human rights and the rope of physicians in
safeguarding and promoting them.129
Driven by the concerns about human rights and attending to its nature as an institution
originated from civil society, from the very beginning, the WMA emphasized on the
professional independence of medicine, and in delineating, declaring, and preserving
ethical standards for medical professions.130
What has made the WMA very special in the relevance with global governance for
health research is the Declaration of Helsinki. Adopted by the WMA at its General
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Assembly in Helsinki in 1964, the Declaration of Helsinki of the WMA has been the
most influential and well-known international ethical guideline for health research in the
past decades. 131 This declaration, created and adopted by a confederation of professional
associations, provides a great example of the roles of independent institutions of civil
society and their created international soft laws in global governance. The Declaration of
Helsinki was lucky to be followed by the Beecher’s revelations in 1966 that showed the
necessity of and the need for such an instrument in the research enterprise.132
Being undergone multiple revisions and amendments until the last one in 2013, the
current version of the Declaration of Helsinki consists of 37 articles organized under 12
topics as follow: (1) Preamble; (2) General Principles; (3) Risks, Burdens, and Benefits;
(4) Vulnerable Groups and Individuals; (5) Scientific Requirements and Research
Protocols; (6) Research Ethics Committees; (7) Privacy and Confidentiality; (8) Informed
Consent; (9) Use of Placebo; (10) Post-Trial Provisions; (11) Research Registration and
Publication and Dissemination of Results; and (12) Unproven Interventions in Clinical
Practice.133
Of 37 articles of the Declaration of Helsinki, 12 of them depict “general principles”.
These principles start with a recall of two mandated for physicians, one of them included
in the Declaration of Geneva of the WMA as parts of a professional oath for them, as
follow: “The health of my patient will be my first consideration,” and another one
asserted in the international Code of Medical Ethics, as follow: “A physician shall act in
the patient’s best interest when providing medical care”.134
The next articles in the “general Principles” part of the declaration, other main values
are asserted, such as (and not limited to): (1) the primary purpose of medical research
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with human subjects being “to understand the causes, development, and effects of
diseases and improve preventive, diagnostic, and therapeutic interventions” ;(2) the duty
of physicians “to promote and safeguard the health, well-being, and rights of patients,”
including the research participants; (3 the priority of rights and interests of individual
research human subjects to the ultimate purpose of research; (4) the necessity of the
appropriate scientific and ethical credentials and qualifications as the prerequisites for
conducting research projects; and the necessity of compensating the harms resulted by
research activities.135
The main claimed weakness of Declaration of Helsinki is its belonging and adherence
to just one side of the parts involved in research. In other words, the Declaration of
Helsinki is created and adopted physicians and addresses them, while for a
comprehensive ethical guidance for research, the voice of other parts such as the
participants and communities should be heard through their active participation in
developing the guidance. It has also been claimed that the Declaration of Helsinki has
taken a partial position in favor of physicians/researchers by loosening the tight criteria of
informed consent that was included in its predecessor, the Nuremburg Code.136
The CIOMS: The Council for International Organizations of Medical Sciences
(CIOMS) is another example of the international nongovernmental organizations that
ultimately belong to the global civil society and play a significant role in Global
Governance for Health Research. Established jointly by WHO and UNESCO in 1949,
and located in Geneva, CIOMS is dedicated to the international biomedical scientific
affairs and coordination among the major role players in this area, e.g. UN, WHO, and
UNESCO.137
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One of the noteworthy features of the CIOM on the map of the existing situation of
Global Governance for Health Research is its being a civil society organization (in the
category of international non-governmental organizations) established by two major
intergovernmental organizations. CIOMS represents the global health-related scientific
community through having a large number or organizations among its members. In 2016,
13 international organizations, 12 national organizations (USA not being among them),
and 19 associate member organizations were among the members of CIOMS. 138
Therefore, CIOMS represent many scientific and biomedical professions and disciplines
in various countries.
One of four CIOM’s main long-term programs is the bioethics program. Through its
mission on bioethics, one of the CIOM’s functions has been developing and
promulgating ethical guidelines for health research. In 1993, CIOMS published its
influential guidelines titled International Ethical Guidelines for Biomedical Research
Involving Human Subjects. The last version of this guideline is published in 2002 and has
recently undergone a new round of revisions and the 2016 has been published under the
slightly modified title of the International Ethical Guidelines for Health-related Research
involving Humans.139 In addition, in 2008, CIOMS published the International Ethical
Guidelines for Epidemiological Studies. This guideline was published as a book with a
slightly modified title of International Ethical Guidelines on Epidemiological Studies in
2009. 140
These two documents (International Ethical Guidelines for Health-related Research
involving Humans and International Ethical Guidelines on Epidemiological Studies) are
substantial and well-known parts of the existing global soft law on health-related research
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ethics and shape the significant contribution of CIOMS in Global Governance for Health
Research. In shaping the soft law of Global Governance for Health Research, these two
documents are complementary additions to the WMA’s Declaration of Helsinki and The
UNESCO Universal Declaration of Bioethics and Human Rights.
3- For-profit organizations: For profit organizations are involved in the global
governance for biomedical research, mainly by funding the international research.141
Their supranational activities have raised ethical concerns regarding the vulnerable
populations,142 even some scandals have occurred. However, they have also contributed
to correcting the ethical flaws of their performance and developing ethical norms and
standards for their research activities. In this way, they have contributed in the global
governance for biomedical research and to the protecting of vulnerable human research
subjects.143
The ethical network for Global Governance for Research will not be successful,
unless the private sector regards ethics as a competitive privilege. The reputation of these
companies should be contingent to their observance for ethical standards. This shows the
important role of media in overseeing the role-players in the global research enterprise
and naming and shaming the ones who are not observant for ethical standards. Also, the
role of civil society in convincing people and states to ban and boycott non-ethical
corporations.
In sum, without active contribution of the private sector, this will be futile to
develop ethical standards for global research enterprise. And the private sector will
participate just when it finds this participation a competitive privilege in the market.
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iii. A Global Network
Organizations vs. Instruments: The existing map of the global governance for
health research can be portrayed based on a Network Model.144 As is briefly shown
above, no single organization has a monopoly on the realm of global health governance.
However, different kinds of national and international institutions take part in this
interconnected network throughout the world. As a matter of fact, the existing situation of
global governance for health research is the sum of all the involved role players who take
part in this network.
As mentioned above, although WHO has been considered the leading organization in
Global Health Governance, at least in the first decades after its foundation and as its
formal and constitutional role, its leadership in the areas of healthcare ethics and research
ethics has never been considered undisputable. Instead, other organizations such as
UNESCO and WMA has always challenged the leading role of WHO in this ethical
guidance of the health sector. In addition to the international organizations, bilateral
initiatives, philanthropies, and private sector have been among the role players that put
the leadership role of WHO in jeopardy.
When it comes to the health research, although WHO has created and adopted some
useful instruments such as guidelines and strategies, the most influential and well-known
instruments have been created and adopted by other organizations. The best examples of
such instruments are the World Medical Association Declaration of Helsinki and the
UNESCO Universal Declaration on Bioethics and Human Rights, both introduced in this
chapter.
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The role of philanthropic and for-profit role players in global governance for health
research is undeniable, as depicted above. However, none of them is, or can be, in the
leading position of global governance for research. They are parts of a bigger network
that should be guided by a larger and more consensual and global size, reach, and
identity. Among the governmental role players, the United States, being the single largest
funder and conductor of international research in the world, can take a constructive
leading role, however, cannot be the sole and unilateral leader of global governance for
health research.
Therefore, the major weakness in the current network of global governance for health
research is the lack of a capable and legitimate world leader in the form of a multilateral
international (not necessarily intergovernmental) organization. These is no international
organization established or considered to be the world leader for health research ethics.
Even WHO that once was supposed to lead the global health, neither proved capable to
establish a monopoly in this leading role, nor was supposed or considered to be the world
leader in the field of health research. In addition, although managing everything in
accordance with broad consensuses seems to be the most democratic way of managing
global affairs, there are some instances where more powerful or wealthy members of
international organizations decide to play unilateral roles.
It seems that the most prominent ways through which Global Governance for
Research is operated in the current world are the soft and hard domestic and international
laws. The history of international soft laws on health research started with the Nuremburg
Code just after the WWII.145 Afterwards, this primary code was replaced by more
comprehensive and realistic ones. Nowadays, the UNESCO Universal Declaration of
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Bioethics and Human Rights, the CIOM’s International Ethical Guidelines for Healthrelated Research involving Humans, and the WMA’s Declaration of Helsinki are two
complementary documents that play the most prominent role in this regard. In addition,
the domestic law of the countries that host the major funding bodies for international
research (USA and European Union) are impactful.
One important feature of these instruments is that they do not specify one or more
certain philosophies as the theoretical bases of their guidelines. Instead, they are
generally based on the common accepted norms and values that can be considered the
common heritage of mankind regardless of specific philosophical or religious traditions.
This feature should be preserved in any ethical framework that will be developed for
Global Governance for health Research.
These guidelines and legislations, in addition to providing a legislative basis for
Global Governance for Health Research, serve as the educational instruments and
resources both for training local experts (including members of Research Ethics
Committees and Institutional Review Boards) and for developing local guidelines. These
instruments are helpful resources for local experts in developing local legislations and
guidelines on health research because they provide them with a basis of globally accepted
and scholarly elaborated set of principles and guidelines that can be tailored and modified
based on their local needs and cultural sensitivities.
Therefore, in the absence of a single world organization in the leading status, guiding
the existing network by a set of principles (or a body of soft laws) can still be considered
a pragmatic (and more realistic) solution for the lack of authority in global governance
for health research. In other words, instead of a single organization, the global
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governance for health research can be realized and exerted by a set of globally consensual
principles and norms. The principles and norms that are accepted, adopted, promoted, and
safeguarded by various role players in a non-hierarchical network.
A Historical Precedent: The normative framework introduced by Emmanuel and
Grady is a noteworthy historical precedent for using the existing instruments for creating
a normative network for research. They argue that having a summative deduction from all
the existing main “myriad guidance’ is helpful because the extant guidance accumulated
in the shape of numerous instruments has some flaws, including:
1.many of these instruments have been the results of scandals and revelations that
shocked the community and led to creating some reactional guidelines that are not
helpfully and comprehensively applicable to all the research projects. For example, the
emphasis that the Nuremberg Code put on the absolute necessity of informed voluntary
consent, was a conscientious reaction to the revelation of the experiments done by Nazi
researchers on the restrained subjects without obtaining their consent. However, this
absolute demand for informed voluntary consent made it almost impossible to do
research on people with diminished autonomy, while they would benefit from such
research addressing their problems and needs. Therefore, this mandate subsequently was
modified by other guidelines. In the same way, the Belmont report was a reaction to the
revelation the Tuskegee Syphilis studies.146
2.Most of the extant instruments lack comprehensiveness. They have either created
for a more inclusive or a less comprehensive purpose, such as the UNESCO Declaration
of Bioethics and Human Rights or are most focused on procedural purposes, such as the
Common Law (45 CFR 46) in the USA, or are developed by just one of the involved
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parties, such as the Declaration of Helsinki. Although some of than have tried to be
complementary to their predecessors, still the lack of a comprehensive and global
research-specific framework is undeniable.147
3.In addition to not being comprehensive, none of the extant pile of guidelines is
systematic. Instead, they are “tend to be lists of claims or principles.”148 Providing a
systematic framework that covers all the phases and steps of research from design to
publication with guidelines that can be clearly interpreted, has been another argument
behind developing this framework for clinical research.149
Therefore, they developed a new framework for clinical research based on the
previous guidance. This framework encompasses 8 principles that cover all the phases of
clinical research from the very beginning to the end. In addition, each principle is detailed
by benchmarks that provide an explicit explanation and interpretation of each principle.
In other words, the benchmarks are practical clarifications of what is necessary to
actualize each principle. The principles included in this framework are a follow: (1)
Collaborative Partnership, (2) Social Value, (3) Scientific Validity, (4) Fair Participant
Selection, (5) Favorable Riske-Benefit Ratio, (6) Independent Review, (7) Informed
Consent, and (8) Respect for Participants.150
In sum, taking all the precedent instruments and framework-making efforts into
consideration, it seems that the next major step in Global Governance for Research
Ethics, will be developing a comprehensive, systematic, impartial, and cross-cultural
ethical framework.
The Crucial Role of Civil Society: In addition to the role of the civil society

organizations in Global Governance for Health Research, this is very important to note
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that civil society as an infrastructure is fundamental and essential for establishing valid
and reliable systems of governance and oversight for research, both at domestic and
global levels.
The main concern in development of the basic theories of civil society and research
ethics has simply been protecting the less powerful and less privileged in social – and
research – transactions.151 Having an organized and well-developed civil society is the
best way to protect and preserve the basic rights and freedoms of vulnerable social
groups. In the same manner, having well-established research ethics instruments and
institutions safeguards the rights, well-being, and interests of research subjects, and their
families, communities, and countries, as the less powerful parties in the related
negotiations and transactions.
As a though experiment for realizing the ethical norms and standards of research
ethics, imagining one’s self on the other side of the table of negotiations will help the
researchers to find the most ethical way to behave. This means that the researcher asks
herself: “what I would like/do if I was the research subject or the representative of their
community or country?” In almost all cases, the answer of this question is compatible
with ethical recommendations and requirements.
One of the most important factors in strengthening the ethical quality of research in a
sustainable manner is having professional bodies for researchers that develop, announce,
support, teach, promote, and enforce the ethical guidelines and regulations for
research152. Independent professional bodies are a main and major component of civil
society. In the absence of civil society, there will be no independent professional
organization. And in the absence of independent professional organizations, there will be
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no substitute for them to accomplish this important mission. Governmental bodies cannot
play this role. Up to down laws and regulations are of limited help in making research
practices more ethical because such regulations should emerge out of the consensus
among the professionals not as governmental commands or directions.
As a historical perspective, one can argue that in both developed and developing
countries, the strengthening of civil society and promoting research ethics follow
correlated and interdependent trends. These trends, however, are more complicated and
stumbling in developing countries.
In almost all countries hosting research enterprise, research ethics instruments and
institutions are thriving and flourishing.153 Many of these countries have compiled their
own research ethics instruments that are in concordance with global values and
standards.154 Developed countries help the developing countries that host collaborative
research trials to develop and strengthen their research ethics infrastructures.155
Some obstacles, however, have remained. The collective historical experience, shows
that just having well-written instruments is not sufficient for preventing violations of
ethical standards and basic rights of research subjects, especially the vulnerable
groups.156 The key factor in effective implementation of the values and requirements of
such instruments is the existence of independent and non-governmental bodies to do an
array of key functions from performing independent review and oversight to advocating
for vulnerable groups and research subjects. This is the main problem in some developing
countries in them the civil society infrastructures are not established and developed.
As a matter of fact, a strong disbelief toward the values of civil society and resistance
against development of independent and non-governmental institutions are the underlying
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causes of the lack of such institutions in the field of research ethics in many of
developing countries. As a result, the instruments, such as guidelines and even laws are
compiled and ratify and announced. In the absence of required civil society
infrastructures, however, they don’t become fully implemented and are not taken
seriously by the involved parties. For instance, in Iran, the research ethics committees are
always consisted of the high brass of the related organization and their members are the
principal investigators – or their bosses, subordinates, or close colleagues – that prevents
them to be effective and make serious barriers against unethical behaviors and abuse of
power.
The other main obstacle in developing countries is the lack or underdevelopment of
independent organizations including the professional bodies that make and represent the
consensus among researchers and the advocate bodies that represent the patients and
research subjects. Non-democratic governments do not tolerate independent civil society
organizations in their territories157. They try to give the ethical role of such professional
bodies to governmental ones. However, the governmental bodies, although possess power
and wealth, are not able to generate consensus and represent all the parties in the power
relations in the research enterprise. Therefore, in the absence of civil society and its
resulted independent professional and advocacy bodies, this is impossible to strengthen
the ethical quality of research in a sustainable manner.
Therefore, actual establishment and strengthening of research ethics institutions in
developing countries depend on prior strengthening of civil society in these countries.
Without taking this crucial step, and in the resulted absence of independent oversight,
relying on just creating new instruments and training efforts won’t do much in preserving
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and safeguarding the basic rights and well-being of research subjects that is what research
ethics is all about.
In sum, describing the global network - through and within which the Global
Governance for Health Research operates - won’t be complete without considering the
crucial role and importance of civil society. Civil society at both national and global
levels provide the infrastructures for implementation any sets of values, norms, and
principles. In the absence of civil society, it seems futile to talk about research ethics and
ethical governance for research at the institutional level. Therefore, this situation analysis
of Global Governance for Health Research entails the crucial role that has already played
by civil society organizations and the importance of civil society in the current and future
situation of this institution.
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Chapter Three - The Main Challenges and their Ethical Nature
In this chapter, the main challenges of Global Governance for Health Research are
presented and discussed. In addition, the ethical nature of these problems and/or their
underlying ethical causes and roots are evaluated and analyzed. Following the conceptual
and situation analyses provided in the previous chapters, shedding light to the main
challenges seems to be the next logical step before presenting an ethical framework that
will be depicted in the next chapters. For portraying a complete picture of the current
situation of the Global Governance for Health Research, complementary to the situation
analysis provided in the previous chapter, nothing is more illuminating than portraying its
main challenges. The global network for governing health research has developed and
took its current shape for solving the global challenges. On the other hand, the existence
of challenges at the global level necessitates the existence of such a network for dealing
with them. In other words, the frontiers and borders of Global Governance for Health
Research has constantly been formed and reformed by the process of encountering these
challenges over the past decades. This claim is true for and relevant to all other aspects of
Global Health Governance, too.158
The challenges that are identified, discussed, and analyzed in this chapter, are
mainly resulted from power relations between parties involved in research. Most of these
challenges arise when a powerful (wealthier and more informed) party conducts research
projects in/on a less powerful party (country, community, or individual) and this power
imbalance ends up to the formation of exploitative –or other kinds of ethically wrong –
transactions/relations. The challenges for Global Governance for Health Research,
however, are not limited to the relations between wealthier and poorer countries and
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communities. Even in the relations and transactions that take place among the highincome communities, the power imbalance resulted from the accumulation of
data/information at the researchers’ side causes problems with ethical nature that needs
the governance’s attention.
As a result of globalization in research enterprise, over the previous decades, the
number of health-related research projects and clinical trials conducted in the low and
middle-income countries (LMICs) has significantly increased .159 Although this can be
looked as a kind of scientific growth or transferring science and technology to the
LMICs, there are some facts and issues that raise ethical concerns. These ethical concerns
need the attention of both the national authorities and the global governance. These
ethical concerns include: (1) In some of these interventional studies and in some area in
which these studies are conducted, the potential participants are mostly poor and illiterate
and lack political power. (2) Due to the poverty of the participants and the weakness of
heath infrastructures in their communities and countries, this may be too difficult for
potential participants to get access to the modern and quality healthcare outside the
research settings .160 (3) Multinational pharmaceutical companies and research funding
institutions in high-income countries (HICs) sponsor most of these health-related research
projects .161 Their focus on their financial interest and competiveness in the market and
bearing the most possible amount of profit as the criteria of their success, may lead to
undermining ethical responsibilities and moral duties. (4) Many of these research projects
are designed in response to the health needs and priorities of the populations of the HICs
and the hosting populations in the LMICs won’t benefit from the ultimate results and
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products of the projects. Instead, the products will be produced and distributed and
purchased only in the HICs.162
The above ethical concerns that are the results of globalization, need global
attention. In other words, they need to be governed globally. In this chapter, the most
prominent forms in which the above-mentioned major ethical concerns are being
materialized in the contemporary world (on the global scene of the expanding enterprise
of international research) are discussed. Through this discussion, the following questions
are answered: (1) What are the characteristics and details of the main problems and
challenges confronting each aspect/sphere of governance in the Global Governance for
Health Research? (2) To what extent the main problems confronting the Global
Governance for Health Research are of ethical nature? (3) What are the ethical aspects or
elements involved in each of these challenges or helpful in finding their solutions? What
are the actual or potential roles of the role-players of global governance (e.g. scientific
community, professional organizations, and educational institutions) in creating or
solving these challenges?
In this chapter, the following challenges for global governance for health research
are recognized to be among the main challenges and depicted in a way that clearly shows
the ethical nature or background or elements of them: Exploitation and Helicopter
Research; the Problem of Double Standards; Ethical Imperialism and Colonialism;
Bilateralism vs. Multilateralism; Biopolitics vs. Bioethics; and the problems associated
with Data Sharing, Big Data, and International Collaborations.
Among the above challenges, the first four ones are mostly relevant to research
collaborations between developed and developing countries. The fifth one, however, is
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more relevant to the collaborations among developed countries, although it is can also be
relevant to the collaborations between developed and developing countries and even the
collaborations among developing countries.163
After analyzing the above-mentioned challenges, this chapter uses a model created
by Thomas Weiss, titled the “frameworks of gaps”, for further analyzing these challenges
in the context of the current theories of global governance. The elements of the above
challenges are categorized within a five-fold set of gaps that exist in the following arenas:
(1) Knowledge, (2) Norms, (3) Policies, (4) Institutions, and (5) Compliance.164 All these
gaps can be demonstrated in the theoretical and practical elements of the challenges
examined in this chapter. Applying the frameworks of gaps as theoretical tool sheds light
on different aspects and implications of these challenges, provides a comprehensive and
classified understanding of these challenges, and reveals that they should be discussed
and their solutions should be sought in the field of Global Governance for Health
Research.
At the final part, this chapter provides some conclusive remarks holding that one of
the main roots/causes of the existing problems and gaps is the absence of a
comprehensive, consensual, and democratically constructed ethical framework. The
existing frameworks are difficult to apply and have not been successful in overcoming
these challenges, partly because they are top-down.165 Developing a comprehensive,
consensual, and efficient ethical framework in one of the next major tasks/challenges of
the Global Governance for Health Research.
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i.

Exploitation and Helicopter Research

On Exploitation: Exploitation is one of the most important, central, and welldiscussed concepts in the field of biomedical research ethics. Although not included as a
distinct principle in the canonical set of principles of biomedical ethics, it has been
argued that the imperative of “minimize exploitation” has been one of the most
prominent (or even the only) moral rationales of these principles.166 This idea seems even
more plausible by looking at the formal birthplace of the modern sets of principles of
biomedical ethics that was the Belmont Report, that has been created in direct relation
with the biomedical research.167
Exploitation can be defined as “taking unfair advantage” of the subject of
exploitation. However, with this definition, the ambiguity persists, because this should
also be clear that which kinds of relations or transactions entail taking “unfair
advantage”. For clarifying this concept and introducing an unblemished definition,
Wertheimer developed a theoretical framework. Examining Wertheimer’s framework
show that it includes different theoretical aspects for recognizing and defining
exploitation in biomedical research. These aspects can be categorized as follow: (1)
essentials of exploitation, (2) differential diagnoses of exploitation, and (3) different
types of exploitation.168 In this part, Wertheimer’s framework in provided in more details
since this framework is best fitted and tailored for discussing the concept of exploitation
in the context of biomedical research ethics. The Kantian and Marxian concepts are also
briefly introduced and discussed (see below).
Essentials of Exploitation: First, the exploiter benefits from the relation or
transaction that entails exploitation. Without an exploiter-benefactor party, the

68

relation/transaction falls into other differential categories (see below). Second, the
exploitation is mainly about the unfair results rather than defective/unfair processes (e.g.
in an exploitative research project, even if the subjects –for any reasons – had given their
informed consent, the research project was still exploitative). In other words, regardless
of the process and methodology, if unfair advantage is taken, exploitation occurred.
Third, being unfair is an essential element of an exploitative transaction, however it is
difficult to define “unfairness”. A proposed definition is that a transaction is unfair when
a party gains more (exploiter) or less (exploitee) than what that party would have gained
in a competitive market.169 In addition, it can be argued that for some transactions, no
competitive and fair market can be theoretically imagined. Transactions that are in
contrary with human dignity, such as selling organ parts or slavery, are exploitative in
nature and such transactions/relations do not have any imaginable counterparts in a fair
and competitive market. In other words, the existence of a market for such transactions is
equal to exploitation. the Kantian notion is more helpful for differentiation the
transactions for them no market is ethically considerable.170
There are other well-known notions of exploitation that imply almost the similar set
of necessities. According to the Kantian notion, exploitation occurs when a person (or a
group of persons) is treated only as a mean. The verb “only” is very important in this
definition, because in many ways where humans are treated both as means and as ends,
no exploitation exists. In the account provided by Marx, however, exploitation occurs
when a person (or a group or persons) does not receive the total and fair worth of their
labor. Both the Kantian and Marxist accounts shed light to the concept of exploitation.171
When it comes to clinical research, they add some significant and useful points to the
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account formulated by Wertheimer. Especially the Kantian notion is very illuminating in
recognizing the transactions that are exploitative in nature, regardless of their imaginative
occurrence in a free market.
On the other hand, there are elements that are not essential to exploitation. One of
these elements is vulnerability. Vulnerability is neither essential nor sufficient to prove
that exploitation has occurred. For example, if a researcher recruits a patient for a
research on a new chemotherapy for cancer patients who are untreatable by the current
treatments, and the patient is desperate and vulnerable because there is no other option
available to deal with the cancer, no exploitation has occurred as long as the process of
recruiting is standard and entail obtaining voluntary informed consent and observing the
rights of the subject. As another example in which vulnerability is not a necessary
condition for vulnerability, if an employer hires a vulnerable person with reasonable
salary and with observance of all laws and rights of the employee, one cannot argue that
the employee is exploited because of her vulnerability and having no other choice to
make a living.
This is very important to note that although vulnerability is not an essential
condition for exploitation, most of exploitative transactions or relations, including in the
realm of health research, occur in the context of vulnerability. For example, the most
important cases that raised the issue of exploitation in international research in the past
decades were about enrolling pregnant women, as vulnerable people, to the HIVprevention trials in Africa.172
Unequal benefits also cannot be considered essential for exploitation. For example,
in the case of surgery, the doctor receives some (unfair amount of) money, and the patient
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will have her life saved, therefore, the patient has received more and at the same time has
been exploited. In addition, legal age or even legal status have not been criteria to limit
the attribution of exploitation. For example, even using human embryos for research has
been accused of exploitation, since the human embryos (who lack ethical status, at least
according to the mainstream secular ethics) are being exploited. These accusations have
mainly based on the Kantian concept of exploitation.173
One of the issues that looks more relevant to international research is differentiating
between “unfair backgrounds that leads to a transaction” and “unfairness of the
transaction regardless of the backgrounds.” The latter always entails exploitation. The
former, however, at least in some cases, may not entail exploitation. For example, when a
company plans to conduct a research project in a poor country, in which the potential
research subjects live under unjust and unfair conditions of poverty and diminished
access to education and healthcare, this does not sound reasonable to argue that recruiting
a group of this people for research necessarily entails some degrees of exploitation.
Instead, what determines that exploitation has occurred or not, is the fairness of the
transaction (the terms and conditions under which they are recruited for the research
project, including the potential benefits for their community), itself. There is no need to
explanation that the relevance between the unfair backgrounds and exploitation is
stronger in the Marxian account.174 The duties of researchers toward the host community,
especially when the research is conducted in developing countries or poorer communities,
has always been a subject of debates. Whether the “local conditions’ can be influential in
shaping these duties largely depends on the theoretical framework that defines
exploitation (see below).175
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Differential Diagnoses of Exploitation: One of the essentials of exploitation, as
explained above, is that the exploiter benefits from the exploitative transaction or
relation. By taking this essential into consideration, exploitation can be differentiated
from discrimination, paternalism, and neglect. In all these types of usually unethical
behaviors, there is no exploiter who “benefits” from the relation or transaction, therefore,
none of them falls under the title of exploitation.
In discrimination, a person is deprived from a specific right or benefit because of a
non-relevant characteristic (e.g. not enrolling black or Jew or Muslim students in public
schools); in denial, a person is not provided with something that she entitles to (e.g. not
giving the prize to a person who really won it); and in paternalism one tries to benefit
somebody by overriding her autonomy (e.g. forcing people to vaccinate their children or
forcing a woman to keep her pregnancy against her wish). In these types of behavior, one
essential component of exploitation is missing: the benefit to the exploiter. This is one of
the important features that relying solely on the Kantian notion might overlook.176
Discrimination and denial are almost always unethical, while paternalism can occur
in both ethical and unethical forms. Many interventions in public health entail degrees of
justified and ethical paternalism.177 For example, forcing people to fasten their seat belts
while driving or avoid driving under the influence of alcohol or drugs are examples of
justified paternalism, while forcing a competent patient to enter a research study as a
participant (that is believed to be beneficial for his health) without obtaining his informed
consent is an example of unethical paternalism.
Types of Exploitation: The exploitation can be mutually beneficial or include
harming one or more parties of the relation/transaction (harmful exploitation vs. mutually
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advantageous exploitation). Also, the exploitation can be mutually consensual or include
coercion, deception, or incompetence (consensual exploitation vs. nonconsensual
exploitation). For example, when a surgeon demands and receives an unfair amount of
money of a necessary and beneficial surgery, a mutually advantageous (the surgeon takes
money and the patient receives the treatment he needs) and consensual exploitation has
occurred. Combinations of these types exist, for example in the case of unfair fee for
surgery, a mutually advantageous and beneficial exploitation has occurred, because both
parties have bene benefited and consented to the transaction ad interaction, and one party,
i.e. the surgeon, has taken unfair advantage from another party (the patient). In the case
of Nazi experiments, harmful nonconsensual exploitation was in case because the
research subjects neither consented nor benefited from the practice.178
It is not always an easy task to differentiate a mutually advantageous exploitation
from a harmful one. For example, in the cases of selling kidney for transplantation, the
seller of the organ is harmed because of the surgery and losing an organ; at the same time
and transaction, he is benefited because of the monetary reimbursement he has received.
In this case, although the transaction is exploitative (unfair advantage is taken from the
organ seller), he has had a net benefit (otherwise, he would not give consent to this
operation), therefore, this transaction can be categorized as a mutually advantageous
exploitation.179 As another example, in commercial surrogate motherhood is an example
of exploitative transactions, this seems to be difficult to tell whether the surrogate mother
is benefited or harmed from the transactions. The problem worsens when the surrogate
woman has no actual control on the money she gained through this transaction and the
benefits are controlled by his husband.180
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In addition, the analysis should be ex ante (before) rather than ex post (after) the
transaction. For example, in the case of kidney selling, since at the beginning of the
transaction there was a reasonable likelihood that the kidney will be beneficial and work
for the receiver, even if it won’t work (e.g. the immune system of the receiver rejects the
transplanted kidney) one cannot argue that the seller had exploited the receiver.
Examining validity of consent is not always an easy task. A valid consent should be
free of coercion and undue inducement. These two terms “coercion” and “undue
inducement” are very crucial terms in research ethics literature and have always been
subjects of confusion and misunderstanding. Therefore, it seems reasonable to provide a
clear definition of them. Coercion occurs when a person threatens another person that if
she makes or does not make one or more certain choices, her rights will be violated. This
is different from the cases in which the person has no choice other than accepting a
certain option. For example, a patient who has just two potions: either accept a surgery or
die from the illness, can still give a valid consent to that surgery. Undue inducement, on
the other hand, occurs when an offer is too seductive in a way that twists the person’s
ability to make a sensible choice. An example for undue inducement is offering a large
reimbursement for participation of children in a research in a poor community that may
lead to the parents entering their children to the research project, while otherwise they did
not.181
Ethical Grounds for Intervention: Exploitation is unethical. However, knowing that
exploitation is ethically wrong is not enough to answer this question that when (or
whether) a government – or governance - should intervene to prevent an exploitative
transaction to takes place? In other words, if the predictable consequence of the actual
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preventing a mutually advantageous and consensual exploitative transaction is that the
potential exploiter leaves the transaction (and does not give an alternative fair proposal)
and the potential exploitee loses the beneficial option provided by the exploitative
transaction (and remain without any other fair or better option), does the governance still
have a moral duty to prevent this ethically wrong transaction? For exploring this issue in
the field of Global Governance for Health Research, the next part of this article provides
a real-world example that has been considered as one of the most noticeable instances of
exploitative transactions and most prominent challenges of Global Governance for Health
Research in the past few decades.182
Helicopter Research: Helicopter medical research entails that “researchers from
HIC institutions flying into a LMIC, taking patient specimens and date, and flying out
without providing any benefit to the host community .”183 Helicopter research typically
entails exploitation. All the above-mentioned theoretical accounts of exploitation (the
ones of Kant, Marx, and Wertheimer) fit with this kind of research.
The significant increase in the number and size of research projects, including
clinical trials, conducted in the LMICs in the past decades made the issue of exploiting
the local vulnerable populations very considered and debated. It has been claimed that the
lower ethical obligations in addition to lower costs of recruiting research subjects and
keeping them in research projects have been the main drives of the pharmaceutical
companies and other research bodies to conduct many of their clinical trials in the
LMICs.184
This has also been argued that these research projects are not aimed to respond to
the health needs of the hosting countries, even are not aimed to benefit them by its
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potential results and products, because these products are too expensive to be purchased
and used by the local patients or their countries’ health sectors. The so-called 10/90 gap is
another explanation of this problem .185 It has been internationally noticed and recognized
that only a small proportion of global spending on biomedical research addresses the
major health problems and needs of large vulnerable, marginalized, and disadvantaged
populations . 186
A part of the following chapter of this dissertation, titled “HIV/AIDS Research in
Africa” encompass good examples of helicopter research. In this part, however, a more
abstract example of helicopter research (using the historical models of HIV/AIDS
research) is discussed to show how the theoretical elements of exploitation math these
research projects. The overall line of argument is as follow:
1- Helicopter Research entails exploitation and can be substituted with nonexploitative research.
2- Exploitation is ethically wrong and if it can be substituted with better options
for the subjects, it should be stopped by the responsible governance.
3- The Global Governance for Health Research should stop helicopter research at
the global level.
A paradigm case of helicopter research proceeds as described below. This paradigm
case is delineated by a title and center text because the next parts of this chapter (the
problem of double standards) also contain references to this case:
A Paradigm Case
1- Researchers from country A that is a HIC go to country B that is a LMCI to
conduct a clinical trial that entails examining an experimental medication (or a
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medication for a new experimental use or in a new experimental dose) on a group of
patients.
2- The researchers deign and practically follow a research protocol in which the
rights of the participants are not considered and observed in the extent that is required by
law and regulations and standards for potential research participants in domestic research
in country A (in terms of risk/benefit analysis, access to ancillary healthcare, respect for
research participants, etc.)
3- The researchers argue that they have modified the risks for or benefits to the
participants from country B because of local conditions in which they live. For example,
they did not provide them with certain types of necessary clinical care that they would
provide in research projects in country B, because these types of clinical care are not
normally accessible for people in country B. Or they paid less to the research participants
from country B. Or they used/examined a sub-optimum experimental dose of the
experimental medication, only because to find a less expensive dosage of an alreadyproven effective medication.
4- If the medication they use/examine prove to be effective, using this medication
will not be affordable for the people of country A (or even the research participants in the
control group of the trial) and will mainly be marketed and used in country A and
countries at the same level of income as country A.
Base on the elements of exploitation explained above, this paradigm case entails
exploitation, because: (1) at the smaller scale, the researchers from country A take unfair
advantage from their research participants and their host community on Country B. (2) At
the larger scale, this paradigm case entails taking unfair advantage from the hosting

77

community and country by the researchers and the ultimate benefactors of the research,
including the pharmaceutical company and country A.
As described above, the responsibility of governance to act to stop exploitation has
been conditioned, at least by some philosophers, to having an available substitute for
exploitative transaction available to the exploitees. In other words, although exploitation
is ethically wrong, if the exploitative transaction is the only beneficial option for the
exploitees, this is ethically wrong for governance to stop it. This premise can be subject
of criticism, however, in the case of helicopter research, there is no need to discuss this
condition, since helicopter research can be replaced by better options if the governance,
including local governments, require the research enterprise to comply with ethical
standards and avoid exploitation. For example, providing standard healthcare to the
research participants or providing the medications, if they trial prove them to be effective,
for a certain amount of time to the hosting communities with affordable prices can be
included in the binding regulations at both domestic and global levels. The recent
additions to the Declaration of Helsinki reflects these considerations.187
Global Governance for Health Research has two general ways to deal with
helicopter research: First, through international legislations; second, through domestic
capacity-building.
1- International Legislation: As described in Chapters 1 and 2, one of the most
important instruments available to Global Governance for Health Research is
international legislation. International soft and hard law makes and promotes ethical
standards for global health research enterprise. Although in the first international codes
on research ethics, such as the Nuremburg Code, the issue if international research was

78

missing, in the following decades, especially in the 1980s and 1990s when the
international research enterprise blossomed and its ethical issues received international
attention, the very issue of international research found its way into international
discourse.188 Consequently, the international soft law adopted new additions dealing with
international research aimed at preventing exploitation in the form of helicopter
research.189
2- Domestic Capacity-Building: The most important agents that have to be aware
of the rights of research participants and hosting communities and protect and preserve
them in the negotiations with the research enterprise are the health authorities and
officials of the hosting countries, specially their research policy-makers, and research
ethics committees. In other words, the hosting communities need well-established
research review and oversight bodies that have the essential knowledge, skills, and
capacity for protecting the rights of local research participants and communities. In the
absence of such review and oversight bodies, the international guidelines cannot be
implemented and efficiently used to protect the basic rights of the vulnerable subjects and
communities. Therefore, one of the major tasks of Global Governance for Health
Research is capacity-building in the countries/communities that host the vulnerable
people who have been exploited for research purposes.190
The last version of the CIOM’s International Ethical Guidelines for Health-related
Research Involving Humans explicitly asserts:
“Health-related research often requires international collaboration and some
communities lack the capacity to assess or ensure the scientific quality or ethical
acceptability of health-related research proposed or carried out in their jurisdictions.
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Researchers and sponsors who plan to conduct research in these communities should
contribute to capacity-building for research and review. Capacity-building may include,
but is not limited to, the following activities: research infrastructure building and
strengthening research capacity; strengthening research ethics review and oversight
capacity in host communities […]; developing technologies appropriate to health care
and health-related research; educating research and health-care personnel and making
arrangements to avoid undue displacement of health care personnel; engaging with the
community from which research participants will be […]; arranging for joint publication
consistent with recognized authorship requirements and data sharing […]; and preparing
a benefit-sharing agreement to distribute eventual economic gains from the research.”191
In the clinical trials conducted in the LMICs there have been many instances of not
observing the rights and freedoms of research subjects as asserted in the related laws,
regulations, and guidelines. Also, the ethical roots of this problem are common with the
problem of helicopter research, however this problem can be discussed more under the
title of the next part of this paper: the problem of double standards.
ii.

The Problem of Double Standards

Most of the HICs have a recent history of adopting strict regulations and
establishing efficient organizations to protect the basic rights and fundamental freedoms
of their citizens, especially the vulnerable groups, when they are recruited as research
participants. However, it has always been claimed that in dealing with people of other
countries, the powerful parties who are from the HICs (who observe all these rights and
freedoms inside their national borders and for their own people) are less willing and
driven to observe the same profile of rights and freedoms in other countries. This claim
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shapes the problem of double standards in a large scale. Part of this problem has showed
itself in the research enterprise and international research activities, that is the subject of
this part of this dissertation. 192
The main question is that if the researchers are ethically obliged to observe the
same ethical standards when they are dealing with different people with different cultural
and geographical contexts and situations? The proponents of “Uniform Care
Requirement” have a positive answer for this question. They argue that in the absence of
uniform care requirements and if decision-making on the quantity and quality of care is
left to the individual agreements between involved parties, then the policy-makers and
other research counterparts in LMIC may overlook the rights and benefits of the
vulnerable potential research participants.
On the other hand, the proponents of a negative answer to the above question argue
that insisting on the uniform care requirements may deprive LMICs from the research
projects that otherwise could be carried out and benefit the local patients and
communities.193 For example, in some infamous examples researchers gave placebo to
the control arm of their clinical trial while the life-saving treatment did exist in the HICs.
Their justification was that in the hosting country that treatment was not available for the
patients because of the high costs. Therefore, if their subjects did not participate in the
research project, they would not have access to that treatment in contrast to the similar
patients in the HICs. Therefore, that treatment is not considered “the standard treatment”
given the special satiation of their research subjects and there are not ethically obliged to
provide that for their control group.194
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Others, however, have commented against the above claim, arguing that the
researchers are ethically obliged to have a single definition of “standard treatment”
especially when it comes to the vital and life-saving treatments. As described below, the
global principles set by UNESCO supports this perspective .195 This perspective is rooted
in the principles such as justice and equity. These principles imply that all the people are
entitled to the same basic rights and it is ethically unjustified to deprive people from lifesaving treatments based on their place of birth or living or their socio-economic status.196
Therefore, they have to provide the standard treatment based on the standards of their
original HIC rather than the realities of their host countries.
In the paradigm case described above (under the title of Helicopter Research) this
part is related to the problem of double standards: “The researchers argue that they have
modified the risks for or benefits to the participants from country B because of local
conditions in which they live.” In other words, when the researchers have two (or more)
different sets of standards (in terms of the rights of participants and their relatives and
their hosting communities) for their research subjects based on the conditions they live in,
the problem of double standards arises. The cases of double standards may include or not
include exploitation.
Having double standards is ethically wrong because it violates the principles of
justice in the canonical Western set of biomedical ethics. In addition, having double
standards is a violation to the ethical principles promulgated in the broader and wore
global set of principles introduced by the UNESCO Declaration of Bioethics and Human
Rights such as equity, human dignity, and solidarity. 197
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Whether the governance, including Global Governance for Health Research, should
get involved to stop practices that entail double standards, follow the same reasoning as
explained for exploitation above. When the practice that entailed double standard can be
replaced by another practice that is more beneficial for the research subjects and their
communities (the weaker party of the power relation) the governance has aa duty to act
against practicing based on double standards. Therefore, in the cases that are similar to
the paradigm case described above, this line of reasoning can be applied:
1- These cases entail practicing based on double standards and can be replaced by
practices that do not entail double standards and are more beneficial for the research
subjects and their hosting communities.
2- Practicing based on double standards is wrong and when can be replaced by
practices that do not entail double standards and are more beneficial for the research
subjects and their hosting communities, the governance should act to stop it.
3- The Global Governance for Health Research should act to stop the cases that
match with the main characteristics of the paradigm case (entail double standards).
The necessity of avoiding double standards had been implicitly or explicitly
included in the international soft law for Global Governance for Health Research,
including The WMA’s Declaration of Helsinki and the CIOMS International Ethical
Guidelines. Although the term “ethical standards” has not been defined in the relevant
literature and can be considered a part of common knowledge.198
Avoiding double standards does not imply ignoring all the contextual necessities
and requirements of designing and conducting research projects. The standards that are
part of unalienable rights of research participants should be uniformly observed, while
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the technical adjustments should be considered based on local contexts. For
differentiating the universal ethical standards from technical and contextual requirements,
the US National Bioethics Advisory Committee (NBAC) has provided a useful
classification that is explained below.
Substantive vs. Procedural ethical requirements: For differentiating between the
global standards that are essential to preserving the rights of research participants and the
standards that can be subjects of cultural variations (in attempt to avoiding ethical
imperialism), the classification provided by the US National Bioethics Advisory
Committee can be helpful. The 2000 report of this committee classifies the ethical
requirements in international research into the substantive and procedural categories.199
The substantive ethical requirements entail fundamental ethical principles that are derived
from and are necessary to observe the main ethical principles of the Belmont Report:
respect for persons, beneficence, and justice. These requirements are global ethical
standards that should be observed globally and are not subjects of cultural variation or
interpretation. However, the procedural requirements are the ones that depend on the
local circumstances and are not essential to preserving fundamental human rights and
freedoms. For example, obtaining informed and voluntary consent from each competent
subject of a research is a substantive requirement and should be considered a global
standard. However, in the communities with hierarchical orders, such as tribes, obtaining
a separate collective consent from the local authorities in addition to the individual
consents does not violate the ethical standards and can be considered a procedural
requirement rooted in the cultural necessities.200
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In conclusion, the problem of double standards in the field of health research is
translated into having double standards of care, double standards for human rights and
human dignity, and even double accounts for defining the “standard treatment”. This
problem is of a strong ethical nature and having such double standards, as mentioned
above in this part, entails obvious violation of the ethical principles of justice, equity,
human dignity, and solidarity.
Although having double standards is ethically wrong, adopting sets of universal
standards has also been criticized. The critiques argue that the standards and values vary
based on the cultural contexts, therefore, adopting or formulating universal standards is
nothing but imposing the values and standards of a culture to the others. In a surprising
way, two conflicting arguments, one in favor of adopting universal standards and the
other one in favor of adopting local and contextual standards, both have presented to
preserve the rights of vulnerable research subjects and their communities. The latter
argument is explained in more details in the following part of this chapter that deals with
the claims of ethical imperialism and colonialism.
iii.

Ethical Imperialism and Colonialism

The terms "imperialism" and "colonialism” have been used in order to describe a
country’s superiority, domination and influence upon other countries or societies.201 In
the contemporary literature, these words have negative connotations and are usually
being used for criticizing the influence of powerful countries on the less wealthy and less
powerful societies.
On Colonialism: Colonialism refers to a practice in a certain historical period in
which newly-modernized European powers expanded their dominance to the continents,
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countries, and communities is Africa, America, and Asia that were less developed.
Settlers from the powerful countries formed colonies in the newly “discovered” lands and
acquired political power and military dominance. They usually exploited the natural and
human resources of host communities and at the same time, exported their cultural norms
and ways of life, along with different features of modern civilization such as modern
governments, judiciary systems, press, parties, and technical advances such as modern
architecture and transportation to the host countries. In addition, a generation of nstive
people acquired modern education (by traveling to the colonizing countries or by
enrolling in the educational institutions established in the colonized countries) and
imported and presented these new and modern ideas and lifestyles into the traditional
communities. These developments have always been shocking and confusing for the host
communities. Conflicts occurred as a result of the clash of values, traditions, lifestyles,
and perspectives and a strong sense of being exploited, dominated, and humiliated
conveyed to the colonized communities. The relations between colonizing powers and
local people were not based on respect and equality.202 Many other countries and
communities were not formally colonized (e.g. Iran), however, the same effects of
confrontation with modern powers occurred within their traditional social institutions and
changed almost all the aspects and trends of their collective lives.
Because of the injustice that was generated (or the sense of injustice that was
induced) by colonialism, resistances arose in the colonized communities and after years
of mostly bloody and violent battles and revolutions, over the last decades of the
nineteenth century and the first decades of the twentieth century, all the colonized
countries gradually became independent. However, with some exceptions (such as the
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United States of America), their conflicting dependence to the former colonizing powers
did not disappear, but remained in two major forms. These two major forms shape the
characteristics of the post-colonialism era: (1) the new cultural norms and ways of life
imported, imposed, and promoted by the colonizing powers attracted layers of local
people, especially the elites and people who were educated from Western or Westernstyle universities. The contrast of the values, norms, and practices of these modern
lifestyles fell in contract with traditional beliefs, values, norms, and standards and in
some cases these contrasts led to violent confrontations with local authorities and people.
(2) the economic and industrial infrastructures of newly independent countries have
remained largely dependent to the colonizing countries. Modern developments such as
modern educational systems, healthcare systems, industries, and enterprises along with
governmental and civil society institutions such as modern judiciary systems,
parliaments, and political parties, although significantly improved the life conditions of
local people, led to a variety of conditions such as unplanned population growth and
urbanization that became major sources of internal instability and dependency to the
former colonizing powers.
The moral analysis of colonialism, itself, is a challenging task. Although nowadays,
almost nobody justifies colonialism as an acceptable or suggestable practice, assessing
this phenomenon in the context in which it occurred, shows that colonialism, along with
numerous unwanted effects on the colonized countries, had some positive consequences
for them such as modernization and improvements is various areas such as health,
industry, and agriculture. In addition, this is not right to judge a historical practice by
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today’s standards. The moral analysis of colonialism, however, is beyond the scope of
this chapter.
The history of colonialism is intertwined with a rise and expansion in the activities
of Christian missionaries. New transportation means and geographical discoveries opened
the doors of the Christian Europe to the vast lands and large populations in other
continents that were not Christians. Christian missionaries had two major effects in their
hosting communities. First, the positive effect that was their promoting humane values
such as unconditional love and charity. Unforgettable figures such as Albert Schweitzer
and Mother Teresa are examples of this effect. Second, the negative sense of threatening
local values, traditions, and lifestyles by imposing the new religion. Cases of violent
forcing local people to convert to Christianity or exploiting Christian teachings for
devaluing local people or traditions (such as what occurred by Spanish conquers in Latin
America) were examples of this kind of effect. Ethical colonialism in the form of
promoting Western-Christian values without respect and consideration for local cultures
and values entails a reminder to the latter negative effects of Christian missionaries in the
former colonized communities.
Ethical colonialism, that means imposing the moral standards and values of
previously colonizing countries to the previously colonized societies, is a concept that has
been used for criticizing the transfer and promulgation of Western ethical values and
standards – including the bioethical ones – in the LMICs. This term implies the negative
account of colonialism that entails ignoring the local and traditional values, standards,
and lifestyles of non-Western countries and undermining their cultural and moral heritage
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and imposing alien and conflicting values that are considered superior to the local ones
without any justification.
On Imperialism The term “imperialism” has mainly been used in the left and
revolutionary discourse throughout the twentieth century. Vladimir Lenin (1870-1924)
considered it as the highest and last stage of capitalism.203 Although the revolutionary
forecasts of the Marxist-Leninist doctrine concerning Capitalism and Imperialism proved
wrong (and practically harmful), this word did not disappear from the global discourse. It
remained as a way of formulating and expressing suspicion and mistrust on the power
relations between the wealthy and powerful countries and the poor ones. When it comes
to ethical standards, this word is obviously revitalized and viral .204
Ethical imperialism is defined as “imposing the ethical values and practices of the
West on communities for whom these values were foreign.”205 In the fields of bioethics
and biomedical research ethics, these debates have been serious .206 The endeavors aimed
to advocating and teaching the ethical principles as were developed and formulated and
expressed by Western scholars and organizations, have been subject of this kind of
criticism, a clear example being the NIH’s initiative for training health research ethics
experts in the LMICs.207
Colonialism and Imperialism in Research Ethics: The terms colonialism and
imperialism, although different in meanings and implications, have been used with
similar connotations and intentions in the discourse of Global Governance for Health
Research. As explained above, they both have been used to criticize the efforts aimed at
importing and promulgating Western-born standards and values of research ethics to and
within the developing non-Western countries and societies. For example, this has been
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argued that the mandate of obtaining informed voluntary consent from the competent
research participants is a standard that belongs to the individualistic Western societies
and may not be applicable to many of Eastern communities in them such decisions are
not made by individuals but are made by the families or tribes or the heads of families or
tribes. This has been argued that the different notion of “person” in non-Western
communities necessitated different notions and practices regarding obtaining informed
consent.208
This kind of arguments that attribute norms such as voluntary informed consent to
the values of Western aliens, in some cases, have also been appealed by local authorities
to deprive their subordinates and local vulnerable population from their basic rights and
freedoms guaranteed by so-called Western bioethical standards and values. The main
challenge is differentiating the values and standards that are really cultural-dependent and
belong to Western cultures and ways of life from the values and standards that belong to
the humanity as a whole and cannot and should not be considered as belonging to a
specific geographical or cultural area or tradition. These values and standards are, as a
matter of fact, the common heritage of mankind regardless of their geographical or
cultural origins or denominations.
Common Heritage of Mankind: The concept of ethical imperialism is mainly
related to the issue of cultural diversity. Respect for cultural diversity is an inalienable
part of biomedical research ethics. It is one of the global principles of bioethics set by the
UNESCO.209 However, there are moral standards and principles that cannot be simply
considered as Western or Christian. Instead, a certain group of principles as delineated by
universal declarations and conventions, are supranational and their legitimacy is beyond
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specific cultural or philosophical traditions, but the belong to all the humanity and can be
called the common heritage of mankind.210 The principles delineated in the UN Universal
Declaration of Human Rights and UNESCO Declaration of Bioethics and Human Rights
can be considered common heritage of mankind. Therefore, the implications of the
principle of respect for diversity can be divided into two main and ethically different
categories:
1-

The cultural practices and behaviors that violate the fundamental human

rights and freedoms, such as not allowing women to take informed decisions on their own
participation in a research or taking collective informed consent from the local authorities
without taking informed and voluntarily consent from each of the human subjects of
research. Respect for cultural diversity never justifies these kinds of practice. As a matter
of fact, human rights, as a significant part of intellectual common heritage of mankind,
are ethically superior to culture-specific local norms and standards .211
This is not a sort of ethical imperialism or colonialism because the principles of the
Universal Declaration of Human Rights do not belong just to the West. They are the
common heritage of the mankind .212 Violating the rights of vulnerable groups under the
title of cultural diversity and accusing the opponents to advocating ethical imperialism is
an unacceptable practice and it has explicitly asserted in the UNESCO Universal
Declaration of Bioethics and human Rights that no principle of this instrument should be
interpreted in a way that violates human basic rights and fundamental freedoms. 213 The
United Nations as an international organization and its affiliated organizations, such as
WHO, are in charge of protecting the vulnerable groups by strictly observing the
principles of human rights and freedoms .214
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2- the cultural practices and norms that do not contradict the principles of basic
rights and fundamental freedoms: This part of local cultures is to be observed according
to the principle of respect for cultural diversity. As an example related to research, the
researchers can take the agreement and permit of the local authorities such as the chief of
the tribe in addition to taking informed voluntary consent from each of their potential
research subjects.215
According to the above discussion, ethical imperialism, as another challenge for
global governance for health research, entails obvious ethical components. Both the
proponents and opponents of this theoretical criticism, appeal to ethical reasoning to
support their side of discussion. Although this criticism entails some real and noteworthy
ethical concerns, it should not be allowed to be misused by the violators of human rights
and by local authorities who want to safeguard their illegitimate power over the rights of
their subjects.
When it comes to health research, this debate shows itself in some areas, one of the
most important of them being the process of obtaining informed consent. The right of
giving individual voluntary and informed consent is an inviolable right of every research
subject in clinical trials and taking collective consents from the local authorities (e.g.
head of tribe or governor of the county) does not override the right of each individual
subject.216
Therefore, adhering to global ethical standards for health research in the research
carried out in developing countries and within local communities is an ethical mandate.
At the first look, this can look like ethical imperialism. However, in the absence of
universal standards, each local power and authority can set its own standards, appealing
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to the local culture and values, in a way that violate the rights and freedoms of vulnerable
populations and benefit a part of the community that is intended by that power or
authority.217
The projects conducted by HICs for capacity-building in LMICs in the fields of
research review and oversight, have been criticized to be aimed for promoting Western
values and standards and imposing them to the local and host communities.
iv.

Bilateralism vs. Multilateralism

International Organizations (IOs) such as the WHO have been established based on
the concept of multilaterality.218 Acting based on consensus among state members
guarantees the democratic nature of such organizations. These IOs are also responsible
for observing the ethical principles of global bioethics in their instruments and
interventions. In recent years, however, some major and powerful players in global health
governance have launched bilateral programs. One of the most prominent examples of
such bilateral programs is the US Government’s Global Health Initiative (previously the
President’s Emergency Plan for AIDS Relief or PEPFAR) .219 These bilateral programs,
although being so fruitful in fighting serious pandemics like HIV/AIDS, have allegedly
weakened the multilateral role players and in the case of global health governance, the
threat was mostly pointed to the WHO .220
As described above the monetary helps of wealthier nations usually come with their
own price tags, least of them being the power granted to the wealthier and more powerful
countries to govern health affairs – and use the gained influence in other political mattersin developing countries, which need and receive these helps. Having financial control in
bilateral relations with other countries makes it possible for richer and more powerful
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countries to play their own role in global health governance. In some cases, the impact of
trade agreements worsens this power imbalance. Avoiding the possible abuse of this
power in political affairs is another reason behind the existing need to move toward more
multilateralism.221 Multilateralism in global health governance make it possible to make
sure that the values of solidarity and benefit sharing (rather than political agendas of
powerful countries) rule in managing global health affairs and in practicing global health
governance.
Some examples of multilateral programs/institutions are as follow: (1) WHO (that is
supposed to assume the leading role), (2) World Bank (in recent decades became a major
role player in funding health-related programs), and (3) The Joint United Nations
Program on HIV/AIDS (UNAIDS). UNAIDS, itself, is cosponsored by several
international/multilateral organizations. Taking a look at the list of these organizations
reveals the very multilateral nature of this program. These cosponsoring organizations are
as follow: (1) United Nations Children’s Fund (UNICEF), (2) World Food Program
(WFP), (3) United Nations Development Program (UNDP), (4) United Nations
Population Fund (UNFPA), (5) UNESCO, (6) WHO, (7) World Bank, (8) United Nations
Office on Drugs and Crimes (UNODC), and (9) International Labor Organization (ILO).
Bilateral programs, however, are formed and conducted by an agreement between a
powerful/wealthy nation state and a country or a group of countries in need. When it
comes to HIV/AIDS the most influential bilateral program has been the US
Government’s Global Health Initiative (previously the President’s Emergency Plan for
AIDS Relief or PEPFAR).
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As mentioned above, bilateral programs, although sometimes successful and
efficient, potentially weaken the role of IOs, in this case WHO, in leading international
efforts against pandemics and other heath crises. This weakening may also become
extended to ethical principles and norms of global bioethics, which guaranties pluralism
as the source of trust and ethical infrastructure for global health interventions. Therefore,
there is a need to a comprehensive ethical analysis of bilateralism and its benefits vs.
risks for global governance for health. In a comprehensive ethical framework for global
governance for health, the bilateral partnerships should be developed and directed in a
way that entails minimal risks for consensus-based multilateral mainstream that is in
charge of finding and executing fair and unbiased solutions for global health challenges
in the future.
One of the most important feature that differentiates and recognizes the principles
and guidelines promulgated by UNESCO or WMA is their consensual nature and
multilateral structures of the organizations that developed, adopted, and announced them.
This consensually and multilateralism makes these principles a part of the common
heritage of mankind regardless of their historical origins. Otherwise, if the ethical
standards and values are imposed, transferred, or dictated in the bilateral relations, they
will always remain the subjects of criticisms as ethical imperialism and colonialism (see
above).
v.

Biopolitics vs. Bioethic

The main question behind the concept of biopolitics is “how bioethics can be
independent?” In other words, this concept, since the very time it was coined, has
prompted reflecting, exploring, and investigating on the influences of politics on
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bioethics. The concerns over the influence of political powers and interests on bioethical
discourses is a legitimate concern at both national and international levels. Considering
that health has moved from the soft politics to hard politics over the past decades, and the
importance of health research, this concern is also valid when it comes to Global
Governance for Health research.
In the realm of the history of thoughts and theories, everything started with a lecture
series delivered by French philosopher, Michel Foucault (1926-1984), at the Collège de
France in 1978 and 1979. The term of biopolitics had been coined before these lecture
series, however, its accompaniment by some other key words ended up to a change in the
meaning of this term in the political and ethical literature. Below, this chapter provides a
closer look to this debate that has played a crucial role in the theoretical evolution if the
concepts of governance and bioethics.
The concepts of “governmentality” and consequently, the concepts of “bio power”
and “biopolitics” have been coined by Michel Foucault, and then expanded by other
thinkers have noteworthy implications in different fields including bioethics and the
ethics of global governance and research ethics.222

Accordingly, political interests and

powers influence the decisions in the field of global governance.223 This influence has
the potential of competing and conflicting with bioethics as directed just by ethical
norms/principles.224 Therefore, the influence of political powers and their interests can be
considered as another major source of ethical concern in the field of Global Governance
for Health Research.225
The ethical nature of this concern/issue is not covert. As a matter of fact, the undue
influences of political power over biomedical decision-makings have always been
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sources of ethical concerns. In the realm of health research, the influence of biopolitics at
every level of research from priority setting and funding decisions to development of
international collaborations and even the decisions on recruitment of subjects and the
methodology of the studies is a subject of ethical concern. For example, prioritizing the
health issues for research budget allocation can be influenced by political interests. In
some cases, the political attention to specific types of diseases can result unproportioned
research budget of effort allocation. On the other hand, ideological interests or even
taboos can be influential in the governance of research enterprise. Limitations on
conducting certain types of research that might entail results in conflict with dominant
ideologies in some countries is an obvious example. At the global level, also, this
problem is present. The debates on patent rights of pharmaceutical industry or mass
transfer of biological samples from developing countries to developed ones are among
the topics that need attention to biopolitics and are discussed in the following chapters of
this dissertation.
When it comes to the problems caused by the influence of politics on bioethical
decisions, this is self-evident that a top-down world order will never be able to solve
these problems. As a matter of fact, this very issue clearly shows how the global
governance for health and health research needs to replace its current top-down ethical
framework with a new collaborative one with emphasis on global justice, equity, and
solidarity.226
vi.

Data Sharing, Big Data, and International Collaborations

Data sharing has been called “an ethical and scientific imperative.” Numerous
evidences and arguments support this claim, for example: (1) The data of previously

97

published trials may entail new information for the researchers who come afterward and
can take a new look and shed a new light to the previously analyses data; as studies show
that reanalysis of the data of the previous clinical trials, in a significant proportion of
cases, have ended to different interpretation compared with the original studies, although
the numbers of studies that entail reanalysis is very small in comparison to 500000
clinical trials that are published in MEDLINE. (2) Data sharing makes meta-analysis
studies possible that produce more strong evidences for clinical practice compared with
each single study that is included. (3) This is possible that the investigators of the original
studies inadvertently were not reported some important findings that may be revealed
through the data sharing with other researchers who may take a fresh look at the data and
unreported findings. And (4) ethical responsibility to the participants of the clinical trials
who put themselves at risk for producing the data that may be beneficial for the society,
therefore, the obligation of research community is unearthing the greatest amount of
benefit that may be extracted from these data which, for the aforementioned reasons, is
achievable through data sharing.227
One of the most important features of data obtained for research purposes –and the
information resulted from them - is their belonging to the humanity as a whole. In other
words, scientific data and information is a part of common heritage of mankind. As
explained above (number 4 in the list of arguments that support data sharing) human
subjects of research projects put themselves at risk for producing knowledge that benefit
all the humanity. This is the basis of a social contract according to which, the scientific
community has an ethical obligation to maximize this benefit for all the humanity and
this is not possible without making data available to other researchers to extract all the
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possible information from it. i.e. data sharing.
In addition, the scientific knowledge (that is used for and increased by analyzing
these data) cannot be produced and accumulated without relying on the great resources of
common knowledge produced by the previous generations of scientists even in ancient
times. Researchers and scientists do not work in isolation or from the scratch. Their ideas,
premises, previous knowledge, and supporting evidences are based on the knowledge
accumulated through centuries by the collective efforts of scientists from almost allover
the world and all the civilizations on earth. Therefore, the research data and scientific
knowledge, at least partly, belong to (and produced intended to benefit) all the humanity.
Therefore, this is an ethical responsibility of the Global Governance for Health Research
to maximize the benefit of all the humankind from the data and knowledge produced by
research by (1) making datasets shared and available, and (2) making scientific
knowledge accessible for all (as much as possible).
Data sharing, however, brings about a series of ethical concerns. When data sharing
occurs among trials that were conducted in different countries, these ethical concerns find
their ways to the realm of Global Governance for Health Research. Among these ethical
concerns are: (1) Privacy of participants: the shared data mush be deidentified. Through
the process of obtaining informed consent, the participant must be informed about this
fact that their deidentified data will be shared. (2) Fairness to researchers: considering the
intellectual right of the original investigators over the data, some relevant ethical issues
are still under the clouds of ambiguity, such as the right to authorship, the time period
between the publication of the original study and the reanalysis, and the fair process for
handling the requests for access to the shared data. (3) Efficiency of the system of data
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sharing: considering the increasing complicated and sophisticated nature of the
methodology of clinical trials, having an efficient system for data sharing proves to be
more difficult than any previous time. In some cases, the support and assistance of the
original investigators in still necessary for reanalyzing the data. Therefore, this mandate
should be included in the original contract between the funder(s) and original
investigators, or can be requested/purchased from them in other ways.228
Other types of international collaborations that involve sharing data or biological
material include biobanks. Biobanks collect and store human biological specimens for
research purposes. It seems that the international collaborations are eager to accelerate
the sharing of genomic and health-related data, including through collaborations with and
among biobanks. This practice raises its own ethical issues.229 Some of these issues, such
as privacy of participants and necessity of modifying informed consents are discussed
above.
Another issue raised as a result of scientific collaborations and data sharing is the
issue of large datasets or “big data”. Big data is the product of a group of recent
developments such as invention and establishment of electronic health records and
formation of national health databases that integrate huge amounts of health-related
information, as well as large scale national and international collaborations that produce
massive databases and other kinds of data storing means. Creation of these large datasets
has been facilitated by new technologies such as the portable computers and mobile
devices, large digital data storages, and widely accessible high-speed internet. These
technological facilities pave paved the way for international collaborations in data
collection and data accumulation. Also, with expansion of digital and electronical
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infrastructures and facilities to developing countries, they have gradually joined the large
projects that collect and create these big data. Therefore, a large part of the current
health-related big data is developed through international collaborations. Accordingly,
part of ethical issues raised by them and their solutions are covered by Global
Governance for Health Research.
The advantages and benefits of access to big data have been enormous. For
example, conducting research projects with larger amounts of data, samples, or subjects
can lead to more valid and reliable results. In addition, in the realm of public health, the
phenomenon of digital disease detection using electronic data sources and availability of
global real-time data have improved the ability of the health sector in dealing with health
crises such as outbreaks because they have accelerated detection of outbreaks by digital
surveillance channels, as was actualized during the 2014 Ebola virus outbreak in West
Africa.230
Development of big data, on the other hand, have led to new ethical concerns about
privacy, confidentiality, technical efficiency, informed consent of the participants, and
the justified uses and users of these “big data” resources. Vayena et al. have classified the
ethical challenges of digital disease detection into three categories: First, “Context
Sensitivity” that encompasses ethical challenges of differentiating between commercial
and public health use of data and include concerns on identification and informed
consent; the privacy of uses of electronic means; and the openness of private data into
global health-related use; second, the “Nexus of Ethics and Methodology” that entails
the concerns on the valid and reliable functioning of the involved technologies and the
public use of personal data in aggregated from; and third, the “Legitimacy Requirements”
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that encompasses the standards of best practice and existence of a globally shared code of
practice, monitoring and response to the inaccuracies and the resulted harms and finally,
communication to the public and dealing with general expectations.231 They have also
proposed an ethical framework for dealing with these ethical challenges. Their
framework encompasses values such as: “Privacy and Contextual Integrity;
Transparency; Global Justice; Risk of Harm; fair use of resources; Trust, Transparency,
accountability; Trustworthiness; Justice; and Common Good.”232
This is also part of the mission of Global Governance for Health Research to
establish efficient and ethical regulation and oversight for big data.
vii.

The Ethical Nature of the Challenges and Five Major Gaps

The Ethical Nature of the Challenges: This chapter examined some of the most
important challenges facing Global Governance for Health Research. A brief look at
these challenges show that they have major ethical roots and components. In other words,
the major challenges of Global Governance for Health Research are mostly of ethical
nature. Therefore, the possible solutions of these main challenges are to be sought in the
realm of ethics and its relevant branch to this subject, that is global bioethics. Therefore,
the Global Governance for Health Research needs a new and properly constructed ethical
framework to deal effectively with these challenges. For depicting the ethical nature of
these challenges in more details, some of the ethical concepts that are closely and deeply
related with these challenges are discussed below. A comprehensive and more detaild
description of the involved ethical principles will be provided in chapter 5. The involved
ethical concerns include but are not limited the ones in this list:
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Respect for Vulnerability: When it comes to some of the ethical debates, concerns,
controversies, and discussions surrounding the Global Governance for Health-related
Research, including exploitation and helicopter research, ethical imperialism and
colonialism, and double standards, one of the central concepts is vulnerability. The
debates are around the vulnerability of weaker parties in the global power relations (and
in this case, international research) and the ethical obligation of global governance to
protect the vulnerable parties, including countries, populations, communities, and even
the future generations. Like other conflicts that involve vulnerability and power relation,
these debates are of a clear ethical nature.233 As stated above in this part, the solutions for
the above challenges are to be sought in the realm of healthcare ethics/global bioethics.
Establishing an ethical framework for Global Governance for Health Research is the
solution that global bioethics can provide for answering the above questions, challenges,
and needs.
Human Dignity: The concept of human dignity is the fundamental basis of the
human rights and freedoms.234 Problems such as exploitation and double standards entail
explicit violation of this principle. Human dignity as a cross-cultural and universal ethical
principle is a certain part of the common moral heritage of mankind and stands beyond
the accusations of ethical imperialism and colonialism. Violation human dignity is the
root and reason behind moral badness of the research practices that entail using human
subjects as mere means. At the same time, human dignity is the basis of a moral
framework that can deal effectively with these challenges.
Justice: Justice is another cross-cultural and universal ethical principle that stands
behind the global ethical norms and values.235 Challenges such as helicopter research,
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double standards, bilateralism, and even biopolitics involve sorts of violation the
principle of justice. As a constant part of all the sets of principles for biomedical ethics,
justice is an inseparable part of any type of ethical framework for Global Governance for
Health Research.
The Role of Organizations: The involved scientific community and professional
organizations have a crucial role in establishing the needed ethical framework. Also,
different aspects and levels of ethics education, as a well-developed field, play an
important role in bringing the theoretical findings into practice and integrate them with
the routine practices of all the role players who are involved in global governance for
health. This is a continuous and never-ending process. Similar to the technical
knowledge, ethical knowledge is subject of constant change and development. Therefore,
ethics education is an endless endeavor. This endless endeavor is also crucial for
safeguarding the basic rights of all the parties involved in heath research and ensuring the
best performance of global governance for health research.
Although the majority of challenges, which global governance for health faces,
have arisen from the ground of HICs-LMICs collaborations, there are other challenges
that are pertaining to HICs-HICs collaborations, too. A perfect example of such
challenges (big data, data sharing, and international collaborations) has been discussed
above in this essay. Therefore, even in the relations between parties of the same power
and influence, there are still challenges ahead of Global Governance for Health Research
that, as argued in the relevant part in this chapter, demand ethical attention and ethical
solutions.
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Five Major Gaps: Thomas Weiss, a renowned world scholar in the field of Global
Governance has described five major gaps in the current situation of global governance.
This analytic framework is helpful in portraying the status and challenges of global
governance. In addition, this framework is dynamic because the characteristics of each
gap are subjects of evolutions and variations over time. These gaps are in the following
areas: (1) Knowledge, (2) Norms, (3) Policies, (4) Institutions, and (5) Compliance. The
order of this list is also important in the analytical framework, for example, the gaps in
knowledge are partly the roots of the gaps in norms and policies.236
This model of gaps is developed for understanding the current situation of global
governance in general. In this part, this model is applied specifically to the challenges of
Global Governance for Health Research as listed and described in this chapter.
Formulating the current situation and challenges in a pre-developed model of gaps will be
helpful in developing an ethical framework that is well-situated with the status of the
issues and challenges.
1-

Knowledge Gaps: There is no theoretical agreement on the characteristics

and nature of the challenges. This knowledge gap has multiple sources, including (1) the
impact of ideologies as was discussed above in this chapter under the title of ethical
colonialism and imperialism. The ideological and political suspiciousness to the efforts
originated from Western countries in addition to the same kind of intention to
undermining values such as human rights and fundamental freedoms in developing
countries have led to a part of challenges in Global Governance for Health Research that
shows itself in the form of resistance against promotion and promulgation of the
universal research ethics norms and standards. (2) the areas of ethical controversy and
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lack of consensus such as the exact definition of standard treatment as discussed above
under the title of double standards is also a major source of knowledge gap that takes part
in creating the main challenges ahead of Global Governance for Health Research.
Another example of such controversies as shown in the discussion of the challenges is on
the meaning of exploitation and the need of action through governance to prevent it. The
existing variation among the ethical guidance provided by different declarations and
guidelines is a feature of this knowledge gap. (3) the emergence of new concerns and
challenges are the result of gradual shaping or filling of the existing or new knowledge
gaps. The same is true for global governance at the larger scale. For example, the
population problem in the 1970s and the global warming in the last decades of the
twenties century were the results of new scientific knowledge that was created and
crossed the lines of deniability. The historical predecessors of this issue in global health
governance is discussed in chapter 1, such as the resistance against the proposed
European sanitary regulations because of the lack of belief to the germ theory and
reliance on the alternative, even superstitious, theories for disease and outbreaks. This
knowledge gap sometimes is the manifestation of underlying ideological, religious, or
material interests rather than merely difference in knowledge and understanding of the
facts.
In the field of Global Governance for Health Research the improvements and
updates in the international soft law and guidelines fill the previously existed knowledge
gaps in a gradual manner. The new consensuses and consensual declarations are new
pieces of knowledge that partly belong to the common intellectual heritage of mankind.
At the same time, on the other hand, the new challenges are also being resulted from the
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new knowledge on the developments and evolutions of international research enterprise.
For example, before revealing the research methods used in HIV prevention trials in
African countries, the problems of helicopter research and double standards had not been
on the list of major challenges of Global Governance for Health Research. The process of
creation and filling of knowledge gaps in Global Governance for Research can be
summarized and portrayed through this simplified model:
New Scientific Knowledge/Questions  New Research Methodologies/ Designs 
New Ethical Challenges/ Controversies  New Ethical Knowledge  New/Updated
Ethical (Governance) Soft and Hard Law
This model shows the continues creation and filling of knowledge gaps in the field
of Global Governance for Health Research.
2-

Normative Gaps: The normative gaps are about the difference between the

norms and values and the levels of abidance by the standards and norms among different
role players (state and non-state) of Global Governance for Health Research. In the
absence of a single global government or global authoritative body, the process of
ratifying and enforcing the standards and norms is more complicated in the realm of
global governance than in the nation-states. Norms, like knowledge, follow their own
cycles of emergence, growth and popularity, globalization, modification, and sometimes
fading and elimination. There is a typical trajectory: A group of norms first emerge as
local ideals, then find their way into domestic laws and then into international soft law,
and after a while, the global consensus paves their ways into taking the shape of
international hard law.
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The most prominent example of such norms are human dignity and human rights as
are embodied in the Universal Declaration of Human Rights.237 The examples of fading
norms are the sanctity of state sovereignty that today is questioned by the right of nations
to exit the nation-states and join to of form new nation-states. In the realm of Global
Governance for Health Research many of the widely accepted norms have passed through
the similar trajectories. Informed consent, as an example, was defined and promoted in
the form of domestic standards over the first decades of the twenties century. It was in the
wake of the WWII that this norm showed itself as a part of international soft law, the
Nuremburg Code.238 The repetition and promulgation of the necessity of obtaining
informed consent from competent subjects made it a universally accepted norm that can
be considered a piece of the common intellectual heritage of mankind in the realm of
research ethics.
3-

Policy Gaps: Policy is defined as “an interlinked set of governing principles

and goals, and agreed programs of action to implement those principles and achieve those
goals…. Moreover, at the national level, policy can also be used to refer holistically to
the entire package of actions and attitudes.”239 In the realm of Global Governance for
Health Research, policies are embodied in the form of research ethics codes, declarations,
guidelines, laws, and regulations. The Nuremberg Code, Declaration of Helsinki, the
CIOMS guidelines, and the Belmont Report are among the examples of policies that are
related to health research.
Who is in charge of global policy-making for research enterprise? This is a major
question that reveals the existing policy gaps. Each of the above-mentioned pieces of
policy have formulated, adopted, and implemented by a different party involved in
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research. As described in chapter 2, the Declaration of Helsinki, as the most well-known
and influential international policy regarding international health ethics has been
formulated by civil society bodies that represent physicians. In addition, the membership
of such organizations that have created such policies (e.g. WMA for Declaration of
Helsinki) do not necessarily cover all the involved role-players in the world. For
example, there are many medical professional bodies that are not among the members of
WMA. On the other hand, one may argue that in the intergovernmental organizations
such as WHO and UNESCO, the voice of non-governmental actors is missing.
Therefore, at the current situation, the challenge of the lack of globally legitimate
and agreed-upon policy-maker forms a part of policy gaps for the Global Governance for
Health Research. The role of experts and networks in influencing the process of policymaking in international bodies is undeniable. The collective efforts of all these roleplayers have already led to formulation, adoption, and even implementation of a large
and valuable body of policies in the realm of Global Governance for Health Research. As
a matter of fact, these policies are the far most prominent way through with the Global
Governance for Health Research has been actualized in the contemporary world.
However, policy-making in this realm still has the gaps resulted from the diversity and
incompatibility of the bodies of policy making.
4-

Institutional Gaps: The weakness of the existing international organizations

and institutions in dealing with the challenges ahead of Global Governance for Health
Research, or the absence of effective ones with sufficient coverage and authority forms
the fourth set of gaps: the institutional gaps. In the previous chapter, in describing the
existing situation of international organizations, such as WHO, their weaknesses in taking
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the leading role in confronting the challenges of health and health research are
discussed.240 Although some international organizations such as UNESCO, CIOMS, and
WMA have been successful in developing soft law for Global Governance for Health
Research, there is no single world institution in charge of dealing with the challenges of
global research enterprise.
The global trend of weakening of international organizations, as described in
chapter 2, shows itself in the field of health research, too. WHO has been supposed to
take a leading role in global heath governance. Regardless of its success in taking this
important role, this is questioned that whether this supposed leading role can be extended
to the governance of health research and research ethics? Are there any differences
between the leadership of WHO in technical aspects of global health and leadership in the
realm of bioethics? The obvious preeminence of other global organizations such as
UNESCO, CIOMS, and WMA in taking part on Global Governance for Health Research
shows that the WHO, even in theory, does not have a monopoly in Global Governance
for Health Research.
This lack of centrality and divergence of leadership efforts and institutions is a
major feature of institutional gaps in Global Governance for Health Research.
Accordingly, this can be argued that the institutional gaps in Global Governance for
Health Research are deeper and more severe and significant than the same gaps on global
governance and global health governance. In developing an ethical framework for Global
Governance for Health Research, the existing institutional gap should be noticed and
considered.
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5-

Compliance Gaps: In a global order made of sovereign nation-states, the

most obvious gaps in the fivefold set of gaps are the gaps in compliance. Since the trials
of Nazi doctors after WWII there has never been any serious enforcement of researchrelated regulations at the international level. Therefore, the compliance to the existing
body of the soft and hard laws on research ethics constantly is a subject of doubt and
question. The real picture of Global Governance for Health Research consists of a large
body of laws in the absence of a global low-enforcement authority.
In the contemporary world, almost all major and international research project is
reviewed and monitored by at least one Institutional Review Board (IRB) or Research
Ethics Committee (REC). The funding of the projects and publication of the result are
highly dependent on the confirmation and ethical clearance provided by these oversight
bodies. Therefore, one can argue that the research ethics norms are being enforced in the
global research enterprise. However, the frequent revelation of scandals such as the HIV
research projects in Africa shows that some other factors such as corporate greed and
rivalry may create noteworthy obstacles against complete enforcement of research
standards and norms. Therefore, the compliance gaps in some shapes and degrees persist
and show themselves.
For overcoming the compliance gaps there is no need to an international court of
justice for research. Instead, collective efforts of all role players, including the funders,
representatives of research subjects, oversight bodies, and publishers for optimizing the
current system of research monitoring and oversight can create an ever-increasing
improvement in filling the compliance gaps.

111

Conclusions: In this chapter, the main challenges of Global Governance for Health
Research are discussed and their ethical nature is shown. The discussions provided above
about each of the main challenges showed that all these challenges have ethical roots and
components. Principles such as human dignity, respect for vulnerability, justice and
equity, and respect for cultural diversity are involved in all the discussed challenges. In
addition, the possible solutions of these challenges are tied to improvement in the existing
ethical frameworks.
After portraying the challenges and their characteristics and ethical roots, this
chapter analyzed the challenges using the gaps model created by Thomas Weiss and
showed that all the gaps described in that model (Knowledge, Norms, Policies,
Institutions, and Compliance) can be traced and depicted in the Global Governance for
Health Research. As a matter of fact, the main challenges described in this chapter are
various manifestations if these gaps.
This chapter concludes that one of the main roots/causes of the existing problems is
the absence of a comprehensive ethical framework. The existing frameworks are difficult
to apply because they are top-down. Developing a comprehensive, consensual, and
efficient ethical framework in one of the next major tasks/challenges of the Global
Governance for Health Research. Consequently, the main question that is to be dealt with
in the next steps of this theoretical endeavor is “What would be an appropriate normative
framework for global health governance for international health-related research?” For
answering this question, in the previous chapter of this dissertation, a conceptual,
historical, and situation analysis of Global Governance for Health Research and its major
role players is provided. In the following chapters, after providing a detailed examination
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of some prominent cases, an ethical framework for Global Governance for Health
Research is provided and its possible impacts in the future are analyzed.
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Chapter Four: Case Studies of Global Governance for Health Research
In this chapter, some of the historic ethical cases of Global Health Governance and
Global Governance for Health Research are introduced and discussed. Exploring real and
historical cases is helpful for portraying a realistic picture of the existing situation and
problems in Global Governance for Health Research and how an ethical framework can
be useful in solving these problems. In other words, each case entails certain lessons to
learn. Also, certain ethical principles are relevant to each case (Table 4.1).
For starting with a broader scope, the first case, Zika pandemic is more related to
Global Health Governance at the large scale. This part shows how Global Health
Governance uses previous experiences to deal with newly-emerged problems. The
following parts are pertaining to different aspects of Global Governance for Health
Research. Research integrity in Iran describes the problem of local practices on research
integrity and how they can affect global research collaborations. HIV/AIDS Research in
Africa depicts a well-discussed case of exploitation in research. Sending Biological
Specimens Abroad deals with the problem of bio-piracy and how international
collaborations may be seen from the weaker sides. Research on Pre-Implantation Human
Embryo shows how different religious and seculars perspectives collective take part in
shaping ethical grounds for Global Governance for Health Research, and Local and
International Alternative Medicines deals with the globalized aspects of sciencepseudoscience debate.
By analyzing the above cases, this chapter shows the real and practical need of Global
governance for Health to certain elements in the form of principles and regulations that
along with other ones will shape a comprehensive and efficient ethical framework. A
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general scheme of the topics of lessons and principles of each case is depicted in Table
4.1. The resulted ethical framework will be discussed in chapter 5.
Table 4.1. The cases, the learned lessons, and the involved principles in Global
Governance for Health Research
Cases
Topics of Learned Lessons
Involved Principles
Zika Pandemic
Cooperation,
 The existence and
Solidarity, Sharing of
functioning of Global
Benefits, Social
Health Governance
Responsibility, and
 Need to a comprehensive
reciprocity,
Respect for
set of principles
Cultural Diversity,
 The variety of roleCompassion
as a Virtue
players
 Importance of the leading
role of international
organizations
(Multilateralism vs.
Bilateralism)
 The need for improving
healthcare and research
infrastructures of
developing countries
 The importance of local
cultural sensitivities
 The Compassionate Use
of Experimental
Medications
Research Integrity in Iran
Honesty, Research
 The importance of
Integrity, Common
research integrity in global
Heritage of Mankind
collaborations
 Global consensus on the
definition and importance of
research integrity
 Inconsistency in
knowledge, attitude, and
practice regarding research
integrity among different
countries
 The role of Global
Governance for Health
Research in promoting
research integrity
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HIV/AIDS Research in
Africa

Sending Biological
Specimens Abroad

Research on PreImplantation Human Embryo

Local and International
Alternative Medicines

 The importance of ethics
education in promoting
research integrity
 The problem of double
standards
 The problems of
exploitation and helicopter
research
 The problem of inability
of poor communities to
afford the vital medications
 Undue influence of
religious or political
interests (the problem of
bio-politics)
 The problem of
bilateralism (vs.
multilateralism)
 The role of bio-politics
 The role of bioeconomics
 An example of hard law
that protects vulnerable
populations (Nagoya
Convention)
 The problem of biopiracy
 The need for protecting
early human life and the
responsibility of global
governance
 The role of religious
institutions
 The importance of global
ethical standards for
research
 Global consensus on
dignity of early human life
 The need for hard law for
some aspects of health
research
 Scientific medicine vs.
pseudoscience and
superstitions (Pseudomedicine)
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Sharing of Benefits,
Social Responsibility,
Informed Consent,
Respect for Cultural
Diversity, Respect for
Vulnerability Human
Dignity,
Multilateralism

Respect of Common
Heritage of Mankind,
Sharing of Benefits,
impartiality and
independence of global
bioethics

Human Dignity,
Sanctity of Human
Life, Respect for
Cultural Diversity,
Respect for
Vulnerability

Safeguarding Scientific
Validity, Respect for
Scientific Methods as a

 The problem of Biopiracy
 Alternative and
Complementary medicine as
a rich resource of
therapeutically hypotheses
i.

part of the Common
Heritage of Mankind

Zika Pandemic
Pandemics are among the health issues that best reflect the necessity, functioning,

and effectiveness of Global Health Governance.241 Global Health Governance can be
defined by a two major defining elements: First, the variety of role players, including
states, international organizations, and non-state organizations that are involved and
shape a global network;242 second, the issues that are cross-border and raise cross-border
concerns and demand cross-border attention and interventions.243 Therefore, Global
Health Governance is a network of the above role-players that deal with cross-border
health issues in our globalized world.
Like any other social institution, Global Health Governance uses a body of
collective experience and wisdom accumulated through many years of experience in
dealing with various health problems. The pandemics are not exceptions. A precious
body of collective experience and knowledge has been achieved through fighting
different pandemics in various geographic areas and in each case, some valuable lessons
are learned and added to the existing body of experience and knowledge. Therefore, this
is not surprising to say that Global Health Governance learned from this body of
knowledge and experience in dealing with newly emerged pandemics like the Zika virus
pandemic.
In this part of this chapter, after explaining the current situation of Zika virus
pandemic and a brief description of previous similar experiences in dealing with other
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pandemics such as Pandemic Influenza and Ebola, this is argued that the main lessons
learned from the previous experiences and applicable to the current efforts in fighting
Zika virus pandemic (and the potential future pandemics of other infectious diseases) are
as follow: (1) The need to an expanded account of ethical principles that govern the
Global Health Governance and Global Governance for Health Research, (2) The need to
strengthening the leading role of the World Health Organization (WHO) in Global Heath
Governance (that implies the importance of having a leading organization in Global
Governance for Health Research) while preserving the “network” nature of global health
governance that facilitates the involvement of more role players and wider array of the
forms of leadership, that is at the same time, an emphasis on multilateralism as described
in the previous chapter as the best model of international collaboration for Global
Governance for Health Research; (3) The need to improve the healthcare systems
especially in lower and middle-income countries along with research facilities that focus
on local health needs and priorities ; (4) The necessity of providing universal health
coverage for all (including affordable medications), as a goal for global health
governance; (5) The need to empowering the mechanisms of governance from below; and
(6) Relying on shared global and cultural sensitive values such as cooperation and
solidarity and benefit sharing as the overarching values of Global Health Governance and
Global Governance for Health Research.
Situation Analysis: This part of this chapter sketches the main factual
characteristics of the recent Zika virus Pandemic. For this purpose, first a brief
description of scientific facts regarding this viral infection is provided. Then, the
epidemiological situation of the recent pandemic is portrayed and then, the predictions
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and expectations on the future trajectory of this pandemic are explained. Having a
realistic portrait of the problem is one of the first major steps of each study and helps the
researchers to ground their arguments and analysis on a firm and reliable basis.
Scientific Facts: Zika virus is a mosquito-borne virus that belongs to the Genre of
Flavivirus. This virus is transmitted through the bite of an infected mosquito from the
Aedes genus, mainly Aedes aegypti.244 These mosquitoes inhabit in tropical regions.
They transmit other viral diseases such as dengue, chikungunya and yellow fever, too.
Sexual transmission of Zika virus has also been reported. Other types of transmission,
including blood transfusion and perinatal transmission have not been proved or
rejected.245
The mosquito that carries Zika virus bites during the day with higher rates during
afternoon hours.246 The incubation period of Zika virus disease is estimated to be a few
days. The signs and symptoms of this viral disease are usually mild and last between 2
and 7 days and include fever, skin rashes, conjunctivitis, muscle and joint pain, headache,
and malaise. However, what have caused a large scale of global fear of this viral disease,
are its potential neurological and autoimmune complications, the most infamous one
among them being microcephaly in babies born to mothers infected with Zika virus.247
Diagnosis of infection with Zika virus is based on suspicion according to
symptoms and history of recent travel to an area where Zika virus is known to be
present and confirmation according to laboratory testing for the presence of Zika
virus RNA in the blood or other body fluids, including urine or saliva.248
Prevention and control is mostly based on reducing the population of
mosquitoes through source reduction and reducing contact between mosquitoes and
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human beings. Source reduction means removal and modification of breeding sites of
mosquitos. Reducing contact between mosquitoes and human beings can be done by
the following methods: regular using insect repellents; wearing clothes that shields as
much of the surface of body as possible; installing physical barriers such as window
screens in houses; keeping doors and windows closed; and additional personal
protection, including sleeping under mosquito nets during the day. In addition,
removing mosquito-breeding sites such as water containers, flowerpots, roof gutters,
sites of accumulation of still water after rains or in discarded containers and waste
materials in and around houses. Special attention and help should be bestowed to
those who are less able to protect themselves sufficiently, such as young children, the
sick or elderly. In addition, during outbreaks, spraying of insecticides can be helpful
and may be suggested by health authorities.249
Travelers should observe the essential precautions to protect themselves from
mosquito bites. Since sexual transmission is one of the methods of transmission of
Zika virus, the infected individuals and their sexual partners should practice safe sex
that means using condoms. Especially the sex partners of pregnant women who live
in or travel to the areas where local transmission of Zika virus happens, should
practice safe sex, wear condoms, or refrain having sex throughout the pregnancy.
Individuals who return from areas where local transmission of Zika virus occurs
should practice safe sex or abstinence for at least 4 weeks after their return.250
The disease resulted by Zika virus is usually mild and does not need any
specific treatment. No vaccine has become available yet for Zika virus infection and
disease.251
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Epidemiological Facts and Predictions: Zika virus was first identified in
1947 in rhesus monkeys and then in 1952 in human beings, both in Uganda, a
country in east Africa (first identifying in human beings concurrently occurred in the
United Republic of Tanzania). Historically, outbreaks of Zika virus have previously
occurred in Africa, the Americas, Asia, and the Pacific. Zika virus disease outbreaks
were reported for the first time from the Pacific in 2007 and 2013 (Yap and French
Polynesia, respectively), and in 2015 from the Americas (Brazil and Colombia) and
Africa (Cabo Verde). In total, 64 countries and territories have reported transmission
of Zika virus since 1 January 2007.252
The recent pandemic that occurred in the Americas and the Pacific began in
April 2015 in Brazil and spread throughout most of Americas.253 The fear from vertical
transmission of virus caused several warnings about avoiding pregnancy for women
residing in or traveling to the affected areas. Also, restricting traveling to the affected
areas and even cancelling events that attract tourists to those areas have been proposed
and discussed.254
Later, it was claimed that Global Health Governance has showed a kind of
“over reaction” to this pandemic. This alleged overreaction was also partly a reaction to
claims about late and insufficient response to previous pandemics, especially the recent
case of Ebola. Therefore, assessing the approaches of Global Health Governance to those
outbreaks and comparing them with the current epidemic of Zika virus, can entail
valuable lessons for the future. For this purpose, the next parts of this chapter, after
examining the concept of global health governance, will provide a detailed comparison
among these world experiences.
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Comparison with Previous Pandemics: Pandemics as a major concern of public
health have been among the main issues that caused and underpinned a paradigm shift
from bioethics to global bioethics and have embodied the nature of globalization in this
field of theory and practice.255 This part of this chapter, assesses and explains the
historical experience of global health governance with three major outbreaks: Pandemic
Influenza, HIV/AIDS, and Ebola and explores how the lessons learned through these
experiences prove useful in approaching the current pandemic of Zika virus.
Pandemic Influenza: There have been about three influenza pandemics in each
century for the last 300 years, the most recent one being the 2009 Influenza pandemic.
This part of this part of this chapter provides a brief examination of the lessons learned
through the approach of global health governance to this pandemic.
One of the issues raises during all pandemics is the issue of surveillance of
infectious diseases. Among the first missions of the WHO was governing the
international efforts for controlling, and in some cases, finally eradicating infectious
diseases. For this purpose, the international community needed a system of surveillance.
This system had been in place before the foundation of the WHO, in the form of
numerous scattered international conventions. The International Sanitary Regulations
(ISR) replaced those conventions with a single internationally agreed upon law with an
organization in place to enforce it at the global level. ISR was adopted by the Fourth
World Health Assembly of the WHO in 1951 and entered into effect in 1952. Then, in
1969 the ISR were revised and renamed into the International Heath Regulations
(IHR).256
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The process of creation and enforcement of the IHR is noteworthy in assessing
the global governance for controlling infectious diseases, including pandemics. This first
major global experience showed that: (1) this is feasible and practical to create and
enforce a global law, system, and organization for collaboration among different
countries with different and conflicting political systems and economical statuses; (2) the
IHR proved effective and ended up to some noteworthy successes such as the eradication
of small pox; (3) this experience showed that how a health-related international law gets
old and reveals its shortcomings through the time and can be revised and updated by the
agents of global health governance; and (4) the last revision of the IHR in 2005 showed
how the international nature of health governance is transforming into a global nature, i.e.
more involvement of non-state actors in the surveillance of infectious diseases in addition
to more flexible and liquid definition and determination of key factors such as the list of
notifiable diseases.257
Isolation, meaning the practices that restrict the free transportation, contact, and
social activities of individuals for the purpose of preventing the spread of a pandemic, is
another important topic. Therefore, quarantine and compulsory hospitalization are also
considered as forms of isolation. One of the first priorities of health systems in
controlling pandemics is preventing further spread of the infection. For this purpose, the
minimum necessary level of restriction of freedoms is to be executed. However, the
principle of reciprocity demands that the individuals, who are subjected by these
restrictions, receive reciprocal benefits such as the best possible quality of stay during the
quarantine and provisions for substituting the lost possible trips.258
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As discussed above, the healthcare workers have a duty to provide health services
during the times of pandemics. This duty is of moral, professional, contractual, and legal
natures.259 At the same time, the principle of reciprocity implies that the governance
provides the best compensation and recognition for their efforts.
At the global level, the principle of cooperation and solidarity requires that even
non-involved countries get engaged in controlling the pandemics in the afflicted areas. In
the current globalized world, no pandemic remains confined in a certain geographic area
for a long time.260 Therefore, in addition to the moral demand out of solidarity, the
national interests of countries, especially the ones that or the major destinations of
immigrants and refugees, demand their attention to timely and efficient controlling of
pandemics.
Ebola: Although Ebola, as a viral disease, had been identified from the 1970s after
its first detected appearance in Central Africa, its 2014 pandemics resulted a new and
specific attention to this disease.261 This specific attention was because of the following
facts. These facts also make this pandemic relevant to the subject of this chapter that is
the lessons learned by Global Health Governance from this pandemic:(1) the spread and
severity of this pandemic was extraordinary. Several African countries were affected and
many people died, (2) the spread of this disease to the wealthier/developed countries,
specially to the USA, (3) various debates with ethical nature that rose during the Ebola
pandemic such as compassionate use of experimental drugs that relates this subject to
Global Governance for Health Research, and (4) the struggle of Global Health
Governance, especially failure of WHO in effective and timely controlling of the
pandemic.

124

Started in 2013 and traced to a 2-year-old girl in Guinea as the index case (who died
from this infectious disease), the outbreak of Ebola virus infection/disease in West Africa
in 2014 is the most widespread and persistent outbreak of this viral infection ever
recorded since the time of discovery of this virus in 1976.262 This outbreak has killed
thousands of people in West African countries during this outbreak.263 It also has
disrupted the activities and programs of the health sector of those countries (like
programs to control Malaria) and imposed huge deals of economic lose to those
countries.264
Some important features and facts about Ebola outbreak, which are relevant to the
subject of this part of this chapter, are as follow:
1- Ebola, like HIV/AIDS, has no curative treatment. Although some antiretroviral
drugs have been successfully discovered to be effective265. Although not curative, the
current available treatment of Ebola virus disease mostly consists of supportive measures
like providing adequate nutrition and hydration.266
2- The recent pandemic of Ebola first started in Western African countries.267 Health
officials in the United States hoped that by adopting reasonable measures, the infection
would not enter inside the borders of the United States. It did. Although this event arose
some discussions about the ethical limitations and requirements of quarantine as a public
health intervention, but the greater lesson was that in the contemporary globalized world,
with this huge network of interconnectedness and huge amount of international travelers,
heath crises, especially outbreaks of infectious diseases, don’t remain confined within the
national borders. Both the experiences with HIV/AIDS and Ebola virus disease simply
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shows the global nature of public health crises and the global impact of outbreaks that
originate in an area but never remain confined to that geographic area.
3- Occurrence of this outbreak in some developing countries showed the challenges
of fighting such outbreaks in regions with people who have various sets of beliefs and
different cultural/economical contexts. For example, the very issue of mistrust resulted
from long lasting political chaos, civil wars, economical poverty, and political
dictatorships in the region is discussed separately in this part of this chapter which shows
the importance of contextual issues in public health interventions within the frameworks
of Global Heath Governance. The same issues can affect research projects in such areas.
The problem that also should be covered by Global Governance for Health Research.
4- Comparing the treatment provided for few cases of Ebola infection in the United
States, with the chaotic situation of healthcare for Ebola patients in affected countries in
the West Africa, uncovers a bitter reality of the current world: the huge disparity and
inequality between these countries in term of health care resources and facilities, both in
treatment and research sectors.268 Equality and justice are among the most emphasized
values of global bioethics. If Global Heath Governance does not take measures to fight
these unacceptable inequalities, the next pandemics will occur in developing countries
and will cause human tragedies again and again.
When this deadly outbreak of Ebola found its way to the inside of borders of the
United States, the very important role of Global Health Governance in dealing with
health crises showed itself again.269 Mass media and social networks extensively covered
this outbreak and the related ethical issues were being discussed in academic circles, and
in the public sphere in the house and days after their causes took place. Several issues
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about quarantine, the function and efficiency of governmental bodies like the Center of
Disease Control (CDC), and the organizational ethics within the US hospitals have been
fiercely discussed inside the United States. There are also other lessons learned from
ethical features of this experience, which are more relevant to the very concept of Global
Health Governance.
It has been argued that in the recent outbreak of Ebola, an existing and ongoing crisis
in global health leadership cost thousands of human lives because of delayed and
ineffective emergency responses.270 At the time of crisis, WHO was not able to exert
proportional reaction in timely manner to this public health emergency at international
level271. Although this inability and late reactions have been attributed to shortage of
monetary funds available to WHO, however, regardless of the possible causes, it shows
the existing need for strengthening the functionality of this leading global organization.272
The problem of double standards in Global Health Governance is explained above, in
chapter 3, by discussing the example of double standards in treating human research
participants in different parts of the world.273 This problem also exists and should be dealt
with at the level of leadership of Global Health Governance.
The problem of double standard in Global Health Governance, however, has other
faces, too. The reaction of mass media to two cases of death from Ebola in the United
States was fiery and sweltering! The related governmental bodies like the CDC were
criticized for not providing guidelines and facilities for preventing transmission in a
timely manner. In addition, the very issue if quarantining of a nurse who had come back
forms an infected area became a subject of boiling debates. At the same time, thousands
of people were dying from this infection in a few African countries and the coverage by
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mass medical and reaction of people and public opinion were dilute comparing with the
ones evoked by the relatively tiny domestic events. When thousands of people are dying
and other countries do possess facilities for preventing such human tragedy, do they have
a kind of social responsibility out of solidarity and cooperation to help them more than
what happens currently in the real world? Is it justified for governments and nation states
to regard the death and suffering of foreigners less important than their own citizens?
And is it ethically accepted to refuse to help desperately needy people who are struggling
with a deadly disease in the presence of enough resources and capacities?
Responding the abovementioned questions in not easy at all. Different factors like
respecting the sovereignty of local states, the responsibility of governments towards their
own people, the scarcity of resources, and lack of real trustful collaboration among the
major world powers, all should be considered in formulating a response/solution for these
ethical questions/problems facing global heath governance. But difficulty of finding a
compelling and practicable answer does not shrink the very importance and vitality of
these questions and should not cover this very fact that the way the major role players in
Global Health Governance respond to these questions is a matter of death and life for
thousands and even millions of people in the present and future of human civilization.
Amid the crisis of Ebola infection, when several institutions where working in that
area and collaboration with local health officials for controlling the outbreak, one of the
most important obstacles against their efforts was the deep mistrust of local people
toward any governmental or international agency or intervention. For example, it was
reported that in Guinea, panicked residents in a village killed all the members of a team
that had been sent to that area to raise awareness about the disease.274
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The long history of dictatorship and abuse of power in African countries, along with
the inevitable side-effects of dictatorship like widespread corruption of police force and
their abuse of power, have resulted in the lack of trust, while trust is crucially needed for
efficient collaboration among various involved parties and for eliciting people’s
partnership which is so central and critical in controlling such health-related crises.
Although Ebola infection has no proven curative treatment, some experimental
medicines have been used hoping to save patients who otherwise would be likely to die.
The long process of approving experimental drugs for using in standard clinical practice
has always been a subject of criticism. During the HIV/AIDS epidemics, sometimes there
were competitions among potential participants (patients/infected people) for entering the
clinical trials. They looked those clinical trials as the last resort and beacon of hope for
receiving an effective treatment. In the case of Ebola infection, however, the clinical
trials were being conducted thousands of miles away from the foci of outbreak. Delivery
of experimental drugs to those patients was not part of any research study or clinical trial.
As a matter of fact, considering the especial context of chaos and shortage of healthcare
workers and facilities, it was impossible to conducts sufficiently well designed and wellconducted clinical trial in those areas.
Providing experimental drugs for those patients hoping to be effective in relieving
their suffering and even saving their lives was an act out of philanthropy. It seems that
outlining the regulations and principles under which this kind of premature release of
experimental drugs can happen again in the future is part of the duties of the institutions
in charge of Global Governance for Health Research. However, it is obvious that the
guiding principles of this action are benefit sharing solidarity and cooperation275.
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Ebola pandemic has been called as a failure for Global Heath Governance.276
However, as explained above, many lessons learned by global health governance that
could be applicable to Zika pandemic.
In sum, although Global Health Governance is accused of “over-reacting” in
approaching to Zika virus pandemic, this over-reaction that might have saved many lives
and prevented births of many defected babies, as a result of previous experiences, such as
the criticism of Global Health Governance because of its late and insufficient reaction
during Ebola pandemic.
In conclusion, in this part of this chapter, the following lessons learned from the
previous pandemics for applying in Zika virus and other future pandemics have been
discussed: First, an expanded account of ethical principles (compared with the classical
ones) is needed for establishing and shaping an ethical framework for Global Health
Governance and Global Governance for Research in dealing with pandemics. This
expanded account includes some restrictions to the original principles such ad respect for
autonomy and addition of new principles such as cooperation, solidarity, and reciprocity.
Second, through discussing more concrete practical concerns, it is depicted that how this
modified account of ethical principles can lead and help in dealing with those concerns
and show the point of balance among the various and conflicting ethical principles,
norms, and obligations. This model needs to be expanded and include other ethical
considerations and practical concerns to provide an inclusive and comprehensive ethical
framework for global health governance in dealing with pandemics. Third, the above
review and comparison shows the need to strengthening the leading role of the World
Health Organization (WHO) in Global Heath Governance while preserving the “network”
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nature of Global Health Governance and multilateralism on Global Governance for
Health Research that facilitates the involvement of more role players and wider array of
the forms of leadership. Fourth, the need to improving the healthcare systems and
research governance especially in lower and middle-income countries is one of the points
that are obvious through the above parts of this part of this chapter. Fifth, the above
review and comparison clearly show necessity of providing universal health coverage for
all (including affordable medications), as a goal for Global Health Governance in which
the research sector can be helpful. Sixth, the need to empowering the mechanisms of
governance from below is another point that can be concluded from the above part of this
chapter. And seventh, relying on shared global and cultural sensitive values such as
cooperation and solidarity and benefit sharing as the overarching values of Global Health
Governance and Global Governance for Health Research is the best way for founding an
ethical framework for the future of Global Governance for Health Research and its future
encounters with pandemics.
ii. Research integrity in Iran
During the second half of the twentieth century, the number of international and
multi-central research projects increases with a fast rate.277 This rate was continued in the
first two decades of the next century. This phenomenon is a part of a bigger picture that
has been named “globalization”. Globalization in any aspect of social human life
necessitates global governance as well as global ethics for that aspect. 278 Research
enterprise has not been an exception. Therefore, the governance and ethics of the
international research ethics are parts of global health governance and global bioethics,
respectively.279
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Among the different topics of research ethics as it pertains to Global Governance for
Health Research, research integrity is one of the most important ones. The reasons of this
importance (in addition to the reasons of the importance of research integrity of research
in general, that is beyond the scope of this part of this chapter) include:
1- Multinational and multi-central research collaborations are based on the values of
honesty and trust. When multiple parties from different parts of the world decide to
collaborate in a research project, they have to trust each other’s honesty and reliability in
following the same methods and standards and in correct and accurate reporting of
results, including the possible adverse effects or inabilities to achieve the expected goals
or milestones. Therefore, having global ethical norms and regulations that support this
mutual trust and a global governance to ensure and promote these norms and regulations
will be an integral part of international research enterprise. Otherwise, the high costs of
mutual monitoring and verifications will render such research projects too expensive to
be practical.
2- Research integrity is among the topics on them it seems possible to achieve a
global consensus. When it comes to global consensus on bioethical issues, it is obvious
that on some controversial topics (such as abortion or discrimination) it is very hard – if
not impossible – to reach to a form of global – and even local - consensus. However,
there are certain areas in them it is possible to found a common ethical ground for global
ethics. Research ethics is a good source for such grounds. The values that shape the
ethical foundations of research include honesty, accuracy, efficiency, and objectivity. 280
These values – at least to the extend they pertain to research – are globally accepted and
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justified and can be used as a common ground for founding and ethical framework for
Global Governance for Health Research.
Like other areas of practical ethics, historical experiences are the engine that produces
force for ethical deliberations, legislations, and enforcement to move forward.281 Without
the bitter experience of human experiments in Nazi Germany, we would not have the
Nuremburg Code282, and without the unpleasant disclosures made by Henry Beecher, we
would not have the Belmont Report283, at least at their current time and place in the
history. The same fact is true about research integrity. Historical cases of research
misconduct and the related scandals have resulted noteworthy achievements in this area.
Therefore, studying, exploring, and analyzing the similar experiences are also valuable in
improving research integrity in the future. This part of this chapter is intended to be a step
in this direction. Therefore, the main question this part of this chapter deals with is: how
the systems of Global Governance for Health Research can learn from the experiences of
collaborative/multinational research in countries like Iran for optimizing their approach to
the issues related to research integrity?
For answering this question, after a conceptual analysis of the notion of research
integrity, and a history review, the concept of global governance for research integrity is
introduced and its achievements and shortcomings are explored. Then, some infamous
cases are introduced and analyzed. Afterward, a historical review and situation analysis
of research integrity in Iran is provided and accordingly, the roots and causes of existing
problems and the way ahead are explored. Finally, this part of this chapter concludes that
expanding international research collaborations is expected to have beneficial effects in
term of improving research integrity in developing countries such as Iran. In addition,

133

research integrity can be considered an agreed upon basis for developing a part of
globally accepted ethical framework for Global Governance for Health Research.
The Concept of Research Integrity: In this part, first, a definition and conceptual
analysis of the notion of research integrity is provided, then some of the most important
historical landmarks are introduced and discussed.
Definition and Conceptual Analysis: According to the National Institutes of
Health, Research integrity includes: “(1) the use of honest and verifiable methods in
proposing, performing, and evaluating research, (2) reporting research results with
particular attention to adherence to rules, regulations, guidelines, and (3) following
commonly accepted professional codes or norms.”284 Therefore, the mandates of research
integrity cover all the activities of researchers through all the major phases of thesis
development, conducting research/study, drafting and finalizing the report/paper, and
publishing the results. Research integrity is very important because of numerous reasons
including the following ones asserted by the NIH:
(1) “Researchers rely on trustworthy results of other researchers to make scientific
progress.”285 Therefore, research misconduct; including fraud, falsification, and
fabrication of data can destroy not only the current but also the subsequent researches that
destroy the reliability of science.286
(2) “Researchers rely on public support, whether through public investments or their
voluntary participation in experiments, to further science.”287 Therefore, violating
research integrity can be considered as betrayal against public trust and support and
finally can deprive the academic/research society from the support provided by the
public, both funding and participating.288
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(3) “The public relies on scientific progress to better the lives of everyone.’289
Therefore, scientific misconduct can also gas deteriorating effect on one of the final
products and goals of science that is the quality of human life.290
(4) “Researchers who are dishonest and act without regards to integrity could
actually harm the public.”291 Therefore, research misconduct is not only a violation of the
trust and norms and rights within the professional community, but also is a violation
against the public and common good.
All the reasons mentioned above for the importance of research integrity can be
defined and mirrored in the global level. The notions of trust, public, and common good
can be defined at the global level. In this level, the public encompasses both the
community of people of the world and the community of nation-states.292 For the
abovementioned reasons, the notion of research integrity has gained increasing attention
in the past decades and should be considered as an integral part of research governance in
both local and global levels.
A Historical Review: Some aspects of research integrity, such as avoiding
plagiarism, are as old as the written history, itself. However, the notion of research
integrity in its current dimensions and characteristics is a relatively new notion. For
example, in the United States, research integrity became a public issue in 1981. In that
year, a congressman named Albert Gore, Jr. who was the chairman of the Investigations
and Oversight Subcommittee of the House Science and Technology Committee, held the
first hearing that was provoked by the public disclosure of certain research misconduct
cases. Those cases had occurred at four major research centers in the previous year.
About twelve cases of research misconduct were revealed in the US between 1974 and
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1981. The attention of the US Congress to the issues related to research integrity was
continued throughout the 1980s because of some added accusations of research
misconduct and reports that the NIH, universities, and other research institutions were
unsatisfactorily reacting to those accusations.293
In 1985, the Congress of the United States passed the Health Research Extension
Act. This Act required the Secretary of Health and Human Services to issue a regulation
requiring applicant or awardee institutions to establish "an administrative process to
review reports of scientific fraud" and "report to the Secretary any investigation of
alleged scientific fraud, which appears substantial."294 In March 1989, the PHS created
the Office of Scientific Integrity (OSI) in the Office of the Director, NIH, and the Office
of Scientific Integrity Review (OSIR) in the Office of the Assistant Secretary for Health
(OASH). The reason behind foundation of these offices was to deal with research
misconduct. The establishment of OSIR also began the course of detaching responsibility
for research misconduct from the funding organizations. In May 1992, OSI and OSIR
were combined into the Office of Research Integrity (ORI) in the OASH. As the
prominent examples of its activities, ORI published the ORI Introduction to the
Responsible Conduct of Research in 2004 and began the RCR Program for Graduate
Schools in collaboration with the Council of Graduate Schools to institutionalize RCR
education in graduate training.295
The above examples show the process of legislative and regulatory attention to the
issues of research integrity and research misconduct in other countries and in the global
scene: First, some cases of violation of research integrity gain public attention, then
gradually the related rules and regulations are passed in the legislative bodies and
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executive offices take shape to enforce those rules and regulations. The global
governance for research needs the same process to take shape at the global scale to deal
with the issues of research misconduct and research integrity through global governance
for research ethics.
Global Governance for Research Integrity: In this part, a situation analysis of the
global governance for research (a general picture) and the global governance for research
integrity (with more details and specifics) is provided. Then, an infamous case is
portrayed to discuss the lessons learned from them to improve the global governance for
research integrity.
Achievements and Shortcomings: Distinct separation between research and
therapeutic clinical practice in health sciences, is a recent phenomenon, dating back to the
first decades of the twenties century.296 Before that time, for centuries, experimenting
new treatment or interventions was considered as a part of the routine practice of
physicians and was supposed to be aimed to providing the best heath interest for the
patient.297 In was in the twenties century that health-related research enterprise
experienced an exponential growth, was recognized as separate from clinical therapeutic
practice, and in the second half of that century international and multicenter research
projects began to sprout and grow.298
Just like other global enterprises, the international health-related research
established its own system of global governance.299 The Global Governance for Healthrelated Research has mainly taken place and been mirrored in the following ways:
First, the international declarations, codes, and guidelines developed for setting
global ethical standards for health-related research. Many of these instruments have
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specific part pertaining to research integrity, a prominent example being the declaration
of Helsinki.300 Almost all the countries involved in international research collaborations
have generally accepted this declaration. Therefore, the standards exerted by this
declaration, although they are very concise and brief, consist a major regulation part of
global governance for research. In addition, other international instruments such as the
Singapore Statement on Research Integrity of 2013 have been promulgated in this
relevance.301
Second, the national rules and regulations made by the countries that host the main
funding bodies and institutions on international research, the most prominent one being
the United States. There are many law and regulations in this country setting the
standards and enforcing them in regard to research integrity.302 In addition, many of the
hosting countries have announced their laws and regulations in this relevance, Iran being
an example.303
And third, the internal regulations, standards, and guidelines of the various sorts of
organizations that fund international research.304 These funding organizations have their
policies and regulations on research integrity. NIH305 and National Science Foundation306
(NSF) are two prominent examples.
Therefore, for sketching a realistic portray of the history of global governance for
biomedical research, the best way is looking at the developments in the above-mentioned
means of implementing global governance for biomedical research.
A Review of an Infamous Case: The case of Hwang Woo-Suk has some
noteworthy lessons for global governance for research integrity; therefore, this part of
this part of this chapter explores this case with more details. Hwang Woo-Suk, a
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professor of theriogenology and biotechnology at the Seoul National University (SNU)
was considered a pioneer and ground-breaking researcher in the field of stem cell
research up to 2006. In his country, South Korea, he was treated as a national hero. His
claimed research achievements including cloning of different mammals got extensive
media coverage and made him a public and admired national figure in South Korea.307
He invited famous global figures to his team.308 His works also gained widespread
international attention, were published in the highest-ranked journals such as the Nature
and he appeared in numerous international meetings as an invited lecturer.309 In two
articles appeared in Science in 2004 and 2005 he claimed that he had created human
embryonic stem cells by cloning. However, in 2006 it was revealed that his claims were
fraudulent and he faked the reported data and results. This was a scandal for him and a
big damage to the scientific reputation of North Korea.310
He also was convicted for obtaining human eggs for his research through unethical
sources that was his female subordinates that raised concerns about coercion.311 In
addition, Gerald Schatten, a professor of cell biology at the University of Pittsburgh, who
was one of two corresponding authors of Hwang’s second article, was accused of
research misconduct, but later a university investigation found that Schatten was not a
party to the fabrication of data and was unaware of it. However, it was also reveled that
his contribution in the study was not at a level that make him eligible for authorship. In
fact, he has also committed research misconduct by accepting a “guest authorship”.312
The case of Hwang Woo-Suk shows that when a research project or a researcher
gains public and political attention, this may have beneficial and adverse effects for
him/her. Beneficial in terms of obtaining more research fund and personal/institutional
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honor and prestige, and adverse in terms of putting pressure to him/her to have
noteworthy results/products and being under the light of media and monitoring bodies. In
addition, political support may cause at least temporary immunity of regular scrutiny and
inspection that postpones the exposure of research misconduct to a time that it has been
worsened and irreversible.
In addition, this case study shows that how detrimental such research misconducts
can be in international research collaborations. Such researchers and research projects
that gain widespread global attention and work on hot topics of health, science, and
technology are very successful in absorbing global funds and collaborations. A case of
research misconduct from each party of such collaborations will damage and deteriorate
the achievements and reputations of all involved parties. The case of Hwang Woo-Suk is
a noteworthy example that shows the importance of research integrity in multinational
health research collaborations and the importance of the attention of global governance
for research to this subject.
Iran’s Experience as a Case Study: This part of this chapter is committed to
exploring Iran’s experience on research integrity and research misconduct as a case
study. After a review and situation analysis, this part will explore and analyze the roots
and causes of existing problems and later in this part of this chapter, it will be discussed
that how global governance for research and use this experience for promoting research
integrity in a global scale.
A Historical Review and Situation Analysis: In the past decades, the health-related
research sector in Iran experienced a fast growth.313 This growth, like other parts of the
world, raised some concerns about ethical issues including research integrity. 314 In the
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recent years some cases of research misconduct reported from Iranian researchers has led
to discussions and debates that shed light to different aspects of research integrity and
research misconduct in Iran.315 This attention was partly because some of the holders of
high-ranked offices in the cabinet of previous president, Mahmoud Ahmadinejad were
among the people who were accused of research misconduct.316 In one case, a faculty
member tried to answer to the accusations saying that the person who committed the
plagiarism was my student and my name in the authorship byline was because I was the
instructor/professor and I had not even read the manuscript.317 This kind of answering
just shows deep unawareness of some of these people from the basic mandates of
research integrity.
Few empirical studies in this regard have been published. Two studies show that the
knowledge and attitude of Iranian students318 and faculty members319 toward plagiarism
shows there are rooms for more education and improvement. These studies, however,
does not reflect a complete picture of the existing situation because they have been
conducted in Tehran University of Medical Sciences that hosts the most elite students and
faculty members in the country. Also, some papers in this regard have been published by
non-Iranian authors, some of them tried to show a darker-than-reality picture of the
existing situation in Iran.320
In one noteworthy development, a group of Iranian scholars launched a blog named
“Professors Against Plagiarism” in which they openly discussed the cases of plagiarism
occurred in Iran. They showed that some high-ranked officials of the government have
committed some severe cases of plagiarism.321 The reaction of government is banning
(filtering) that blog and accusing them to produce anti-regime propaganda.322
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In the medical universities of smaller cities, it seems that the rate of research
misconduct is higher. Personal experience of the author of this part of this chapter and his
colleagues form conducting research ethics workshops and many medical universities
throughout Iran and their conversations and discussions with faculty members, students,
and researchers who took part in those workshops shows that in some cases, some
practices such as guest authorship, ghost authorship, and gift authorship are common. Of
course, this high prevalence is mostly occurring in the literature published in Persian.
Among the researchers who write and publish in English, research misconduct still
occurs but with a lower rate. The reasons of this phenomenon are discussed below in this
part of this chapter.
In some parts of larger cities such as Tehran, some private institutions that target
graduate students (who are obliged to publish a certain number of ISI-indexed articles for
their graduation) advertise for selling research services, including fully-completed
dissertations and published articles for certain amounts of money! These businesses have
been criticized however have not been removed and continue their marketing and
activities.323
In one case, the Iranian party of a multinational research project was accused of
research misconduct and their contribution was withdrawn from the published results of
the study. This case occurred in Isfahan, a central city of Iran and in a prestigious
research center. The problem was that the main investigators, as usual, had many
academic and administrative jobs and duties, so the work they accepted was being done
by a team of junior researchers with insufficient training about research integrity and
especially with lower interest and dedication to the project and the integrity of its results.
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Therefore, they allegedly committed data fabrication that was reported by a fired
employee to the central team of research and they remover Iranian tem from that
collaboration.
Roots and Causes of the Existing Problems: With a review of the historical review
provided above and a deep look at the related developments and their dynamisms in the
past decades, one can explore the roots and causes for the existing problems regarding
research integrity in Iran. This part of this part of this chapter discusses some of the most
important ones of these roots and causes in more detail and digs deeper in the underlying
grounds of the existing problems regarding research integrity in Iran.
The first point is that Iran is not totally different from other countries regarding the
causes and drives that may push the researchers and academics towards violating the
norms and values of research integrity. These causes and drives include:
1- The need –and sometimes- greed toward achieving higher academic ranks,
prestige, money and power in academia.324
2- Interpersonal and professional rivalry and competitions that urge people to have
more academic achievements.325
3- The monetary or academic gain of reaching to significant results in analytical
researches that assesse new theories or products.326
However, there are some factors that are more relevant to the situation in Iran as
explained below.
Iranian academic centers rely on the number of articles published in the journals that
are indexed in the directories of the US National Library of Medicine (PubMed) or
Institute for Science Information (ISI) for academic ranking and promotion. Therefore,
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each academic institution or faculty member has to have a number of articles published in
the above journals to achieve academic status, promotion, prestige, or recognition.
Otherwise, that person may fall to backwardness in academic rankings and competitions.
Therefore, the faculty members and institutions (including research centers, higher
education schools, universities, and other academic centers) feel obliged to have a
number of such papers in their report card at the end of each year. This system, i.e.
relying on the indexing databases such as PubMed and ISI has been extensively
criticized. The critiques have mentioned the below weaknesses for this system of ranking
and promotion:
1- Some journals are being indexed in these databases/indexing systems while they
do not have enough scientific and academic status to be used for this purpose. Some of
these journals had been included in the list of the journals indexed by those databases,
however before they lost their academic standards. In some cases, these journals accept
manuscripts even with a monetary cost. This phenomenon has even led to appearance of
some private institutions in Iran that sell the indexed and published articles to their
student or faculty costumers!
2- Many valuable and highly ranked academic journals, especially in certain fields
such as healthcare ethics, are not being indexed in these databases. Therefore, a student
or faculty member who has published an article in one of these journals will gain no or
less credits in comparison with a colleague who has published in a very weaker journal
that is published in an indexed journal!
3- The credit gained by an article should not be defined and calculated just by the
indexing status and Impact Factor of the journal in which that article is accepted or
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published. Instead, other factors related to that article such as its scientific value, being
innovative or ground breaking, relevance to the real problems of the country of the field
of study have to be considered while these factors are foregone in the current system of
academic promotion.
On the other hand, the defenders of the current system argue that by using indexing
sites such as PubMed and ISI, the academic authorities rely on an objective and impartial
source for judging about the scientific value of the articles. Otherwise, if they substitute
this system with an internal system in the ministry of health, ministry of science,
universities, or departments, they will be alleged to being unfair and partial and may be
influenced by the authorities or pressure groups to give unfair value/rank/score to certain
papers or authors. Therefore, relying on those foreign-based impartial and agreed-upon
websites is the best among the available options.
In addition, the proponents of the current system notice that a significant group of
the critiques and opponents of the current system are the scholars who have entered the
academia using the rant of political power. They typically are unable to contribute in the
current scholarly debates by authoring publishable articles. Instead, they write weak and
worthless papers and publish them in domestic journals and websites taking advantage of
their power and influence. Therefore, if the reliance on the objective systems of PubMed
and ISI is removed, this group will be able to force their institutions to accept their
worthless papers as valuable articles and basis for their academic promotion.
The debate on whether to continue the current system of academic ranking and
promotion or not is continuing in Iran. Even in one time the Supreme Leader warned
about over-relying on the ISI indexing system.327 However, because of the
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abovementioned concerns, this system has not been substituted yet. As regarded to
research integrity, the problem with the current system is that many of the Iranian
students, researchers, and faculties are not well prepared and trained for doing research
and writing scholarly papers, especially in English. The causes of this unpreparedness
include:
1- The weakness of English language education in pre-academic and academic
educational centers. After the revolution of 1979, the new Islamic government removed
the foreign language programs from elementary schools and limited them in the middle
and high schools. The weakness of English language education had several causes
including (a) the political and ideological challenges and conflicts of the Islamic Republic
with Western countries that caused hesitation of the educational system to promote
Western languages; (b) the overall weakness of educational system because of the longlasting Iran-Iraq war and other factors that led to a struggling economical situation; and
(c) the isolation of Iranian people from the global community and diminished
encountering and transactions with foreign people that necessitate learning a foreign
language. The resulted weakness of English language skills among Iranian students and
faculty members led to (a) their overall inability or difficulty in contributing in scholarly
debates and communicating with their colleagues from other parts of the world, and
authoring scholarly papers in English and (b) some kinds of plagiarism in the form of
copying the paragraphs of the previously published articles in English and substitute their
findings (numerical values, measurements, etc.) with the original ones. Before the recent
movements toward improving research integrity in Iran, even some well-recognized
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scholar advised their students to use this technic for overcoming their inability in writing
in English from the scratch.
2- The weakness in research skills training that begins from as early as the
elementary school. The educational system mainly relies on memorizing the content of
textbooks and has little room for training innovation and research. Therefore, the students
and even faculty members who enter the academia have little previous training on
research and research methodology. In the medical schools and during the residency
programs, the main emphasis is on memorizing the content of textbooks and learning the
skills, not understanding and conducting clinical trials or other kinds of research.
However, the system expects its medical residents, PhD students, fellows, and faculty
members to write and publish scholarly papers as to fulfill the requirements of graduation
or promotion. This pushes them to find fast tracks and short cuts to have enough
published articles that are indexed in the ISI to fulfill this requirement.
The other cause of the existing problems had been the lack or scarcity of education,
training, and regulations regarding research integrity until recently. Research ethics is a
young filed in the world and even younger in Iran.328 The first national code for
publication ethics was promulgated in 2009.329 Inclusion of current standards of research
integrity on formal content of research training courses and workshops has started a few
years before that time. Therefore, part of the reason of the cases of research misconduct
has been the lack of enough and correct education. For example, during the author’s
clinical residency in Shiraz University of Medical Sciences (2002-2005), it had been
considered a standard that the dissertation is an intellectual property of the instructing
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faculty member (the director of thesis/dissertation) and s/he has the right to exclude or
include the name of anybody in the byline of the resulted paper(s) as an author!
The other noticeable problem is that many of faculty members hold high-ranked
official and governmental offices at the same time. In one case, a faculty member of a
medical university in Tehran had at least 18 other executive positions simultaneously.
These faculty members try to keep their status in the academic race by relying on their
students or other subordinates to write papers and include their names in the authors’ list.
This phenomenon has sometimes leads to cases and scandals of plagiarism.
When it comes to international research collaborations, the same factors explained
above in this part of this chapter, cause the problems. It seems that the rate of research
misconduct in international collaborations is lower than the one in the general research
sector in Iran, because the researchers who are involved in international research are
usually among the best and best trained and experienced researchers who are unlikely to
commit research misconducts. However, in some cases factors such as the weakness of
management and monitoring in the cases in them the high-ranked officials got the
privilege of involvement as a partner in international research projects, such cases and
scandals occurred.
The Way Ahead: As mentioned above, in 2010 the Iranian Ministry of Health and
Medical Education has promulgated a national guideline for publication ethics.330 In
addition, many courses and workshops have been conducted to make Iranian researchers,
students, and faculties more familiar with research integrity.331 This can be expected that
in the predictable future the trend toward higher degrees of research integrity will keep
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continuing in Iran, especially in more central and higher ranked institutions and
universities that are typically engaged in International research collaborations.332
This is also expected that after lifting the economical sanctions, more Iranian centers
will get involved in international research collaborations. This phenomenon will result in
importing and getting more familiar with the ethical standards of research ethics
including research integrity as they exist and are being practiced in the developed
countries. The funding institutions, universities, pharmaceutical companies, and other
research partners in the developing world demand their partners from the developing
world to observe and fulfill certain level of ethical mandates, standards, and
requirements. This, per se, will entail some degrees of education and requirement for selfeducation in this field for Iranian researchers. Therefore, it seems that having
international collaborations, per se, will have positive impacts on research ethics and
research integrity in the field of health-related research in Iran. Although many ethical
problems arose during research collaborations in LMI countries in the previous decades,
considering the awareness of research policy-makers and governing bodies in Iran, it is
unlikely that those problems, such as exploitation of research subjects, helicopter
research, or double standards, will be repeated in future international and multi-central
research projects in Iran.333
Some organizational changes can also improve the situation in the future, one of
them being strengthening internal review systems for academic ranking and promotion to
substitute the current system of relying on the quantity of papers indexed in the ISI. Also,
not expecting the people who hold executive offices to publish in academic journals
unless they had enough time to contribute as an author in producing that paper.
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Global application of Iran’s Experience: Iran’s experience, although has local
characteristics and specifics, has also some valuable lessons for global governance for
research. This part explores the possibilities and limitations of using Iran’s experience at
a global level and for improving global governance for research integrity.
Possibilities: Growing international research partnerships is anticipated to have
valuable effects in promoting research integrity in developing countries. Iran’s
experience shows the higher standards of research institutions in the developed world will
be transferred to the developing countries through research collaborations and the
unfavorable effects such as double standards and exploitation are avoidable through
suitable global and local governance for research.
Research integrity can be considered as a field with mostly agreed-upon norms
and standards among different cultures, traditions, ideologies, and political systems.
According to the NIH, the shared values in scientific research are (1) Honesty that
means to convey information truthfully and honoring commitments, (2) Accuracy that
means to report findings precisely and take care to avoid errors, (3) Efficacy, that means
to use resources wisely and avoid waste, and (4) Objectivity that means to let the facts
speak for themselves and avoid improper bias.334 All these values can be considered
cross-cultural and globally acceptable. Therefore, research integrity and research ethics
and be considered as a core and first step/chapter for compiling the ethical standards for
global governance of heath research.
At sum, Iran’s experience shows the importance of research integrity in
establishing research partnerships that shape global research network and enterprise. In
addition, it shows that how promoting globally accepted ethical standards can help local
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and global governances in establishing and maintaining acceptable foundations and
practices in the field of research and research integrity.
Limitations: Using a local experience at a global scale always has some
limitations. The specific cultural context of Iran makes some of its experiences locally
valuable but non-generalizable to other regions. The specific characteristic of health
system in Iran, such as the faculties holding high ranked executive offices, are not
common in other countries, especially in the developed world.
Also, Iran’s relative isolation during the past decades has had specific consequences,
such as the relative scarcity of international collaborations that may not be found in many
other parts of the world. This is possible that in future, with gradual removing the
sanctions, the situation will change in Iran and more international partnerships will be
possible, however, still great obstacles remain in front of realization of this development,
at least in the near future.
Some other specifics of Iranian universities also contribute in shaping more
limitations. For clarifying this source of limitations, one can mention two examples as
follow:
(1) The leadership of universities is largely influenced by the political sector.
Presidents of universities are appointed by the suggestion of the minister of health or
minister of science and technology and approval of the Supreme Council for Cultural
Revolution. Therefore, after each election that leans to change in the leadership of the
executive branch, the presidents of universities and consequently the heads of schools
and sometimes departments change. This instability of academic positions is a source of
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some difficulties that do not occur in countries whose academic sector is more
independent from the political sector.
(2) In 1988, after the end of Iran-Iraq was, the Islamic parliament passed a
legislation according to that, the veterans of the war and the relatives of martyrs of the
revolution and war, bestowed with a specific quota (more than 40% of the capacity of
universities for admission) for entering the universities.335 This legislation led to entering
a huge number of unqualified students to the universities including medical schools.336
Many of these students when needed to do research and prepare scholarly works,
compensated their inability with purchasing research credit from the black market. This
also has been a problem rarely encountered in developed countries.
Conclusions: The main question of this part of this chapter has been: how the
systems of Global Governance can learn from the experiences of
collaborative/multinational research in countries like Iran for optimizing their approach to
the issues related to research integrity?
For answering this question, this part of this chapter first provided a conceptual
analysis of the notion of research integrity. Then a historical review showed the main
related historical milestones and examples. Afterwards, this part of this chapter
introduced the concept of global governance for research integrity and explored its
achievements and shortcomings. Then, some infamous cases are introduced and
analyzed. In the next part, a historical review and situation analysis of research integrity
in Iran is provided and accordingly, the roots and causes of existing problems and the
way ahead are explored.
This part of this chapter concludes that:
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(1) Expanding international research collaborations is expected to have beneficial
effects in term of improving research integrity in developing countries such as Iran. As
described above, the higher standards and practices of research institutions in the
developed world will be transferred to the LMICs through research collaborations. The
adverse effects of such collaborations such as double standards and exploitation are
preventable through a good global and local governance of research sector.
(2) Research integrity can be considered an agreed upon basis for developing
globally accepted research ethics for global governance for research. In contrast with
many other ethical topics (e.g. topics pertaining to the beginning and end of life issues),
research integrity can be considered as a field with mostly agreed-upon norms and
standards among different cultures, traditions, ideologies, and political systems.
Therefore, research integrity and research ethics and also be considered as a core and
first step/chapter for compiling the ethical standards for global governance of heath
research.
(3) Establishing an effective and efficient global network for health-related research
won’t be possible without having global standards for research integrity and promoting
and training these standards in all the countries that host centers taking part in
multinational research projects. There are some international instruments available in this
regard. Continuous updating and optimizing these instruments, transforming the soft rule
into hard rule, and promoting and enforcing them in the global research network is a
crucial and ongoing mission of global governance for research ethics.
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iii. HIV/AIDS Research in Africa
In this part, the case of “the experiment of preventing vertical transmission of HIV in
Africa” is discussed. The central concept is the problem of double standards and the
importance of benefit sharing.
The AIDS research was among the first that attracted a global attention to the global
governance for research. The high costs of antiretroviral drugs lead to different debates
about the ethics of intellectual property and patent. 337 The high costs made such drugs
unavailable for many people who were in desperate need of such drugs. Even people of
countries that tolerated the burdens of hosting the clinical trials that resulted in the
creation and production of such drugs could not afford those final products while many
people in those countries were in desperate and emergent need of them. 338
HIV/AIDS: First reported in 1981 in the Morbidity and Mortality Weekly Report
under the title “Pneumocystis pneumonia — Los Angeles” denoting a new infectious
disease found in a cluster of homosexual men, human immunodeficiency virus infection
and acquired immune deficiency syndrome (HIV/AIDS) is a disease spectrum of the
human immune system caused by infection with HIV.339 Soon after its discovery,
HIV/AIDS became pandemic with millions of infected people and millions of deaths all
around the works with huge cultural, political, and economic impacts. The importance of
HIV/AIDS in addition to the size of infected and diseased populations is originated in
several factors including:
1-

Its perceived relevance to sexuality, especially to homosexuality, which made

this disease a taboo in some communities and even a subject of anti-Western propaganda
in other countries as explained below. This relevance to sexuality and sex education was
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one of the main obstacles for the prevention of this disease in the societies in them
speaking about sexual subjects in public, including sexual education for young people, is
not permitted by cultural/religious authorities. Because when it is impossible to speak and
educate about sex and sexuality, it will be impossible to provide effective education for
preventing the sexual transmission of HIV/AIDS. Also, the resulted stigmatization and
discrimination (from the communities, families, social partners, and even from the
healthcare workers and political systems) against infected people, which instigates a large
deal of ethical debates.
2-

The lack of effective treatment and 100% case-fatality rate of this disease

which exacerbated the panic around the world and resulted sometimes in unnecessary and
unfounded fear which acted as an obstacle in fighting this infection/disease.340
3-

The long latency period which resulted in a relatively long period (medium 10

years) in which an apparently healthy infected person (even may be unaware of his
infection) is able to transmit the virus to other people through sexual contact or other
means of transmission.341
4-

Its global feature (being a pandemic that affected almost all the countries

around the world) that makes it relevant to Global Health Governance342. During the past
decades, treatment, prevention, and research on HIV/AIDS arose fierce ethical debates
and challenged the existing models and frameworks of Global Heath Governance and
Global Governance for Health Research in various technical and ethical ways. The
lessons learned from this global experience are useful for enlightening the way ahead of
global health governance in fighting inevitable future pandemics.
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The pandemic of HIV/AIDS have had a huge impact on different aspects of Global
Heath Governance. Different ethical issues arose during the past few decades when the
pandemic of HIV/AIDS developed, affected millions of people and several countries and
communities, and a huge deal of scientific, political, philanthropic, and economical
activities were conducted in dealing and fighting with this deadly infection/disease. Some
of the lessons learned from different aspects of this crisis, which are relevant to global
health management, are discussed in this part of this dissertation.
Research Activities and Intellectual property: The high costs of antiretroviral
drugs lead to different debates about the ethics of intellectual property and patent. The
high costs made such drugs unavailable for many people who were in desperate need to
such drugs. Even people of countries that suffered the burden of clinical trials ended to
production of such drugs could not afford those final products while many people in
those countries were in desperate and emergent need to them.343
The high costs of medicines and allegedly unfair profit margin of pharmaceutical
industry has always been a subject of fierce debates. The so-called HIV/AIDS activism
was a social movement appeared in reaction and response to uncovering of such ethical
shortcomings and aimed to protection the community and HIV/AIDS patients.344
The pandemic of HIV/AIDS alongside with globalization of biomedical research
industry added to the heat and extent of this debate. It has been argued that the scandals
resulted from uncovering the unethical behavior of biomedical research enterprise in
relation to HIV/AIDS has been one of the major causes behind the last paradigm shift in
research overview at least in the United States of America. This paradigm shift led to
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more emphasis on the very concept of “collaborative partnership”. Thank means more
involvement of communities is designing of research and setting research goals.345
As a matter of fact, collaborative partnership as far as it is related to the subject of
ethics in international biomedical research, can be red under the abovementioned
principles of the UNESCO Universal Declaration on Bioethics and Human Rights,
especially respect for cultural diversity and pluralism346. Other principles, also, are
relevant to this issue like equality, justice, and equity; solidarity and cooperation; Social
responsibility and health; and Sharing of benefits.347
Bilateralism vs. Multilateralism: Both multilateral and bilateral programs have
been efficient in combating the pandemic of HIV/AIDS. Some examples of multilateral
programs/institutions are as follow: (1) WHO (that is supposed to assume the leading
role); (2) World Bank (in recent decades became a major role player in funding healthrelated programs); and (3) The Joint United Nations Program on HIV/AIDS
(UNAIDS).348
UNAIDS, itself, is cosponsored by several international/multilateral
organizations. Looking at the list of these organizations reveals the very multilateral
nature of this program. These cosponsoring organizations are as follow: (1) United
Nations Children’s Fund (UNICEF), (2) World Food Program (WFP), (3) United Nations
Development Program (UNDP), (4) United Nations Population Fund (UNFPA), (5)
UNESCO, (6) WHO, (7) World Bank, (8) United Nations Office on Drugs and Crimes
(UNODC), and (9) International Labor Organization (ILO).349
Bilateral programs, however, are formed and conducted by an agreement between a
powerful/wealthy nation state and a country or a group of countries in need. When it
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comes to HIV/AIDS the most influential bilateral program has been the US
Government’s Global Health Initiative (previously the President’s Emergency Plan for
AIDS Relief or PEPFAR).350 As mentioned above, bilateral programs, although
sometimes successful and efficient, potentially weaken the role of IOs, in this case WHO,
in leading international efforts against pandemics and other heath crises. This weakening
may also become extended to ethical principles and norms of global bioethics, which
guaranties pluralism as the source of trust and ethical infrastructure for global health
interventions.
Politics, religion, and medicine: Respect for cultural diversity is one of the
ethical principles, which guide global health governance, and is a separable part of its
obligation to plurality.351 As a sexually transmitted infection/disease, the prevention and
control of HIV/AIDS in communities, inevitably faces with cultural/religious
conventions, beliefs, taboos, and dogmas, especially in developing countries. To be
effective, Global Governance for Health Research has to find a way for dealing with such
obstacles. A way, which takes advantage of potentially useful cultural features, like
avoiding extramarital high-risk sexual behaviors, and at the same time get rid of obstacles
resulted by other sets of such features like resistance against sexual education especially
for women and young adults, resistance against availability of preventive measures like
condom, stigmatization and discrimination against certain groups like patients and
homosexual/transsexual persons.
In some countries such as in Islamic Republic of Iran, The governmental media
took advantage from the information about HIV/AIDS outbreak, which was firstly
discovered in Western countries and among homosexual males, to claim that this
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outbreak is a result of non-obedience to moral norms in Western countries.352
Consequently, for many years, some high-ranked officials of the Ministry of Health
ignored the need to taking preventive measures, including proper education, in the
country claiming that this disease is pertaining to immoral Western countries and has
nothing to do with the people of Islamic Republic. This resistance and ignorance replaced
by an expensive program for controlling HIV/AIDS after the government realized that
this disease was spreading with a fast pace in the country353. Even now, however, the
resistance of the Islamic government and religious leaders against taking some proposed
preventive measures like sex education in schools and easy availability of condom for
young and unmarried people is part of the reality behind the rising prevalence of this
disease in Iran.354
An Infamous Case in Africa: One of the paradigm cases of global research ethics
that has been very influential in shaping the ethical frameworks for Global Governance
for Health Research has been the trial on preventing vertical transmission of HIV virus in
Africa. This case drew a large deal of attention and raised ethical concerns on the
research in developing countries. Issues such as exploitation and double standards and
benefit sharing were discussed seriously after revelation of the ethical concerns of this
study.
The effect of oral use of zidovudine in prevention vertical transmission (i.e.
transmission of virus from pregnant mother to her future child) was shown in clinical
trials in the United States in 1994. Afterwards, the US Public Health Service
recommended a regimen containing zidovudine as the standard treatment for pregnant
women in the United States. However, the recommended dosage was not affordable for
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most affected people in developing countries. Afterwards, several research projects,
including 15 placebo-controlled clinical trials were conducted in developing countries,
mostly in Africa, most of them funded by US funding bodies and assessing the effects of
prescribing lower doses of zidovudine (in some cases, combined with other medications)
for pregnant women in preventing the vertical transmission of HIV virus. Two major
ethical questions were raised concerning these trials: (1) were these trials ethical? In other
words, is this ethical to examine a lower than effective dose of a vital medication, while
its efficacy is proven in higher doses, just for financial reasons? (2) Was it ethical to have
placebo arms in these trials?355
The major ethical concern was that whether the research subjects of these trials and
their communities were exploited because of their contextual poverty? Does the poverty
as a contextual factor can be ethically relevant in deciding to examine a lower-thaneffective dose or having a placebo arm with this justification that these subjects, if not
recruited in research, had no access to the standard treatment (the full or even reduced
dose of the medication that was proven as standard treatment in JICs)?356
This case raises the challenges of double standards and exploitation and can be
discussed in the light op principles of human dignity, justice and equity, non-maleficence,
and non-discrimination.
iv. Sending Biological Specimens Abroad
Bioethical and Biopolitical Concerns: This part of this chapter deals with the
problem of real and imaginary threats and their implications on research policy and
research ethics. Research on samples derived from human body and other living
organisms (biological samples) and transporting these samples through international
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research collaborations has raised its specific ethical concerns. Since the exchange of
biological specimens is a frequent and integral part of global research collaborations, the
challenges associated with this issue is relevant to Global Governance for Health
Research.
This part of this chapter describes the bioethical and biopolitical challenges of
sending biological specimens abroad under two main topics: the biopolitical concerns
regarding possible genome mapping and the ethical/economical concerns (can be called
bioeconomical concerns) regarding commercial benefits and patents produced by the
specimens collected freely from developing countries, the problem that has been also
discussed under the title of biopiracy.
Biopolitics of Biological Specimens: In some countries, including Russian
Federation and Iran, there have been some concerns about sending biological specimens
with human origin that are containing DNA to other countries, especially the Western
countries. It is argued that the information that is potentially obtainable from such DNAcontaining samples may include sensitive information about the biological characteristics
of the people living in those countries that may be used even in producing weapons that
target that people in a specific way. In addition, in countries with racial/ethnic tensions
such as Iran, the local authorities are sensitive about research on racial/ethnic issues, such
as the origin of local ethnic groups. For example, in Iran, governmental authorities
including the research officials in the ministry of health are suspicious about any research
activity trying to attribute the origin of ethnic groups who live within the national borders
of Iran to other countries.
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The question is that to what extent these sensitivities are realistic and based on real
existing threats in the real world and to what extent they are just imaginary threats raised
from their over-suspiciousness towards the Western world? Although no reliable answer
can be found for this question in the available literature, the sure thing is that with
escalating the tensions among countries and hostile rhetoric from the both sides, this kind
of mutual suspiciousness will persist and will act as an obstacle for the research
enterprise. Therefore, this can be considered as a biopolitical issue that makes challenges
for research and as the interface of biopolitics and Global Governance for Health
Research. Although the ultimate solutions of these problems are mainly beyond the scope
of bioethics or Global Governance for Health Research, creating and adopting reliable
and consensual international guidelines in this regard can be useful to promote trust and
facilitate international research collaborations hat entail exchange of biological
specimens.
On the other hand, it can be argued that the biological samples are a part of common
heritage of mankind and cannot be restrained for political reasons or patented for
commercial purposes. This argument can be used to suggest a free and uncontrolled
network of sample sharing for non-profit research purposes. This suggestion, although
looks humane and remarkable, seems to be far from practicality in the current political
and commercial atmosphere of the world.
Bio-economics of Biological Specimens or Bio-piracy: In the recent decades, it has
been argued that the companies and research enterprise of developed countries use the
natural and genetic resources of developing countries and less powerful communities
(e.g. tribes and indigenous people) to make products that are beneficial for the companies
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and researchers while the communities that provide the natural resources do not have a
share of this benefit.357 This practice is a violation of the principle of benefit-sharing.358It
has been claimed that using the natural resources and knowledge of indigenous
communities and developing countries without benefit-sharing is a sort of colonialism
and can be called bio-piracy. A term coined in the 1990s that became popular in the
relevant discourse afterwards.359
The result of these debates and arguments was the adoption of The Nagoya Protocol
on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising
from their Utilization to the Convention on Biological Diversity by 92 UN Member States
and the European Union. This protocol was a by-product of the Convention on Biological
Diversity and was ratified in Nagoya, Japan, therefore it is also known as the Nagoya
Protocol on Access and Benefit Sharing (ABS). 360 This protocol is a supplement added
in 2010 to the 1992 Convention on Biological Diversity (CBD) and came fully into force
in October 2015 in the form of a treaty. This protocol mandates that any company that
uses genetic resources obtained from each of the countries signed this protocol, must
have a contract that ensures benefit sharing. Research-related benefits are included.361
Although the arguments demanding benefit-sharing have been very strong and even
named using the natural resources without adequately benefit-sharing as bio-piracy,362 as
a counterargument, it has been claimed that the insistence on benefiting the source
countries from exporting biological specimens may cause delay in producing or
inadequacy in coverage of vital medications. For example, each year, the seasonal
influenza vaccine is produced based on the prevalent strains of influenza virus of that
year determined by a panel of experts that meet twice a year (once ahead of each
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hemisphere’s winter) through a process conducted by the WHO’s Global Influenza
Surveillance and Response System (GISRS). Then, the pharmaceutical companies have
to produce vaccines against the specified strains and for this purpose they need the
biological samples from all over the world. If some countries refrain to deliver the
samples or put unreasonable price tags on them or require long negotiations to reach the
benefit-sharing agreements, this may undermine the efficiency, timeliness, and coverage
of the new vaccines. This problem will cause risk and harm to public health at least in
some parts of the world.363
Conclusions: Sending biological specimens abroad and the arguments, discussions,
and controversies around this issue is another good example of the ethical challenges
ahead of Global Governance for Health Research. It seems that there are not enough
reliable and consensual international guidelines in this regard available to the countries
that express concern on political or military misuses of biological specimens. In addition,
the attempts for safeguarding the fair share of the source countries and communities, such
ad the Nagoya Protocol have had adverse implications in timely and effective production
of vaccines. In the case of sending biological specimens abroad, in addition to explaining
the com the complex and complicated nature of the existing issues, the principles of
benefit sharing along with solidarity and attention to the concept of common heritage of
mankind have been used to provide an ethical framework that has been helpful in
approaching and solving this challenge and its related problems.
v. Research on pre-implantation human embryo
The ethical status of human embryo from the time of conception until its implantation
in the womb has been among the most controversial topics in the field of biomedical
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ethics during the past decades.364 In this phase, the human embryo can be called PreImplantation Human Embryo (PIHE). Various interventions with various purposes,
including research, treatment, and enhancement can be done on the PIHE.365 In some
cases, these interventions cause damage, change genetic make-up, or destroy the PIHE.
Are these interventions ethically permissible? The answer to this question depends on
one’s perspective toward ethical status of the PIHE.
The ethical debate on the ethical status of the PIHE is a relatively new and modern
one. For many centuries, these phases of human life have been out of reach of scientists
and physicians. Although abortion has always been an uptight subject of moral debate,
nobody could isolate, create, or manipulate a PIHE; therefore, the artificial creation or in
vitro destruction of human embryo has been out of scope of such debates.
In the recent decades, the technology if In Vitro Fertilization (IVF) made it possible
for scientists to conduct the fertilization of human gametes and produce human embryos
in their labs.366 This new technology opened the black box for human fertilization and
made the PIHE exposed and vulnerable to experimental interventions and manipulations,
the most notable among them being stem cell research and human cloning (see below).
Now, human being has the power of –even mass- production, manipulation, destruction,
and transformation of some of their own in the very earliest stages of their lives.367
As described below, different religions and moral schools have different views on
ethical status of the PIHE. At one end, some ethical schools totally condemn producing or
killing the PIHE in the laboratory. On the other end, there are some who consider the
PIHEs as a commodity at full disposal of their owners.
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In the contemporary globalized world, where such technologies, their usage, and their
consequences cannot be confined within national borders. The people created by these
technologies move to other countries and jurisdictions and take the concerns on their
identity with themselves; human embryos also can be transferred across the national
border; and people who are in desperate need to treatments provided by such research,
also, can move across national borders to find allowing jurisdictions and willing
providers.368 Each ethical or legal approach to this subject potentially had global
consequences. Therefore, research on PIHE is also a subject for Global Governance for
Health Research.
This part of this chapter is composed of three main parts. The first part provides a
brief review of scientific facts about research on PIHE. This is necessary to introduce the
subject of this ethical analysis, show its importance, and portray the areas of ethical
concerns. Then, the second part provides a portrait of ethical perspectives and concerns
of three main ethical schools of thoughts regarding this subject. This part shows that there
are some significant, well justifies, and almost globally consensual concerns and ethical
principles/norms regarding research on early human embryo that can be used as the basis
of the ethical framework for Global Governance for Health Research on early human
embryo. The third part examines this subject and its ethical controversies in the global
scale and on the global scene. This part shows that there are unaddressed ethical
concerns and gaps in this regard that need global attention in terms of legislation and
enforcement. In other words, research on PIHE needs a global ethical framework. This
global ethical framework should be developed, adopted, and implemented by Global
Governance for Health Research.
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At the end, this part of this chapter argues that: (1) there seems to be a global
consensus on the principle of respect for human embryonic life. Therefore, some
implications of this principle such as refraining of producing human embryo just for
research purposes can be considered as globally accepted standards of practice. These
standards can be delineated and enforced as parts of global governance for research on
PIHE, and (2) for preventing the noteworthy harmful consequences of unleashed and
uncontrolled exploitation of human embryos, the existing soft international laws are not
sufficient and there is a need to hard laws that protect early human life from destruction
and exploitation.
Genetic Research on PIHE: As explained above, the reason behind arising the
furious debates and controversies on the ethical status of PIHE in the previous decades
has been the scientific and technological advances that made it possible for scientists to
produce in vitro embryos and use them for research purposes. Among these research
purposes, the most notable ones have been stem cell research and cloning.
Human reproductive cloning has never been attempted or ethically approved, at least
to the public and available knowledge.369 Research/therapeutic cloning has not been
successful on providing real treatments yet, however, is a promising field of research.370
Stem cell research, however, with use of embryonic cells that destroys PIHEs has been
developed, and has raised many promises and hopes for finding cure for some serious and
untreated health problems.
In this part of this chapter, a concise description is provided on the scientific aspects
of these technologies, their status quo, and their foreseeable future or futurology. This
scientific review is useful to grasp a broad perspective of the realities in the field. This
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perspective/knowledge is necessary for discussing the ethical importance, implications,
and controversies in this field.
A Scientific Review: Stem Cell Research and Cloning: Stem cell research is a
promising and expanding field of research in genetics and medicine that has opened
doors to new hopes for finding treatments for a group of currently incurable diseases such
as Parkinson’s disease or Degenerative Heart Failure.371
There are two main sources for stem cells: Adult cells and Embryonic Cells. Adult
stem cells can generate replacements for the cells and tissues that are lost through injury,
disease or normal wear and tear. Adult stem cells are also called somatic stem cells.
Adult stem cells usually develop into the same type of cell as the tissue from which they
have been extracted. For instance, Stem cells found in muscle tissue normally give rise
to new muscle cells. Embryonic stem cells, however, are “starter cells” that can be
directed into becoming any of the specialized cells of the body. That’s why the
embryonic stem cells are called “pluripotent.” Embryonic stem cells are derived from
human embryos that have been created in the laboratory, not in a woman’s body. A new
achievement in the field, however, is creation of what are called “Induced-pluripotent
stem cells” that are adult stem cells that have been genetically manipulated to behave like
embryonic stem cells. At present, they serve a valuable role in research and drug
testing.372
Creating and using embryonic stem cells through in vitro fertilization and then
destroying the PIHEs for retrieving stem cells has been the subject of many controversies
as it is apparent in the history of banns and then permissions on such research in the past
decades in the United States.373 The invention of Induced-pluripotent stem cells is a

168

promising stem toward abandoning the use of human embryos for harvesting stem cells.
However, the potential of Induced-pluripotent stem cells for replacing human embryonic
stem cells is still a subject of research and uncertainty.374
In addition to developed countries those have always been pioneers in advanced
scientific and technological developments, some developing countries have also taken
noteworthy steps in these fields. For example, Iran has been one of the pioneers in the
field of stem cell research. This was partly because of flexibility of the religious
authorities in permitting such research as described below.375
Futurology: Humane Genetics or a New Brave World: Scientific and
technological advances in the field of human genetics have always raised concerns on the
potential endangerment of human life or values by them. There have always been deep
concerns about the legitimate and ethical boundaries of human science and technology
that distinct humane achievements from building a “Brave New World”.376
As describe above, stem cell research and cloning have been very promising for
finding cures for a group of most debilitating and fatal human conditions such as
degenerative and congenital diseases. On the other hand, creating, using, manipulation,
and destroying PIHEs for this purpose have been subject of furious criticisms, especially
from the religious and prolife perspectives.377
Although Induced pluripotent stem cells have created a promising perspective of
abandoning the use of human embryos for harvesting stem cells, the potential of Inducedpluripotent stem cells for replacing human embryonic stem cells is still a subject of
research and uncertainty.378 Therefore, it seems that in the foreseeable future, the
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scientists will need and keep using the PIHE for research purposes that will be a source of
ethical controversies about the moral status and inviolability of early human life. 379
In addition, because of globalization, international and multicenter research projects
on PIHE are growing in number and quantity.380 This means that in the era of
globalization, they embryos that are created in one country and jurisdiction can be
transported and used on other countries or jurisdictions. This makes the governance of
such research a subject of global governance for biomedical research. These facts
necessitate the existence of an overarching law to regulate this enterprise and prevent
violation of human dignity and the sanctity of early human life.381
Ethical Status and Protection of PIHE in Genetic Research: In this part, a
perspective is provided toward the current viewpoints on the ethical status of the early
human embryo. For this purpose, three of the main and most influential ethical
accounts/schools in the contemporary world that have distinct and leading perspectives
toward this subject have been selected and discussed. These three schools are:
Secularism, Catholicism, and Islam.
Secularism is the basis for legislation in developed countries, also is the basis of
international and cross-cultural legislations.382 An international consensus or legislation,
which is needed in global governance, should be based on secular reasoning.383
Therefore, this is important to shed light on this perspective toward ethical status of
embryonic human life.
Catholicism is also a very influential school of thoughts, especially when it comes to
protecting the dignity and sanctity of early human life. 384 The formal position of the
Catholic Church toward in vitro fertilization (IVF) and research on PIHE has been very
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influential and controversial at the same time.385 It seems that Catholicism has adopted
the most conservative approach in defending the ethical status of PIHE; therefore, this
perspective should be included in any review of current influential and important
perspectives toward the ethical status of human embryo.
Covering at least 10% of all Muslims in the world and making the second largest
bough of Islam (After the Sunni branch), the Shiite branch of Islam has its own
theological, jurisprudential and ethical schools. Among the Islamic countries, Iran, Iraq,
Azerbaijan, Lebanon and Bahrain are Shiite majority ones. In all the aforementioned
countries, Shiite jurisprudence and ethics have a great influence on life style of large
groups of people, including their decisions about child bearing, using assisted
reproduction technologies, or abortion. In Iran, according to the constitution, all the rules
and regulation should be in accordance with Shiite jurisprudence.386 Therefore, the Shiite
perspective towards such important issue as the moral status of early human embryo, not
only is important as a noteworthy part of religious ethics, but also deserves attention
because of its great impact on some vital aspects of lives of more than 200 million people
in the world.387
Considering the above facts and reasons, in this part of this paper, a review is
provided of the perspectives of these influential schools of thoughts, namely Islam,
Catholicism, and Secularism, toward the ethical status of PIHE. This critical review is
necessary for establishing sound theoretical grounds for global governance for research
on the early human embryo.
Secular Perspectives: According to the secular perspectives, in ethical assessment of
using human embryos for stem cell research, two ethical duties come into conflict: (1)
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The duty to prevent or alleviate suffering and (2) The duty to respect the value of human
life.388 Both of these duties are cross-cultural and can be considered secular and primafacie. Therefore, the main ethical challenges in front of secular bioethics in dealing with
stem cell research on PIHE is weighing these two duties and compare them in the case of
PIHE.389
For providing a sound answer for the above question, secular bioethics has to
determine the ethical status/value of the PIHE. A wide variety of viewpoints in this
regard can be defended by secular reasoning, varying from bestowing full ethical status to
a fertilized egg to postponing ethical status to even after birth. However, when it comes
to collective –international or domestic – agreements in secular societies, it seems that
human life in its first 14 days is considered valuable, but not as full human life with
ethical status. Therefore, they incline to permit use of human embryos for valuable and
scientifically sound purposes, but restrict this use to surplus embryos remained after InVitro Fertilization (IVF) procedures.390
The secular perspective to the ethical status of human embryo has also been reflected
in international soft and hard regulations that have been discussed in a later part of this
part of this chapter (see below).
Catholic Perspectives: Catholicism is the largest one, in the size of population,
among the denominations of Christianity391. In dealing with bioethical debates and
issues, Catholicism mostly relies on the discipline of theology392. Therefore, the moral
debates and deliberations in Catholic bioethics are based on reasoning rather than only
the Holy Scripture393.
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Catholic ethics relies on the concept of natural law394. According to the theory of
natural law, human beings are able to differentiate between right and wrong, morally
speaking. They do so by appealing to their reason and life experience, either individual or
collective, because God has created them and the universe in a way that makes it
possible.395 In its normative meaning, however, the theory of natural law infers that there
are some acts, which are against nature (contra naturam). Accordingly, these acts are
intrinsically evil. This concept of being intrinsically evil is an important concept in the
approach of Catholic bioethics toward practical issues like terminating an early human
life.396
According to the Catholic perspective, the human being is created in the image of
God. This is the very basis of human dignity and sanctity of life in Catholicism. The
human person ordered to God by grace and alienated from God by sin. However this is
about their conscious life. The human early life, or the PIHE has not gotten the chance of
choosing between grace and sin. This person. However, is protected by human dignity
and sanctity of life because he or she is created in the image of God.397 This is the basis
of the sometimes controversial positions of the Catholic Church is safeguarding the early
human life and considering it as eually dignified as other stages of human life.398
In the Catholic perspective, human embryo is bestowed by ethical status or
personhood from the very moment of the infusion of soul into its body. However, no
official Catholic Church document specifies an exact age or developmental phase of
human embryo as the time of ensoulment. This uncertainty, however, has led to adopting
a position that covers all the probable times of ensoulment. In the other words,
considering that from the time of conception, the human embryo, even if pre-implanted
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and pre-differentiated, constitutes human life and is ready and capable for accepting a
human soul, therefore, according to the official Catholic Church documents, should be
treated as if it has ethical status and personhood. 399
The position of Catholic Church on the ethical status of PIHE is based on church
doctrine and its interpretation of scientific facts. According to this interpretation, the early
human embryo is the earliest form of human life and should be protected by dignity and
sanctity of life. The validity of such interpretation, considering the developing nature of
current knowledge on human embryo and the existing findings, has also been a subject of
controversy and criticism.400
Although there are some alternative perspectives among Catholic scholars and some
of them argue that the ethical status and personhood starts at the later phases of
embryonic life, the official position of Catholic Church is still based on bestowing full
ethical status and personhood to human embryo from the time of conception.401
Islamic Perspectives:
Early Human Embryo (Nutfah) in the Holy Qur’an: The term “Nutfah” by which the
semen and early human embryo have been named in the most Islamic classical texts and
scriptures, has been repeated 12 times in Holy Qur’an. In some verses, the consecutive
stages of embryonic and fetal development are described. For example:
“We created the human from an essence of clay. Then we made him, a drop (Nutfah),
in a secure receptacle (the womb). Then we created of the drop, a clot (of congealed
blood) and we created the clot into bite size tissue, then we created the bite size tissue
into bones, then we clothed the bones with flesh, and then produced it another creation.
Blessed is Allah, the best of creators”!402
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And: … and that it is he who created pairs, the male and the female, from an
ejaculated drop (Nutfah) and that upon him is the second creation.403
Obviously, the term used for referring to early human embryo in the Holy Qur’an and
Islamic Holy Scripture is Nutfah. Other terms, like Alghah (the clot) and Muzghah
(tissue) that represent the subsequent stages of fetal development, are not covered by this
part of this chapter.
According to Holy Qur’an, Nutfah is the very first stage of development of an
embryo. Whether it is attributed to: (a) the sperm (male gamete) which continues to form
an early embryo in the womb (the traditional understanding of embryonic development);
Or (b) just to the result of conception which develops in the womb after fertilizing an egg
by a sperm (the modern understanding of embryonic development), is not very clear in
the verses themselves. However, the commentators, based on their understanding of
embryology, have read the text differently.
In some verses, the former interpretation is more obvious, for example:
…was he not a drop of fluid which gushed forth?404
While, the proponents of the latter interpretation, refer to the verses which denote a
“mixed Nutfah” as the very first stage of embryonic development, for example:
Indeed, there came upon the human a period of time when he was an unremembered
thing. We have created the human from a drop (Nutfah), a mixture, testing him; we made
him to hear and see.405
As a matter of fact, in describing natural issues – from the human body to astronomic
facts – Qur’an never obviously contradicts the knowledge of the era in which the Prophet
lived. Therefore, the commentators of Qur’an, before the modern era, never understood

175

the Qur’anic verses describing the growth and development of fetus in contradiction with
the Aristotle’s or Galen’s descriptions of early human life. Accordingly they did not
consider any difference between semen and the early human embryo (before 40th day).
Even now, some commentators and jurists utilize this word with ambiguity. Some
others, however, clearly recognize the findings of modern science, which show the very
difference between sperm (the male gamete) and early embryo (the result of conception
in which a male and a female gamete are combined to form a zygote and then the zygote
multiplies to form the embryo).406
The Importance of Implantation: In their assessment of the tort committed against the
fetus, jurists have regarded implantation of the Nutfah in the uterus as the beginning point
of the sacred embryonic life beyond which any infliction of harm to it requires
compensation (Diah). Before implantation, destroying the Nutfah without any justifiable
reason is considered as wrong, but, according to the majority of Shiite scholars, no
monetary compensation has been considered for it. The monetary compensation gets
higher with growth of the embryo and fetus and reaches its maximum level after 120 days
which is the very point of ensoulment.407
Ensoulment and its Implications: As mentioned above, the later phases of fetal
development, including the one in which ensoulment takes place- is beyond the scope of
this part of this chapter. However, because of the important implications of this event on
the ethical and legal status of human fetus, it is worth mentioning, albeit briefly.
According to Muslim jurists, including the Shiite ones, ensoulment, which is the
breathing of divine soul into the human body, takes place after 120 days of embryonic
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life after implantation. It does not mean that this is the exact time of ensoulmant, but it
means that ensoulment never takes place before 120 days after implantation.
After the very point of ensoulment, the human fetus is considered as a human person
entitled to all moral and legal advantages attached to personhood. Before this point,
however, the human embryo or fetus (including early human embryo) is not considered
as a human person entitled of all legal and ethical rights. Accordingly, killing the human
embryo or fetus before ensoulment is forbidden but is permissible under certain
circumstances. After ensoulment, however, the fetus is considered as an inviolable human
person.
Controversies on Withdrawal: It has been claimed that withdrawal (the pull out
method for contraception) is the oldest contraceptive method used by human being. In
Shiite jurisprudential scriptures, the legitimacy of this method, which is named Azl, has
been discussed and different opinions have been expressed. According to the traditional
understanding of the very meaning of the term Nutfah, this method is a kind of wasting
Nutfah. Although today we know that during withdrawal it is only semen, not embryo,
which is wasted, but Muslim scholars, at least until recent scientific discoveries showed
the difference between semen and embryo, considered the semen as the very beginning
stage of human development (i.e. Nutfah).
Reviewing the above- mentioned discussions can shed light on the ethical status of
early human embryo in Shiite jurisprudence. Some Shiite scholars consider Azl as
permissible and plausible, provided the consent of wife has been obtained. They refer to
the Sunnah in which Prophet and Imams considered Azl as permissible. Some of them
consider it as permissible even without informing the wife.
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Other scholars, however, consider Azl as forbidden, as they mostly argued that the
purpose of marriage is child bearing and avoid bringing a baby is unacceptable for a
Muslim couple. Also they refer to the part of Sunnah whose documentation is less valid
than the part, which permits Azl. Accordingly, we can conclude that both the proponents
and opponents of this method did not consider any ethical status for Nutfah before
entering the womb.
Pre-Implantation Embryo: Bearing in mind that no monetary compensation (Diah) is
considered for destroying pre-implantation embryo, it seems that there is no ethical
relevance and worth for such embryos. Some contraceptive methods like intrauterine
device (IUD), which prevents implantation thus destroys the early embryo, have been
approved by religious authorities and used widely in contraception clinics in Iran. Most
Shiite scholars, however, consider this stage of embryonic life as respectful which means
that it should not be wasted or destroyed without having a justifying reason. Medical
research and health-related interventions such as contraception or infertility treatment are
among such reasons.
In 2003, Iran was the first Muslim country that adopted an act on embryo donation, as
a treatment for infertile couples. The act of embryo donation to infertile couples states
that the surplus early human embryos, produced by IVF for a legally married couple, can
be transferred to the womb of the recipient. This legislation paved the way for numerous
infertility clinics in Iran to use this technology, however, raised major ethical concerns
that is discussed elsewhere.408
As a matter of fact, almost all Shiite religious authorities and scholars, accepted in
vitro fertilization (IVF) as a permissible and legitimate mean for treating infertility. Also,
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they permitted scientists to conduct stem cell research involving destruction of human
embryo, with the purpose of finding new treatments for fatal or chronic diseases.
Regarding human embryonic stem cell research, Shiite authorities issued Fatwas and
declared it as permitted and legitimate.409
Moreover, mostly influenced by the guideline developed in the Western world, the
Iranian National Guideline for Research on Human Gamete and Embryo requires
researchers to perform research only on surplus embryos remaining after infertility
treatment and forbids producing human embryos just for research purposes.410
This chapter is inclined to conclude that according to the dominant reading of Shiite
jurisprudence, early human embryo, before implantation, does not have any ethical value
and can be utilized, manipulated or destructed for justified medical purposes. The ethical
value of human embryo is considered and talked about whenever implantation takes
place.
Global Governance and Genetic Research on PIHE: As mentioned in the previous
chapters of this dissertation, the Global Governance for Health Research has mainly took
place and been mirrored in the following ways: First, the international declarations,
codes, and guidelines developed for setting global ethical standards for health-related
research; second, the national rules and regulations made by the countries that host the
main funding bodies and institutions on international research; and third, the internal
regulations, standards, and guidelines of the various sorts of organizations that fund
international research.411 In the following parts the approach of global heath governance
toward research on human embryo is discussed. First, as an important and integral part of
global governance, the related international legislations and guidelines are discussed.
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Then, the existing ethical problems and gaps are introduced and at the final part, the
possible and practical ways toward an ethical consensus are depicted.
International Legislations and Guidelines: The most well-known and influential
international declaration on biomedical research that can be called as the cornerstone of
global governance for biomedical research is the World Medical Association's
Declaration of Helsinki. The principles of the Declaration of Helsinki will apply to all
clinical research in respect to human embryo, including PIHE, as well as all problems
that arise out of such clinical research. The World Medical Association recommends that
physicians refrain from intervening in the reproduction process for the purpose of making
a choice as to the child’s sex, unless it is to avoid the transmission of serious sex-linked
disease. Also, the World Medical Association expressly condemns any
commercialization by which ova, sperm, or embryo is offered for purchase or sale.412
In 2005, the United Nations (UN) approved a Declaration on Human Cloning that
urged member states to ban all forms of cloning, including therapeutic cloning.413 In the
same year, the UNESCO Universal Declaration on Bioethics and Human Rights was
approved and promulgated by UNESCO.414 The perspectives of George W. Bush
administration influenced the UN Declaration on Human Cloning, therefore, this
declaration entailed a total ban on human cloning even for research purposes.415 The
UNESCO Universal Declaration on Bioethics and Human Rights, however, does not
explicitly mention early human life, but some of its principles/articles are applicable to
this subject. These articles are as follow:
(1) human dignity that includes protecting human embryo regardless of considering it
as person or not.416 The principle of human dignity is the cornerstone of the theories that
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support the inviolability of early human life. This concept is very important in both
secular and religious schools of thoughts.417
(2) Respect for Human Vulnerability and Personal Integrity that covers early human
life according to Catholicism.418 The PIHE can be considered among the vulnerable
entities that need legal support and protection.419
(3) Protecting Future Generations, in a broader understanding of this principle, is also
applicable to this debate.420 Early human embryo is the very beginning of the next
generation. Therefore, protecting the future generations implies protecting and
safeguarding the early human life and the PIHE.421
The Existing Problems and Gaps: From what explained in this part of this chapter,
one can conclude that despite the great achievements and promises in the field of research
on PIHE, there are some ethical problems and legislative gaps than need the attention of
Global Governance for Health Research. These problems and gaps are as follow:
(1) The need to explicit inclusion of the rights of early human life in the international
declarations and legislations in the way that the ethical norms on them there is a global
consensus (such as forbidding production of human embryos for research purposes) be
included in these instruments. An explicit recognition of the ethical status of early human
life is a necessity for establishing sound ethical grounds for legislations that will protect
early human life through the global health governance.422 The international organization
such as the WMA, WHO, and international treaties can shape the organizational
backbone and support for these legislations.423
(2) The need to protection early human life by enforcing the related regulations
on the global scene. The organizational backbone of global health governance (see

181

above) should be in charge of enforcing the legislations that protect the early human
life.424 Enforcing the legislation through the mechanisms and power relations within the
global heath governance is complicated because in goes beyond and across the authority
of sovereign states.425 Therefore, there is a real need to establishing global and
international organizational background to support and enforce the related legislation on
the global scene.426
The Way towards an Ethical Consensus: Despite the existing conflicts and
disagreements among the main schools of ethical thoughts regarding the ethical status of
PIHE, as described above, there are some norms that can be considered as the area on
consensus among all these major schools. For example, all of these schools are in favor
of banning of production of human embryo for research purposes. This common area can
be used as a common ground and first step for establishing consensus on broader
concepts, also consents on creation global instruments (soft or hard international law) to
protect early human life as a function of global health governance.
Moving toward legislation and enforcement in this area is one of the main
functions of global health governance.427 Research enterprise has always been one of the
concerns of global health governance.428 The areas of consensus among the major schools
of thoughts have always shaped the bases for developing such soft and hard
legislations.429
For this purpose, interfaith dialogue can be used as a well-designed and
experienced method in the contemporary world.430 Through interfaith dialogue, different
schools of thoughts can explore their similarities and differences in order to found a
consensual basis for developing consensual legislations for global governance.431
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Therefore, one of the most crucial endeavors that can shape the future of such debates
and be suggested as a useful mean to achieve consensus on sensitive issues is interfaith
dialogue.432
This can be suggested that the organizations that are involved in global health
governance develop the specific global guidelines and legislations with reliance on the
above common and consensual areas and using the well-developed methods such as
interfaith dialogue as described above.
Conclusions: This part of this chapter, after a brief review of the scientific facts,
provided a critical ethical analysis of different significant and influential schools of
thoughts regarding the ethical status of early human life. Then, concluded that this has to
be one of the functions of global health governance to provide legislations and safeguard
the rights of early human life, at least as far as there is a consensus among different major
schools of thoughts. This is also argued that in face, some areas of consensus exist. As a
noteworthy example, this part of this chapter presented the currently existing consensus
on the necessity of placing a legal ban on producing human embryos for research
purposes.
As a more detailed summary, this part of this chapter discussed its subject in these
main parts: (1) the first part provided an overview of scientific and factual realities about
research on early human embryo. This part showed that for this kind of research, there is
real need to using and destroying PIHEs and there is a hope that in the future the
embryonic cells will be replaced by manipulated adult cells, however, this promising
development has not been able to completely replace the use of embryonic cells yet; (2)
the second part of this part of this chapter portrayed the ethical perspectives and concerns
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of three major ethical schools of thoughts regarding this subject. This part showed that
there are some significant, well justifies, and almost globally consensual concerns and
ethical principles/norms regarding research on early human embryo that can be used as a
basis for developing a consensual ethical framework for global governance for research
on early human embryo; (3) the third part of this part of this chapter examined this
subject and its ethical controversies in the global scale and on the global scene. This part
of this part of this chapter showed that there are unaddressed ethical concerns and gaps in
this regard that need global attention in terms of legislation and enforcement.
Based on the above-mentioned parts, this part of this chapter can list its conclusions,
and then limitations and suggestions, as listed below:
Conclusive Remarks: (1) there seems to be a global consensus on the principle of
respect for human embryonic life. Therefore, some implications of this principle such as
refraining of producing human embryo just for research purposes can be considered as
globally accepted standards of practice. These standards can be delineated and enforced
as parts of global governance for research on PIHE; (2) For preventing the noteworthy
harmful consequences of unleashed and uncontrolled exploitation of human embryos, the
existing soft international laws are not sufficient and there is a need to hard laws that
protect early human life from destruction and exploitation.
Limitations: The limitation of this study is as follow: This study does not include
other influential schools of thoughts those have their perspectives toward the ethical
status of early human life, such as Judaism, Buddhism, Zoroastrianism, and others.
However, the area of consensus that is provided in this part of this chapter does not seem
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to be violated by examining other schools and religions. However, a more comprehensive
study can be suggested for the future.
Suggestions: Further studies can be suggested in this area to further clarify the areas
of consensus among the major global schools of thought. In addition, further studies are
needed to explore the best ways in integrating these consensual norms into the
legislations that shape global governance for health. In addition, this part of this chapter
suggests more studies on the best and most efficient ways of enforcing the legislations to
safeguard early human life and at the same time, to protect and facilitate valuable
research and treatments.
As the final conclusion, this part of this chapter shows that in the era of globalization,
this is crucial to establish a comprehensive ethical framework for Global Governance for
Health Research, so the rights and welfare of the future generations will be protected and
safeguarded, even in the very first stages of their human life.
vi. Local and International Alternative Medicines
At the Intersection of Market, Medicine, and Politics: Using different sorts of
alternative and complementary medicine have had a growing trend in the USA and in the
world during the past decades. Many kinds of practices name themselves as alternative
medicine; therefore, there is a wide range of them from herbal/traditional medicines to
energy therapy, homeopathy, pressure therapy, and using the ones entail different sorts of
verbal or material practices. Efforts to revitalize traditional medicine in some developing
countries have also had political backgrounds and connotations. For example, one of the
elements of cultural revolution in China at the time of Mao was self-relying and in the
field of medicine, this was translated into using traditional Chinese medicine to replace
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Western Medicine.433 In India, establishing new organizations with the mission of
safeguarding the traditional medical heritage has been considered and effort to fight
against bio-piracy.
Two Accounts of Alternative Medicine: The term “alternative medicine” might be
misleading and confusing, even may lead some patients to abandon their conventional
therapies and appeal to the unproven methods that present themselves as “alternatives”.
The cautiousness on using this term, led the NIH to rename its institution from “National
Center for Complementary and Alternative Medicine” to “National Center for
Complementary and Integrative Health”.434 Research on local traditional medicine aiming
at marketing them in the global market has always raised challenging ethical concerns. 435
The existence of real clinical equipoise on some of the clinical trials on alternative
medicine is questionable.436
Although the above position seems to be prudent and scientific, in the reality of the
world of various kinds of alternative and complementary medicines, two different
accounts exist: The first account believe that the current modern medicine is just one of
the possible paradigms of medicine and there are alternative and rival paradigms to them
their respected branch of alternative medicine belongs. Therefore, they are not bound to
follow the criteria and methods of modern evidence-based medicine for showing the
efficiency and safety of their products or methods. They can just rely on their traditional
(and sometimes ancient, mystical, or superstitious) theories to find and prove them. The
second account, however, regards the alternative medicine as a resource for potentially
useful hypothetical and potentially useful treatments that have to be examined by welldesigned clinical trials and be added to the current arsenal of medical treatments if their
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efficacy and safety is adequately proved. Each of these accounts implicate a different
kind of research. The first account relies on the obsolete –even superstitious -paradigms
of science and research and can be categorized as pseudoscience. The second account,
however, is useful if governed properly by local authorities and Global Governance for
Health Research. Below, a brief analysis of these two accounts and their ethical
implications for Global Governance for Health Research is provided.
Alternative Medicine as a Brach of Pseudoscience: Emanuel and Grady in their
work on the ethical framework for research explain that scientific validity of research (in
the phase of creating research ideas and deigning research projects) is an important
ethical necessity.437 In other words, prior to assessing the rights of potential research
subjects, the review and oversight (i.e. governance) systems have to look at the scientific
validity of a proposed research. Allowing or conducting a research project that lacks
scientific validity is unethical.
Considering scientific validity ad an ethical requirement, the part of alternative
medicine described as the first account above, raises serious ethical concerns. The only
valid way available to show the efficacy and safety of medical treatments (medications or
interventions) is through evidence-based medicine. If a branch of alternative medicine
systematically flees from scientific evaluation (i.e. clinical trials), or claims that it relies
on theories beyond the regular understanding of science (the fallacy of different
paradigms), then there is a serious suspicious that it belongs to the realm of
pseudoscience and superstitions.438
Complimentary Medicine as a Useful Resource for Research: All the branches of
alternative and complementary medicine do not belong to pseudoscience and superstition.
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In fact, the branches of alternative medicine, especially the local traditional medicines,
that used various kinds of herbal, natural, and body-mind medications and interventions
have been practiced for thousands of years and are valuable resources of hypotheses that
should be evaluated and screened by evidence-based medicine. In this way, the efficient
and safe medications and interventions can be found and added to the local and even
global arsenal of medicine. In this way, first it is possible to find more natural, affordable,
and trustable means of treatment and health promotion for local communities, and
second, it is possible to market the medications found in the natural resources of local
communities to the world in a way that they benefit from it. This is a way to prevent and
counteract the problem of bio-piracy (see above).
Humoral and Herbal Medicine in Iran and India as a Case Study: Founded and
developed by ancient Greek and Roman and Medieval Muslim physicians and
philosophers, humoral medicine is based on theories about human anatomy and
physiology that nowadays are outdated and obsolete. Founded by Aristotle and
Hippocrates and expended and optimized by Galen and Avicenna, humoral medicine is
founded on this belief that human body contains four major bodily fluids or humors
(yellow bile, black bile, phlegm, and blood) and health is equal to balance among these
humors. Each of these humors are correspondent with a temperament. For optimum
health, there should be a balance among different temperaments. Indian ancient medicine,
Ayurveda, was also founded on a slightly different account of humors and their
determinant effects on health. The humoral medicine was closely related with the theory
of four elements, per that, all things are made from four basic elements: fire (presented in
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yellow bile), water (presented in phlegm), air (presented in blood), and earth (presented
in black bile).
Although the humoral theories of medicine are obsolete, some of their methods and
medications, especially herbal medicine can still be used as a resource for medical
hypotheses. The traditional Iranian and Indian physicians, who practiced based on
humoral medicine, often used herbs for creating balance among their patients’ humors
and temperaments. Some of these herbs can be beneficial, however, their efficacy and
safety should be proven by evidence based medicine.
The Case of Pseudoscience: Over the previous decades, a group of Iranian traditional
physicians (some of them call themselves hakim that is a name for wise physicians in the
Medieval era) tried to revive the humoral medicine with its traditional theories.439 They
argue that humoral medicine belongs to a different paradigm from the Western medicine,
therefore, does not need to be examined by modern standards of evidence-based
medicine. They appeal to conspiracy theory (modern medicine is West’s plan to destroy
health and good habits in Muslim societies) and religious beliefs (traditional medicine is
endorsed by religious figures such as the prophet and holy imams) for promoting their
practice. This group of traditional practitioners have also got governmental support
because they seem to promote self-reliance and relying on domestic and Islamic
resources/knowledge instead of Western ones. The same cause that promoted Chinese
traditional medicine at the time of Cultural Revolution. They argue that the traditional
medicine follows a different paradigm of knowledge and is not obliged to follow Western
standards (i.e. evidence-based medicine). They have taken advantage of the political
support and established numerous clinics and medical institutions all over the country and
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attract thousands of patients. In some cases, they provide very misleading and even
dangerous comments and guidance in the media. The principle of respect for scientific
validity urges Global Governance for Health Research not to verify these kinds of
practices and insist on the universal standards of evidence-based medicine and medical
research that are not Western but are a part of common heritage of mankind.
The Case of Preventing Bio-piracy: On the other hand, a group of politicians and
physicians both in Iran and India argue that the herbal medications and regimes of
traditional medicine should be examined by modern standards to discover the effective
and safe ones before they are discovered and patented by Western pharmaceutical
companies (bio-piracy). This is the right and ethical way of using the knowledge of
traditional medicine and should be supported by Global Governance for Health Research.
For example, in the Bt Brinjal case, the National Biodiversity Authority of India (NBA)
sued a US-based transnational company because they had used indigenous varieties of
brinjal to create a kind of genetically modified food without prior contract or agreement.
Similar claims have been made about numerous produces such as Curcuma, Neem, and
Basmati Rice.440 These legal cases showed the legal legitimacy of claims on bio-piracy.
The best wat to fight bio-piracy, however, is not making lawsuits after it occurred.
Instead, the best way is trying to conduct research on natural resources and traditional
knowledge and patent them before being stolen by bio-pirates. Supporting these efforts
by facilitating scientific research on traditional medicines is part of the ethical duties of
Global Governance for Health Research.
Conclusions: Scientific validity as an ethical requirement is the first ethical point
relevant to the debate on alternative and complementary medicine. Scientific methods for
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assessment and evaluation of efficiency and safety of new treatments are a wellestablished part of medical science all over the world. Therefore, they also can be
considered as a part of common heritage of mankind. Abidance to the standards of
scientific validity and protecting the patients/consumers/research subjects from the
danger of medical pseudoscience and superstitions in an ethical duty for Global
Governance for Health Research and should be included in any ethical framework
developed for it.
On the other hand, alternative and complementary medicine should be considered as a
valuable resource of hypotheses to be evaluated by scientific methods and presented to
the communities. In this account, local traditional medicines can be used to find new and
more natural, culturally acceptable, and cost-effective treatments to be used for treatment
and health promotion in local communities and to be marketed with benefits to local
communities so to counteract bio-piracy.
vii. Conclusions
The six cases discussed in this chapter reveal different aspects of the issues and
challenges that Global Governance for Health Research faces and the ethical principles
that are needed to approach these challenges and issues. A brief depiction of the lessons
learned and principles that are needed to approach the ethical issues of each cases in
provided in table 4.1.
The variety of the factors involved in the challenges of Global Governance for Health
Research is stunning. A broad range from the problems of exploitation and double
standard in research in developing countries to the issues of biopolitics and bioeconomics
in transferring biological and natural samples, to the problems of honesty and integrity in
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research and publication of the results of research, and to the problems of noteworthy role
of religious ethics in research on early human embryo. This broadness and variety shows
that various ethical principles are needed to develop an ethical framework that is capable
to approach these different issues with efficiency and competency.
A look at the list of the principles mentioned in table 4.1. show that their number and
scope is vaster than the traditional set of four principles of biomedical ethics. In other
words, Global Governance for Health Research needs a broader set of ethical principles
for approaching its issues and for developing a comprehensive and efficient ethical
framework.
Because of the global nature of this field, only cross-cultural principles can be used and
relied in developing an efficient ethical framework. Fortunately, three major works have
already provided a framework and two sets of principles that have proved cross-cultural
and consensual. The framework developed by Emanuel and Grady,441 the canonical set of
four principles of biomedical ethics,442 and the principles provided by the UNESCO
Declaration of Bioethics and Human Rights.443 In the following chapter of this
dissertation, these theoretical works will be relied upon to develop and ethical framework
for Global Governance for Health Research.
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Chapter Five: A Normative Framework
Adoption of the Universal Declaration of Human Rights by the United Nations
was actualization of a dream and embodiment of a promise: a global consensus on a
framework composed of a set of fundamental ethical principles based on the common and
shared understanding of human dignity among all the cultures and communities and
inspired by the spirit of cosmopolitanism.444 This historic event showed that reaching
such a framework is not out of reach of humanity. However, what happened afterwards,
historically speaking, showed that keeping the promise of human dignity and equity is
easier said than done.
When it comes to the realm of global bioethics, the UNESCO Declaration of
Bioethics and Human Rights, adopted in 2005, is the legitimate and genuine successor of
the Universal Declaration of Human Rights. Taking a look at the current scene of global
research, as depicted in the previous chapters of this dissertation, also shows that keeping
the promise embodied in this declaration is not easy either. However, relying on these
consensual principles that are an invaluable part of the common heritage of mankind is
the only legitimate ground for founding an ethical framework for a global enterprise such
as health research, i.e. an ethical framework for Global Governance for Health Research.
In this chapter, the main question of this proposal/dissertation is answered. After a
review of the existing approaches, the suggested ethical framework is provided. This
ethical framework for Global Governance for Health Research has three main elements:
First, a background of personal and subjective virtues that are the merging points of the
traditional masculine and modern feminist accounts of virtue ethics; second, a core of
principles mainly from the UNESCO Universal Declaration of Bioethics and Human
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Rights combined with the systematic framework that is named the NIH framework (see
below), and third, a place for situation ethics embodied in the crucial role of Research
Ethics Committees (RECs) and Institutional Review Boards (IRBs) composed of welltrained experts and lay persons from all the involved parties and communities. A brief
scheme of this framework is depicted in Table 5.2.
i. A Systematic Framework:
The necessity of a normative framework for Global Governance for Health
Research is shown in the previous chapters of this dissertation through depicting and
discussing the existing ethical challenges and examining the cases that show how these
challenges affect individuals and communities around the globe (see chapters 3 and 4).
Research activities involve and entail power relations. For example, power relations
between researchers and research subjects, researchers and communities that host
research and research subjects, health policy makers and researchers, corporations and
researchers and communities, etc. And wherever there is any kind of power relation, there
is a need to ethics and at the larger scale, an ethical framework. Globalization has brought
the power relations of research enterprise to a global level. Therefore, it has become a
subject for global bioethics that assesses and examines the ethical aspects of power
relations at the global scale. This is the gist of the reason behind the need to an ethical
framework. The details are provided in the previous chapters.
The NIH Framework: In this part, the framework developed and introduced by
Ezekiel J. Emanuel, David Wendler, and Christine Grady is introduced and described.
This framework helps to tailor the principle-based approach to the special subject of
research ethics and find the most relevant ethical principles included in other, typically
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more general, frameworks. Although Emanuel, Wendler, and Grady have not named this
framework the NIH framework, since all of these authors had been working at the
Department of Bioethics of the Clinical Center of the NIH, and two of them are still
working there, and since the current and former heads and the founder of this department
are among the authors who developed and created this framework, this chapter names this
framework “the NIH Framework”.
The NIH framework is the result of the authors’ work on the numerous domestic
and international research ethics guidelines published during the past 6 decades in
different countries or by international organizations. They have provided a list of a
selected group of these guidelines as follow: Nuremberg Code, Declaration of Helsinki
(WMA), Belmont Report, 45 CFR 46 (Common Rule), International Ethical Guidelines
for Biomedical Research Involving Human Subject (CIOMS and WHO), Good Clinical
Practice: Consolidated Guideline (International Conference on Harmonization [ICH] of
Technical Requirements for Registration of Pharmaceuticals of Human Use), Resolution
196/96: Rules on Research Involving Human Subjects (National Health Council, Brazil),
Convention on Human Rights and Biomedicine (Council of Europe), Medical Research
Council Guidelines for Good Clinical Practice in Clinical Trials (United Kingdom),
Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda
(Uganda National Council for Science and Technology), Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans (Tri-Council Working Group, Canada),
National Statement on Ethical Conduct in Research Involving Humans (National Health
and Medical Research Council, Australia), Ethical Guidelines for Biomedical Research
on Human Subjects (Indian Council on Medical research), Guidelines on Ethics for
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Health Research in Tanzania (Tanzania National Health Research Forum), Guidelines on
Ethics in Medical Research: General Principles (Medical research Council of South
Africa, Guidelines for Good Clinical Practice in the Conduct of Clinical Trials in Human
Participants in South Africa (Department of Health, South Africa).445 This list shows that
they reviewed a variety of influential and pivotal guidelines along with other ones
representing different geographical areas.
Emanuel, Wendler, and Grady argue that all these guidelines suffer from a number
of common problems such as: they have either created and published in response of a
specific scandal (e.g. Nuremberg code in response to the revelation of the experiments
done by Nazi researchers and Belmont Report as a reaction to the revelation of the ethical
flaws in Tuskegee Syphilis Study) or had an specific practical aim rather than taking a
comprehensive approach (e.g. International Conference for Harmonization was held to
develop common rules of registration of pharmaceuticals for human use). In addition, to
some extent because of their reactional nature, they are mistaken in some of their
guidance’s (e.g. The Nuremburg Code regards taking voluntary consent as an absolute
requirement that makes beneficial research on incompetent and incapacitated people
impossible). Therefore, none of these guidelines have created a broad, comprehensive,
and systematic ethical framework for research on human subject. They also have overlaps
that should be organized into a consistent whole. 446
For creating a comprehensive and systematic ethical framework that is free of the
above-mentioned shortcomings and flaws of previous guidelines and minimizes the
possibility of exploitation, Emanuel, Wendler, and Grady developed and published a new
framework for clinical research. This framework consists of eight principles and each
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principle entails a number of benchmarks that elaborate and explain each principle by
providing practical interpretation on the requirements that each principle entails. A
characteristic of the principles of this framework is that they are presented in a sequential
manner, i.e. orderly from the stage of designing a research project to the stages of
conducting and oversighting them. The principles on the NIH ethical framework are as
follow:
Collaborative Partnership: The role of communities that host research is
incorporated in this principle. This role starts from the very first stages of research, when
the research idea and design is shaping and the first drafts of the proposal is being
prepared. This principle implies the participation of community representatives in all the
stages of research projects, from designing to the dissemination of results. The
community representatives as the partners of research team, also hold responsibility in
safeguarding the ethical principles and regulations. They also help the research team in
abiding with this benchmark of this principle that the values, norms, and cultures of host
communities will be respected.447 The limit of this respect will be the principles implied
by human dignity and fundamental human rights as described in the UNESCO
Declaration of Bioethics and Human Rights.448 This principle also entails assuring the
fair benefit of the community from the research. This is corresponding with UNESCO’s
principle of Sharing the Benefits.449 Tangible benefits such as intellectual property and
authorship should be considered too. Collaborative partnership is the principle that
prevents unethical patterns of research behavior such as helicopter research and is helpful
in preventing others such as having double standards. Therefore, the ethical principle of
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collaborative partnership is a crucial component of the ethical framework for Global
Governance for Health Research.450
Social Value: This is an ethical imperative for health research to be beneficial for
the society. Otherwise, the resources used for research are wasted and the risk imposed to
the research subjects is unethical. Assessing the social value of research should be done –
or started- from the first stages of designing and proposal-writing in a prospective way.
Although there is no principle in the UNESCO Declaration of Bioethics and Human
Rights that can be considered exactly equivalent to the principle of social value, some
principles of this declaration are partly consistent with the principle of social value,
including: Benefit and Harm; Equality, Justice, and Equity; Respect for Cultural
Diversity and Pluralism; Solidarity and Cooperation; Social Responsibility and Heath;
Sharing of Benefits and Protecting Future Generations.451
The benchmarks of the principle of social value entail a number of considerations.
For example, determining the group (or groups) of person to whom the research is
valuable. In Global Governance for Health Research, this is important to see if the
communities from them the research subjects will be recruited is among the potential
benefactors of the short-term and long-term results of the research. In addition, the
consistency of the research project with the health priorities and needs of the host country
is of crucial importance. One of the challenges of Global Governance for Health
Research is conducting research in LMICs that are designed to cover the health needs of
HICs. This problem was examined in the case of HIV/AIDS research in the previous
parts of this dissertation. Another example is Malaria research. Although Malaria is a
health problem of LMICs, however, when the exact questions of research are assessed in
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relation with the health needs of the host community, new challenges arise. In the case of
Malaria, for example, research on medications for preventing Malaria for a short period is
more useful for tourists who travel to the Malaria-infested regions, while research on
Malaria vaccine is more compatible with the health needs of local people. In addition,
provisions for maximizing the social value of research is of ethical importance. Requiring
data-sharing, as discussed in Chapter 3, is one of the regulations adopted by Global
Governance for Health Research to fulfil this ethical imperative. Also, the burden of
research on the healthcare infrastructures of the host community/country is another
benchmark derived from the principle of social value.452
Scientific Validity: Observing the scientific and methodological standards is an
ethical imperative. Any deviation from the generally accepted scientific and
methodological standards should be justified. In addition, the research should be designed
and conducted in a way that is useful for solving the problem or answering the question
for which it was designed and conducted. In other words, to be used for solving the health
problems of people. Providing essential healthcare services for research subjects and
preventing them from unnecessary or serious harms is another benchmark of this ethical
principle.453 This principle is compatible with the following principles in the UNESCO
Declaration of Bioethics and Human Rights: Benefit and Harm; Equality, Justice, and
Equity; and Social Responsibility and Health. The value of scientific validity, however, is
not emphasized in this declaration in the shape of an individual principle.454
When it comes to Global Governance for Health Research, respect for scientific
validity shows its importance in challenges such as the one described in the case of
Alternative and Complementary Medicine (see chapter 4). The lack of scientific validity
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causes wasting of resources, harming the subjects, and unwanted promoting of
pseudoscience in research enterprise. Only scientifically valid research is useful for
promoting health and dealing with health problems in communities. Therefore, Global
governance for Health Research should emphasize on the importance of scientific
validity through including it in the soft law and require research funding, oversight, and
policy-making bodies to consider this important factor in funding, confirming, and
monitoring research projects.
Fair Participant Selection: This is the first principle of this framework that mostly
pertains to the phases of conducting research projects. This principle requires that the
criteria of recruiting human subjects for clinical research be limited to only the ones that
necessitate by the research objectives, risks, benefits, and the feasibility of conduction the
research. No other factors, such as availability and vulnerability of the potential subjects
is ethically justified. The benchmarks of this principle entail that the research population
be selected to ensure and maximize the scientific validity and reliability of the data and
results based on research objectives and methodological considerations, minimizing risk
for the research subjects, and maximizing the social value of research and the benefit of
the research project of its individual subjects.455 This principle is more compatible and
consistent with the following principles of the UNESCO Declaration of Bioethics and
Human Rights: Human Dignity and Human Rights; Benefit and Harm; Respect for
Human Vulnerability and Personal Integrity; Equality, Justice, and Equity; NonDiscrimination and Non-Stigmatization; Solidarity and Cooperation; and Social
Responsibility and Health.456
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The importance of this principle for Global Governance for Health Research
cannot be overemphasized. Some of the major challenges of Global Governance for
Health Research, as explained in chapters 3 and 4, are related to the fairness in
recruitment of research subjects. The challenge of double standards entail having unfair
double standards in recruiting research subjects in developing countries or poor
communities. The vulnerable populations in marginalized and poor communities are at a
greater risk of exploitation by research purposes. Other considerations are also important
and relevant, for example including the imperative of conducting phases I and II of
clinical trails only in developed countries, with the purpose of protecting potential
research participants in developing countries, once included in the CIOMS guidelines in
1993, subsequently was removed because of objections made by the representatives of
developing countries.457
Favorable Riske-Benefit Ratio: Clinical research imposes risk on research
participants to produce beneficial knowledge. The risk of research should be assessed and
minimized. This is the first benchmark of this important principle. This benchmark
entails that the assessment and minimizing the risk should be done based on scientific
evidence. In addition, the research should be conducted by qualified researchers.
Benefits, on the other hand, should also be assessed, maximized, and enhanced. The
benefits of research can be categorized into two groups: first, the benefits for the society
that entails the social value of research. Second, the benefits of research for its individual
research subjects. The ethically important imperative is that in risk-benefit assessments
for justifying a research, only the health benefits of research interventions or medications
should be considered and calculated. In other words, although payment to research
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subjects for reimbursing their time and efforts is not ethically wrong, and enhancing the
health benefits and ancillary care for research subjects, especially in communities that
they cannot receive them outside the research setting, is an ethical standard, these
secondary gains (e.g. payment or ancillary care) should not be considered as the benefits
of research in risk-benefit assessment.458
This principle is clearly consistent – and even identical- with the principle of
Benefit and Harm in the UNESCO Declaration of Bioethics and Human Rights: Human
Dignity and Human Rights.459 Also is consistent with the principles of Sharing the
Benefits, and Social Responsibility and Health.460
In the perspective of Global Governance for Health; the risk-benefit analysis and
the imperative of maximizing the benefit to risk ratio; preventing unnecessary and
unjustified harm; and enhancing health benefits for research subjects, especially for
vulnerable groups are very relevant to ethical issues in research in developing countries,
as explained above under the titles of double standards and helicopter research in chapter
3. The vulnerable populations in developing countries may not be able to assess the risks
and benefits and make decisions independently. In addition, politicians and political
representatives of such countries may have conflicts of interests and may not be the fairly
selected and democratic representatives of local people. Their deals with pharmaceutical
companies should be under scrutiny of a sort of governance that takes care of the interests
of local and vulnerable populations in risk/benefit analysis of research. For this purpose,
having real representatives of local communities and populations in oversight bodies (e.g.
Research Ethics Committees and Institutional Review boards) is important and should be
emphasized by Global Governance for Health Research. In addition, empowering local
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members of Research Ethics Committees and other oversight and policy making bodies
for performing efficient and accurate risk-benefit analyses is of crucial importance. As an
example, the programs funded by Fogarty International Center (FIC) of the NIH for
research ethics education LMICs has been a noteworthy step in this regard. Although
accused of ethical imperialism, these programs have empowered local experts to take part
in research oversight and monitoring and tried to keep its funded training programs
compatible with local cultures and value systems.461
Independent Review: Over the first decades after WWII, when utilitarianism was
the predominant paradigm in research ethics and research oversight (mostly in the United
States as the pioneer in health research and bioethics), it was thought that ethical research
is dependent on ethical virtues of researchers. In other words, good and virtuous
researchers and doctors necessarily do ethical research. It was believed that the unethical
behavior of Nazi doctors in their experiments on human subjects during WWII was
because of them being wicked and having unethical ideas and purposes. After the
revelations made by Henry Beecher in 1967 that showed that unethical behavior
happened in prestigious American universities and institutions and by reputable doctors
and researchers, the above perspective changed and the importance of independent
review based on ethical principles was proved.462 Consequently, the importance of
establishing Institutional Review boards (IRBs) or Research Ethics Committees (RECs)
and independent review as an institution in the governance of research enterprise was
emphasized and entered the soft and hard law of research oversight and Global
Governance for Health Research.
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Independent review is aimed at protecting all parties involved in research,
especially the more powerless and vulnerable ones, against the possible conflicts of
interests and ensuring “public accountability”. The benchmarks of this principle include:
establishing regulations for independent research review and oversight by law and
regulations and making sure that they are properly followed; ensuring the independence
and competency of the IRBs (or RECs); and the decisions of review and oversight bodies
being transparent, legitimate, and ethically informed.463
The UNESCO Declaration of Bioethics and Human Rights, also puts emphasis on
the importance of independent review. In article 19, this declaration states that:
“independent, multidisciplinary, and pluralistic ethics committees should be established,
promoted, and supported at the appropriate level.” This imperative is consistent with
principles such as: Benefit and Harms; Respect for Human Vulnerability and Personal
Integrity; Equality, Justice, and Equity; Respect for Cultural Diversity and Pluralism;
Sharing of Benefits; and Protecting Future Generations.464
In this part of this ethical framework, again, the importance of empowering local
experts and individuals for taking part in independent ethical review of internationally
funded research is obvious. In other words, fulfilment of this important part of ethical
framework for research and its benchmarks is dependent on having enough expertise and
research ethics knowledge to take the role of independent review and represent local
people and their interests in reviewing research projects. In sum, this principle has two
major implications for Global Governance for Health Research: first, including the
necessity and obligation of independent review in the related laws and regulations, and
second, empowering MLICs and vulnerable communities/populations to take part in
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independent review via their informed, trained, and qualified representatives. The latter
implication, again, raises the issues of research ethics training, the duty of HICs to
provide this training, the concerns on ethical imperialism and colonialism, and the respect
for local cultures and value systems as discussed above under the title of Favorable RiskBenefit Ratio.465
Informed Consent: One of the characteristics of the NIH framework is its
accordance with the sequences of research projects. It starts with the considerations
mainly relevant to the phase of developing research idea and proposal and continues with
the obligations of the phase of subject recruitment and afterwards deals with the ethical
concerns that are related with the rights of the people who are selected to be invited to
join the research as research subjects, the most important among them being informed
consent. Informed consent has been the most discussed topic in research ethics. In other
research frameworks, usually informed consent takes the first place in order. Although
Beauchamp and Childress assert that their framework of principles does not connote any
order or ranking among the four principles, however, in Western culture the principle of
respect for autonomy has always taken the utmost priority. In other guidelines and
frameworks, such as The Belmont Report, the principle that entails the obligation of
taking informed and voluntary consent (respect for person in Belmont Report) is placed
at the top.466 In the UNESCO Declaration of Bioethics and Human Rights consent is the
fourth in the order of principles, however, human dignity and human rights, as the
theoretical background of consent, is the first principle of this declaration.467
The benchmarks of this principle entail attention to the sufficiency and adequacy
of information provided for the participants in a way that they are nor ambiguous and
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inadequate nor too detailed and overwhelming. In addition, considering the surrogate
decision making if the subject does not have capacity and taking additional informed
consent from local authorities if demanded by local norm and the consistency of the
informed consent with the cultural and political contexts in which the subjects are
recruited. 468
The UNESCO Declaration of Bioethics and Human Rights incorporates Consent as
an individual principle. In addition, the following principles are also in relevance with
consent: Human Dignity and Human Rights, Autonomy and Individual Responsibility,
Persons without the Capacity to Consent, Respect for Human Vulnerability and Personal
Integrity, Non-Discrimination and Non-Stigmatization, and Respect for Cultural
Diversity and Pluralism.469
Informed consent is one of the most crucial and discussed topics in Global
Governance for Health Research. All the competent participants of research, regardless of
the contextual factors such as the country of residence or the socioeconomic status,
deserve to be respected by obtaining voluntary and informed consent. The contextual
factors, such as the cultural issues cannot override this fundamental right. In addition, the
content of the informed consent should be compatible with cultural context and
conditions, for example, the information should be provided in a language that is
understandable for the research participant. In the cases that local authorities demand to
be asked for permission for research, their permission can be added to the individualized
informed consents but cannot replace them. For example, if a research project needs to
recruit subjects from a tribe, the researchers can obtain a consent from the head of tribe
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but does not exempt them from the obligation of taking informed consent from each
individual research participant from that tribe.
Respect for Participants: The ethical duties of researchers to the participants is not
limited to informed consent, but they start with it. The ethical responsibility of
researchers toward the participants start when they approach the participants to invite
them to join the research project and continues even after the end of the project. The
researchers are responsible to continuously do their best to minimize the risk and harm
for the participants. The researchers should monitor the health and well-being of the
participants all over the study and as long as the effects of the experimental study might
persist. Other rights of the participants, including privacy and confidentiality, should be
strictly observed. This is also applicable to the data that are kept for a period of time after
the research, such as the data that may be shared (see data-sharing in chapter 3) and the
samples kept in biobank and big data.470
The other benchmark of this principle is the right of the participants to withdraw
themselves from the research project without any penalty or adverse effect on their
healthcare. During and after the end f trial, the researchers should pay attention to the
healthcare of patient. This may include providing ancillary care during the trial and
referring to local healthcare providers at the end of research project. Also, paying proper
attention to the accidental findings during the research and informing the third parties of
their health interest is at stake.471
This principle is consistent with the following principles of the UNESCO
Declaration of Bioethics and Human Rights: Human Dignity and Human Rights; Benefit
and Harm; Autonomy and Individual Responsibility; Consent; Persons without Capacity
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to Consent; Respect for Human Vulnerability and Personal Integrity; Privacy and
Confidentiality; Non-Discrimination and Non-Stigmatization; Respect for Cultural
Diversity and Pluralism; Solidarity and Cooperation; Social Responsibility and Health;
and Sharing of Benefits.472
This principle and its consistent principles in the UNESCO declaration have
numerous implications for Global Governance for Health Research. The challenges of
double standards, exploitation and helicopter research, and data sharing and big data are
in close relevance with this principle. The researchers should take care of both
fundamental rights and health needs of their research subjects and their communities and
abide to this ethical responsibility with considering the cultural contexts (to provide the
best care in a culturally friendly and consistent way) and socioeconomic contexts (to pay
attention to the health needs of the participants that cannot be met outside of research) in
which the research is being hosted and the participants live and will continue living after
the end of the research projects.
The Missing Parts of the NIH Framework: The most notable missing parts of the
NIH framework are the principles that would govern research integrity, conflict of
interest, and publication ethics. The NIH framework is created to govern clinical research
and is focused on the practical/clinical aspects of research and their ethical issues and
concerns. This characteristic makes this framework even more relevant to Global
Governance for Health Research. A review of the challenges and case studies presented
in chapters 3 and 4 of this dissertation shows that the most prominent ethical concerns of
global health research are in relation with clinical research. Epidemiological research
creates less ethical issues. Research integrity and intellectual property and patenting are
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among the prominent ethical issues in global health research and are covered by
principles provided by the UNESCO Declaration of Bioethics and Human Rights that is
appealed in developing an ethical framework for Global Governance for Health Research
in this chapter (see below).
ii. Principle-based Approach: Pros and Cons
In this part, the principle-based approach will be analyzed. The pros and cons of
this approach will be reviewed trying to answer this question that whether the principlebased approach provides an effective and comprehensive ethical framework for Global
Governance for Health Research or not? As described below, the most consistent and
comprehensive framework of principles available to be used in formulation and ethical
framework for Global Governance for Health Research, is the framework adopted by
UNESCO in 2005. As described above and depicted in Table 5.1., Each principle of the
systematic framework of the NIH is consistent with a certain number of principles of the
UNESCO Declaration on Bioethics and Human Right. In this part of this chapter, after a
review of the existing sources of ethical principles for Global Governance for Health
Research, the comprehensiveness of the UNESCO model is shown and its principles are
adopted to be combined with the research-specific and systematic approach of the NIH
framework to shape the main element of the ethical framework that this chapter suggests
for Global Governance for Health Research.
The Existing Resources of Principles: One of the fundamental ethical principles in
research ethics is the principle of non-exploitation.473 This principle was discussed in
detail in chapter 3 of this dissertation. The framework suggested by this chapter for
Global Governance for Health Research adopts this principle as one of its fundamental
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components along with two other principled, Human Dignity and Human Rights. Other
major sources of principles for health research (that are also the main sources of
principle-based approach in global bioethics) are the four principles theory of Beauchamp
and Childress474 and the UNESCO Declaration on Bioethics and Human Right.475 In
addition, as described above, an ethical framework for health research in developed and
another one for developing countries is developed and presented by Emanuel and
Grady476.
The Principle of Non-Exploitation: As explained above, this principle in not among
the principles of UNESCO Declaration of Bioethics and Human rights, however it has
been argued that the most fundamental concern in research ethics, especially when it
comes to clinical research, is avoiding exploitation. It has been argued that nonexploitation is an overarching principle for all the principles and regulations in the field
of research ethics, including the most general ones such as respect for person and
beneficence.477 A detailed conceptual analysis of this principle is provided in chapter 3
under the title of Exploitation and Helicopter Research. The accounts provided by
Wertheimer, Kant, and Marx are discussed there (see chapter 3).
In clinical research, human subjects are “used” to generate health knowledge,
therefore, they are at the risk of exploitation. The same is true about the host communities
and countries (see Exploitation and Helicopter Research, above in chapter 3). This risk of
exploitation is compatible with both classic Kantian account (using individuals merely as
a mean and not simultaneously as an end) and the more recent account presented by
Wertheimer (unfair distribution of the benefits and burdens of an interaction) and
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explained above in chapter 3. Minimizing exploitation is the fundamental ethical purpose
behind the ethical framework of Emanuel, Wendler, and Grady (see above).478
The Canonical Set of Four Principles: A set of principles for biomedical ethics
had previously been presented at time of drafting the UNESCO Universal Declaration on
Bioethics and Human Rights. This set of principles presented by Beauchamp and
Childress is called the four principles approach (or the Georgetown approach) to
biomedical ethics. A version of these principles had previously been developed and
published in the Belmont report. Those set of principles includes: (1) Respect for
autonomy: This principle demands the healthcare providers to respect the informed
decisions made by their patients or their legal representatives. This principle is part of the
wider one entitled “respect for person” in Belmont report. (2) Beneficence: This principle
denotes that the main purpose of health care should be maximizing good results and
outcomes for the patients. This principle in addition to Non-maleficence (the next one) is
entitled “beneficence” in Belmont report. (3) Non-maleficence: This principle implies the
old motto that says: “first, do not harm” and implies the obligation of health care
providers to minimize harms for their patients. (4) Justice: This principle with the same
name exists in the Belmont report. This principle can be discussed in different levels
from the bedside to the entire heath system of country or even global heath
governance.479
The above principles are crucial and fundamental. They are relevant to every level
and scale of health-related research, from the small projects in local institutions to the
large multicenter and internationally collaborative ones. Global governance for
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biomedical research, however, needs more principles for dealing with its specific ethical
challenges as described above.
The UNESCO Universal Declaration on Bioethics and Human Rights: For
portraying the most multilateral and inclusive ethical frameworks for a branch of global
governance, as discussed above in this chapter, one should rely on the most consensual
sets of such principles/norms. The UNESCO developed this consensual set of principles
of global healthcare after long discussions and deliberations of the delegates of almost all
of live and large cultural traditions in the world.
The UNESCO Universal Declaration on Bioethics and Human Rights has been
compiled and finally adopted by acclamation by the General Conference of the United
Nation’s Educational, Scientific and Cultural Organization (UNESCO) in October 2005.
It is noteworthy that many of the principles presented by this instrument are the ones that
were proposed by delegates of developing countries to the previously existed classical
sets of principles, which had been developed and introduced by Western bioethicists.480
In the UNESCO Universal Declaration on Bioethics and Human Rights, all the
above principles do exist, but other ones are added which are more relevant to global
health governance. Therefore, in discussing this very issue in seems that the UNESCO
deceleration provides the best available – and internationally agreed upon – framework of
values and norms in the form of a set of principles.
As described above in this chapter and depicted in Table 5.1., among the
principles presented by this international instrument, some of them are the most relevant
ones to the realm of health research ethics and consequently to the Global Governance for
Biomedical Research. These principles that shape a crucial part of the ethical framework
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suggested by this dissertation. The list of these principles can be found in Table 5.2. A
certain number of the most repeated (see Table 5.1) and referred ones are listed and
briefly described below:
human dignity and human rights: This principle, along with non-exploitation that
has been called the “fundamental ethical purpose” of the NIH ethical framework for
health research,481 shapes the fundamental/basic layer of principles of the principle-based
element of the ethical framework for Global Governance for Health Research. The
concept of human dignity, although not fully and exclusively defined yet, and despite the
large amount of theoretical debates and controversies that exist on its bases, limits, and
implications, is the conceptual basis of fundamental human rights and freedoms as
asserted in the UN Universal Declaration of Human Rights.482
The concept of human dignity and its implications formulated as the fundamental
human rights and freedoms are a part of common heritage of mankind and shape the
limits and red lines for various interpretations of other principles. In other words, no
interpretation or understanding of other principles, including the principle of Respect for
Cultural Diversity and Pluralism, is ethically allowed to violate and restrict the principle
of Human Dignity and Human Rights.483 These are the reason behind placing this
principle among the ones in the more basic/fundamental layer/level of principles in the
suggested framework for Global Governance for Health Research (see Table 5.2).
Respect for Human Vulnerability and Personal Integrity: Vulnerability can be
defined as special fragility and susceptibility to confronting with risks and harms. In a
broad sense, all human beings are vulnerable. Therefore, research ethics considers this
general vulnerability and safeguards different parties of research interactions from
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exploitation. However, some groups of people have specific traits and characteristics that
make them more vulnerable. In health research, vulnerable groups included infants and
children, captive populations, unborn humans, people with mental or physical
impairments and disabilities, people who live in poverty, the elderly, among other social
and demographic groups. These groups deserve special attention and consideration in all
the phases of research. The relevant ethical guidelines should be observed. And the RECs
and IRBs should pay attention to safeguarding the rights and safety of these groups of
potential research subjects.484
Equality, Justice, and Equity: The fundamental equity of all human beings is rooted
in the concepts of human dignity and human rights. All human beings, regardless of the
sources and sorts of dignity that may acquire or lose throughout their lives, are bestowed
with fundamental human dignity that guaranties their fundamental human rights and
freedoms. In addition to this basic equity, the concepts of justice, fairness, and equality
are crucially relevant to Global Governance for Health Research. Seriously considering
the shares and benefit of research participants and the host communities/countries is
among the implications of this ethical principle. In all phases of research, from
formulating research idea and proposal (considering the social value and avoiding to
waste common resources by scientifically invalid designs) to the phase of recruiting the
research participants and the phase of distributing the results of research and taking
advantage of them (e.g. patents, affordability for people of host communities), the
principles of justice and equality are relevant. Therefore, this principle of the UNESCO
declaration is included among the principles of the suggested framework for Global
Governance for Health Research.485

214

Respect for Cultural Diversity and Pluralism: This principle has numerous
implications in global health research. As an instance, the issue of taking consent from
local authorities has been previously discussed in this chapter. Although this crucial
principle is the backbone of global collaboration and solving the problems such as ethical
imperialism and colonialism, it is limited by distinct red lines, that is the fundamental
human rights and freedoms. Within the area allowed by these red lines, however, respect
for cultural diversity and pluralism brings about social capital and mutual respect and
collaboration that is earnestly needed by the global research enterprise.486
Solidarity and Cooperation: In a broader perspective than social the ones of social
responsibility and sharing of benefits, the concepts of solidarity and cooperation are in
consistence with the virtues of empathy, compassion, and care. Human beings ultimately
belong to a specie with shared origin, inhabitant, and destiny. Well-being and prosperity
for some is meaningless when is accompanied with misery and poor health for others,
even in far distances. The historic scandals of global ethics enterprise as described in
chapters 3 and 4 have been rooted in the lack or deficit in the sense of solidarity.487
Virtues such as solidarity and cooperation are antidotes of unethical global trends such as
the ones promoted and desired by neoliberalism (see chapter 6).
Social Responsibility and Health: Access to healthcare is among the human rights
that guarantee equal opportunities. Health research is not free of responsibility of
providing healthcare for the society, either through the results of research activities that
should be of social value, or through providing healthcare for research subjects and host
communities and considering both the short and long-term benefits of the communities
from hosting research projects. In this direction, the duty of research is dealing with the
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real and serious health needs of the society. In addition, researchers should not be
ignorant to the health needs of their research participants and host communities.
Especially about the ancillary and follow-up cares that otherwise they won’t afford or
have access to them.488
Sharing of Benefits: When it comes to Global Governance for Health Research, one
of the most cited and appealed ethical principles is sharing of benefits. Research has
short-term and long-term benefits. Being of social value is a precondition for health
research to be approved and conducted (see above). These benefits, however, are not
always distributed fairly. As described through various challenges and cases in chapters 3
and 4, different kinds of exploitation violate the principle of fair benefit sharing. In
Global research interactions, this concern has always been raised that the less powerful
parties, i.e. research subjects and the poor host communities and countries receive an
unfair share of the benefits of research. The challenge of helicopter research and the case
of HIV research in Africa are among the examples of the situations that have raised this
concern. This principle asserts that the short and long-term benefits of research should be
shared in a fair manner.489 This principle covers multi-central and international research
in developing countries and the share of the host communities of the benefits of research
(e.g. affordable access to the resulted medications and vaccines) and even the issue of big
data and data sharing in the sense that the benefit obtained from imposing risk to research
subjects should be shared in the best possible wat through data sharing and fair access to
biobanks and big data.490 The debates on bio-piracy and exploitation of local natural and
knowledge resources of developing countries by pharmaceutical companies (see chapter
4) is another example of ethical issues that necessitates the inclusion of the principle of
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sharing of benefits in any suggested ethical framework for Global Governance for Health
Research.491
Protecting Future Generations: Protecting future generations is mostly relevant to
the genetic research and research on human gamete, embryo, and fetus (see chapter 4).
Although included among the vulnerable groups and covered by the principle of respect
for vulnerability (see above) the importance of protecting human gametes and embryos
from unethical research interventions (e.g. mass production of human embryos only for
research purposes) necessitates another principle to be included in the ethical framework
to establish a globally accepted, adopted, and enforced protection of the future
generations. Other issues such as inducing and producing permanent genomic changes in
germlines and research on human enhancement are among other ethical concerns covered
by this principle both in domestic and global research enterprise.492
Protection of the Environment: This principle is titled as “Protection of the
environment, the Biosphere, and Biodiversity”, however, is shortened to “Protection of
the Environment” because the other two components were in in the same direct and
crucial relation to the ethical issues of Global Governance for Health Research.
All the above principles, including cultural diversity should be accepted and
respected within the limits of human rights and fundamental freedoms. This important
point is explicitly made in the declaration to prevent any kind of abuse under the name of
cultural diversity.493
Principles and Ethical Framework: In this part of this chapter, the UNESCO
Universal Declaration on Bioethics and Human Rights is used to shape the principlebased element of the ethical framework of the Global Governance for Health Research.
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The UNESCO framework incorporates other major relevant ethical frameworks such as
the ones included in the Universal Declaration of Human Rights and the four-principle
framework of Beauchamp and Childress.
These principles and principlistic approach form one of the three major elements of
the ethical framework suggested in this chapter. This element is divided into two layers:
the more basic/fundamental layer that is consisted of more fundamental principles,
including human dignity, human rights, and non-exploitation. The second layer is
consisted of other principles that are of crucial importance in the ethical framework for
Global Governance for Health research (see Table 5.2).
iii. Particularistic Approach: Pros and Cons
Particularistic approaches that sometimes are called “situation ethics” claim that
ethical principles are not useful in determining moral goodness or badness in the real
world. Instead, one should rely on the specific context and specifics of each act/situation
for moral judgment/decision-making about it This is why this approach to ethics has also
been named “situation ethics”.494
In the fields of global/international health research and Global Governance for Health
Research, each situation or problem has its own specifics and characteristics, including
the context in which that situation or problem takes place. Situation ethics claims that the
principles outlined in the previous part of this proposal are not able to lead the ethicists,
researchers, policy makers, or other decision makers toward the ethical
solutions/answers. Instead, in each case, those specifics and characteristics compromise
the ethically relevant features that should be examined, analyses, and balanced on a caseby-case basis to find the most ethically acceptable/suggestible solutions, answers, or
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approached. Situation ethics does not reject the ethical principles as morally acceptable
and enlightening thoughts and accepts their role in teaching ethics for students. However,
claims that in approaching the real, complex, multifaceted, and complicated ethical cases,
these principles are not helpful as described above.495
As an example pertaining to the realm of Global Governance for Health Research, the
challenge of bio-piracy as explained in chapter 3 is one of the major challenges related to
health research. The principles of sharing of benefits led the global community to act.
The result was the Nagoya Convention (see above). However, the production of Influenza
Vaccine has been adversely affected and delayed because of the obligations made by this
principle and the resulted convention (see chapters 3 and 4). Therefore, a generally good
and acceptable principle may cause irregularities and adverse implications in its practical
application.
Another example is the problem of risk-benefit analysis. In non-therapeutic health
research, it has been argued that the risk imposed to the participants (who obviously
won’t benefit from their participation) should be limited to the standard of “zero risk”
that means the risk of normal activities of life. However, considering this double-track
assessment (i.e. dividing health research projects into two major groups: therapeutic and
non-therapeutic ones and conducting their risk-benefit analyses in two separated tracks)
brings about some serious practical problems. For example, the phases I and II of many
of clinical trials would be banned if the standard of zero risk was followed. Therefore,
instead of adopting the double-track process, the risk-benefit analysis should be done for
both therapeutic and non-therapeutic research projects because in some, of course well-
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considered and analyzed – cases, the great social benefits can justify some levels of risk
for research subjects even in non-therapeutic research.
RECs and IRBs for Situation-Based Practical Approach: The above argument
(asserted by the proponents of situation ethics) and examples, show that having a
framework of principles is not enough but is just the beginning of the sophisticated
process of ethical oversight and governance for research, either domestic or global. The
ethical analysis, considering all the ethically relevant items and characteristics and details
of each case, should be done by a group of well-trained and ethically and culturallyinformed people. This lesson of situation ethics has been the basis of establishment of
Research Ethics Committees (RECs) and Institutional Review Boards (IRBs). The RECs
and IRBs consider the principles provided by the framework, however, they also examine
and analyze each case with specific attention to all its ethically relevant details.
For ethical review and oversight of international research, the RECs and IRBs of the
host countries should be involved, because they are well-informed on the cultural
specifics of the host community and can safeguard the benefits and interests of research
subjects and their communities and countries. Therefore, as described above, one of the
ethical imperatives for Global Governance for Health Research is training people in host
communities to take part in research monitoring and oversight through RECs and IRBs.
In addition, sharing the experiences and ethical wisdom of all people who take part in
research monitoring and oversight (i.e. governance) all over the world through shaping
and strengthening networks among RECs and IRBs is another ethical imperative for
Global Governance for Health Research.
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Therefore, in the ethical framework for Global Governance for Health Research
provided in this chapter, one of the three major elements is the situation ethics and its
practical implication that is assessment and analysis of each research project and research
governance system by a network of RECs and IRBs (see Table 5.2).
iv. Virtues as the Subjective Backgrounds
Principles are crucial in shaping a framework and solid knowledge on ethics.
However, genuine abidance to the principles and normative frameworks is dependent on
personal (internal or subjective) virtues of professionals. In the realm of research ethics
and Global Governance for Health, only virtuous researchers genuinely follow the ethical
principles and normative frameworks. Otherwise, the abundance of principles, laws, and
regulations can never actually minimize the unethical research behaviors, abusive power
relations, and exploitation. This part of this chapter belongs to depicting a set of virtues
that (1) are grounded in both classical/traditional masculine virtues and feminist virtues,
and (2) are crucial in forming a solid subjective/personal background for health
researchers. These virtues are empathy, compassion, and care that shape the
internal/subjective solid backgrounds of the ethical framework for Global Governance for
Health Research. It has been argued that these virtues are the “desired moral attitudes of
physicians”.496
Compassion has been called “the emotional and virtuous core of the desired
professional attitude” in medicine.497 The Ethics Committee of the American Society of
Academic Emergency Medicine (SAEM) considers compassion “a part of professional
competence” which is “perhaps as important as technical competence.”498 These
emphasizes on the central role of compassion in the shaping of the professional character
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of healthcare providers shows the central importance of this concept in medicine and
medical ethics as well as in research ethics at its domestic and global levels.
Compassion is internal/subjective reaction to the suffering of other sentient being(s)
and is conjoined with recognition of the suffering, detesting and disapproving that
suffering, feeling personal responsibility and engagement with the experience, and
tendency to relief the suffering with good intentions toward the sufferer(s).499 Therefore,
one can argue that compassion is always a good trait and there is not such a thing as a
“bad compassion” (see below).
From the ancient times, the utmost obligation of physicians has been to alleviate or
eliminate human suffering.500 Daniel Callahan calls this very obligation “a foundation
stone of the practice of medicine.”501 Patients’ suffering is not limited to pain or other
symptoms of their diseases; it also encompasses their mental and social discomfort. This
suffering originates from all different sources including their disease, the treatment, their
realistic or unrealistic fears and anxieties, their financial and social distresses and all
other sorts of discomfort they experience through the courses of their disease, treatment,
and recovery.502
The broadness and existential importance of the concept of suffering and its
importance in the life of a patient, shows how crucial the virtue of compassion is in the
practice of medicine and in the pursuit of its goals. Suffering elicits the “impulse of
compassion” in almost every normal human being,503 but it should develop into a virtue
in physicians to make them more similar to the ideal ones.
This part of this chapter analyzes the notion of compassion as a common virtue
between the traditional/masculine and care/feminine sets of virtues and shows that
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compassion as a reunion and merging point of the both sets of human virtues has a crucial
role in the pursuing the goals of medicine and healthcare and medical research. This role
can be actualized by development and promotion of compassion as an important part of
the character of an ideal physician/healthcare provider/health researcher. In addition, this
part argues that the notions of empathy, compassion, and care can shed light on some
important debates in the contemporary debates on healthcare provider-patient and health
researcher-research subject relationships.
Empathy, Compassion, and Care as Virtues: According to Alasdair MacIntyre, a
virtue is a developed trait of a human’s character that tends to qualify him/here to realize
the goals of a certain practice (in our case, medicine and health care) with excellence. 504
Traditionally, according to the Aristotelian understanding of the virtues and virtue ethics,
the human virtues have been considered related to masculinity.505 In recent decades,
however, the founders and advocates of the ethics of care described and introduced a set
of virtues with feminine nature (see below). This part of this chapter portrays empathy,
compassion, and care as the common virtues between these two sets of universal virtues.
Both the traditional and feminist theories of virtue ethics emphasize on the importance of
these virtues when it comes to healthcare ethics, healthcare provider-patient relationship,
and health research ethics. At the end of this part, one can conclude that empathy,
compassion, and care as a set of virtues are the merging points of the masculine and
feminine virtues in the realm of medicine and health research and are of crucial
importance in shaping the character of a virtuous physician/researcher.
Masculine Virtues: Virtue Ethics: Andre Comte-Sponville argues that contrary to
sympathy, compassion is a virtue.506 Other scholars have also noticed the difference
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between concepts like sympathy, empathy, and pity with the concept of compassion.507
This differentiation as described briefly below shows how one can consider compassion
as a virtue, not a feeling that can be morally good or bad.
Comte-Sponville differentiates sympathy and compassion in this way: Sympathy,
which means “fellow feeling”, is not a virtue by itself. Its goodness or badness depends
on the “feeling” which is being shared between fellows. Having sympathy to malice
intents is not good, therefore, sympathy, by itself, can never be a virtue.508 Compassion,
however, is sympathy in suffering and every form of suffering, even the ones originated
from wrong causes such as wrongful jealousy or rivalry, deserves sympathy. 509 In
addition, compassion encompasses other specifics such as benevolence and inclination to
relief the suffering.510
Comte-Sponville brings Christ’s compassion for his executioners as an example of
the goodness of compassion even for evil people who suffer because of their evil and
malice acts, intents, and characters.511 Andre Comte-Sponville argues that compassion, as
the same time, is a feeling and a virtue because we can feel it as a feeling and we can
want and gain the capacity of being compassionate.512 In this sense, compassion is similar
to love. In the Buddhism, compassion is regarded a great virtue. In Christianity, charity
has the same status. However, charity is not identical with compassion. As a matter of
fact, the feeling and capacity of empathy, compassion, and care can lead to and resemble
charity.513
As a set of virtue in its traditional/masculine sense, empathy, compassion, and care
are in close relation with biomedical and health research ethics. As mentioned above,
alleviation of suffering is a core obligation/goal in medicine and healthcare. The virtue,
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which targets suffering, is compassion. Therefore, the pursuit and realizing this main goal
of medicine depends on the establishment of this very virtue in healthcare
providers/physicians.
Feminine Virtues: Ethics of Care: The ethics of care is among the most recently
emerged moral theories and attracted a large deal of attention in the recent decades.514 Its
new and innovative approach and viewpoint in dealing with ethical issues has shed light
to some formerly dark and overlooked parts of human beings’ moral obligations and
duties. As a moral theory, ethics of care has its implications and influences on biomedical
ethics. Healthcare is one of the most prominent manifestations of care and caring relation
in the world of humanity.515 Therefore, it is obvious that ethics of care has much to say
when it comes to health, healthcare, health research and the goals of medicine.
The ethics of care as a distinct moral theory was born inside the feminist ethics. The
founders of this theory were feminist philosophers who found the caring nature of
femininity of enormous ethical value.516 As described above, traditionally, in moral
theories and even in moral psychology it was considered for granted that ethical virtues
are stronger in males.517 It was because ethical norms and virtues like justice and
impartiality were consistent with the role of males as hunters and breadwinners. The role
of females, as cares had always been underestimated, morally speaking. According to the
founders of the ethics of care, however, this caring nature of female role is of utmost
moral superiority and importance and can be considered as a basis for a self-sufficient
moral theory. Although some of them believe that the ethics of care is not a sort of virtue
ethics, but still it is obvious that this moral theory is founded based on considering care
and compassion as unambiguous virtues.
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One of the main themes of the ethics of care is considering partiality as a virtue. In
the traditional/masculine virtue ethics, justice and impartiality have always been
indubitable virtues. However, in the ethics of care, special caring relations come along
with obligation of special care and partiality. This is very true in the case of physicianpatient and health research-research subject relationships. Medical ethics and research
ethics ask physicians and health researchers to always give priority to the health and
health needs of their own patients. This priority comes from a relationship: the
physician/doctor/healthcare provider-patient relationship. It seems that the typical model
of the ethics of care shows itself in this case. Physician should be partial and give priority
of his/her patients because of the specific relationship established between them. This
partiality shows itself in the form of care and compassion. This care and compassion is
aimed to realize the goals of medicine as described below.
Compassion and the Goals of Healthcare: Daniele Callahan specifies the goals of
medicine as follow: the prevention of disease and injury and the promotion and
safeguarding of health, the relief of all kinds of suffering resulted by maladies, the
treatment of disease and providing care for non-curable ones, and the evasion of a
premature death and the pursuit of a serene death.518 It seems that the virtues of empathy,
compassion, and care play crucial roles on realizing all these four goals of
medicine/healthcare.
Empathy, Compassion, and Care in Researcher-Research Subject Relationship:
The root of the word “compassion” is in Latin language where it means “suffering with”,
equal to the Greek root of the word “sympathy”.519 It is interesting that compassion
shares its Latin root with the word “patient” meaning sufferer.520 This common root
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symbolically shows the relation between compassion and caring for parents and relieving
their suffering as embodies in the healthcare and medicine. Medicine relies on science but
is not merely a sort of science. It also is an art: art of establishing a healing and trustful
relationship with the patients. This art depends on certain virtues in physicians, among
which is the very crucial one of compassion.
Recent developments in medical technologies along with reliance on science have
transformed doctor-patient relationship in the post WWII era.521 However, these changes
and evolutions have not led to elimination of humanistic aspects of doctor-patient
relationship and transforming it to a mechanical/machine like relationship. Therefore, still
the therapeutic relation depends largely on development of trust and rapport between
physician and patient. This trust and rapport take place when patient realize that his/her
doctor recognizes his/her suffering and feels for his/him and is intended to alleviate or
eliminate his/her suffering. And this is the very definition of compassion as described
above in this paper. Therefore, it seems that despite all the evolutions and transformations
in the modern medicine, the cornerstone of doctor-patient relationship is still personal
virtues and among them, the very important one of compassion.
Taking a look at the history of debates in the contemporary biomedical research
ethics clearly shows that no single moral theory has a monopoly on the realm of truth in
biomedical research ethics. Instead, in each situation and in analyzing each specific issue
of searching for each specific ethical solution, one or more of ethical theories show to be
helpful and reliable. In this part, the viewpoint of the virtue ethics has been used and
analyzed to shed light on some aspects of biomedical research ethics and to show that
empathy, compassion, and care as a set of virtues play a vital role in the pursuit of the
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goals of healthcare and medicine in the realm of research, at both the domestic and global
levels.
Healthcare, in practice and research activities, involves a great deal of interpersonal
involvements and interactions. Therefore, the character of physician/healthcare provider
is of crucial importance. This importance paves the way for virtue ethics to play a
considerable role in analyzing and problem solving in healthcare provider-patient issues.
In this context, compassion, as a virtue, is of extreme importance in pursuing the goals of
medicine/healthcare as described above.
Empathy, compassion, and care are common virtues between the
traditional/masculine and feminist/feminine theories of virtue ethics and according to the
both of them are crucial virtues in biomedical ethics and medical professionalism. The
traditional/masculine sense of the virtue of compassion can strengthen the relationship
between physician and patient (in this case, researcher and subject) with trust and mutual
understanding. In addition, the partiality resulted from this relationship shows itself in the
form of giving priority to the one’s own patients and is compatible with the feminine
account of virtues such as compassion and care. The main goal of medicine is to alleviate
or eliminate suffering. Therefore, compassion, along with empathy and care, are the most
crucial virtues in pursuing the goals of healthcare and medicine both in practice of
medicine and in health research.
Despite the recent technological and scientific transformations in medicine, still the
interpersonal relationship between healthcare providers and patients (and researchers and
research subjects) play a vital role in pursuing the goals of healthcare and health research.
For establishing effective and trustful physician-patient and researcher-subject
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relationships, the virtues of empathy, compassion, and care play central roles. These
central roles show themselves in ethical issues such as ancillary care and following
ethical principles such as sharing of benefits (and in general, the most fundamental
ethical principle of Global Governance for Health Research, that is non-exploitation).
Making the best decisions in the situations that raise such concerts, depends largely on
the trust and rapport which are achievable by virtue of empathy, compassion, and care in
the researchers and recognizing this compassion by the patient/subjects and the host
communities.
In sum, empathy, compassion, and care can be called the merging and reunion points
of the feminine and masculine virtues in pursuing the goals of healthcare and medicine
both in practice and in research. Therefore, they shape the virtuous grounds of the ethical
framework for Global Governance for Health Research.
v.

Global Norms and Cultural Diversity

This part deals with the debate about the potential conflicts between universal norms
and cultural/local values. Respect for cultural diversity and the priority of fundamental
human rights and freedoms over local ethical variations are discussed above. However,
the importance of this subject in global bioethics, especially its relevance to the ethics of
health research, demand and necessitate a specific attention to this subject at this part of
this dissertation. One of the most famous cases on this kind of conflicts in international
health research is the debate over who has to give an informed consent in specific
communities, such as tribes in some developing countries, where the traditional
authorities overrule the personal right of individuals to give voluntary informed
consent.522
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Since asking for informed consent is one of the fundamental rights of every
competent human subject, appealing to cultural diversity is not enough to compromise
this basic right and ask for collective consent from the local authorities. Instead, a
possible solution would be insisting on obtaining individual informed voluntary consent
in addition to the permission of those authorities.
The above case is just an example of cases in which the local cultural norms and
traditions come into conflict with universal ethical standards and how the researchers and
ethicists can manage to find creative ways to keep adherent to global ethical standards
and respectful to cultural diversity and local traditions at the same time.
In sum, this part of this chapter argues that the principles adopted in the Universal
Declaration of Human Rights and UNESCO Universal Declaration of Bioethics and
Human Rights are parts of common heritage of mankind and do not belong and are not
limited to a specific culture or geographic area. In addition, the principle of respect for
cultural diversity, as discussed above, cannot be interpreted in a way that comes with
conflict with human dignity and fundamental rights and freedoms. Therefore, the
principles that consist the principle-based element of the framework suggested in this
chapter are of universal and cross-cultural nature and although they include the important
principle of respect for cultural diversity, they are not limited to any culture or nation or
geographic region. The limitations of this universal and cosmopolitan approach will be
discussed further in chapter 6.
vi. The Global Framework for a Global Network
This part of the dissertation, suggests an ethical framework for global governance for
research. This framework is developed to encompasses all the strengths of both principle-
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based and particularistic moral approaches. In the light of the above discussions about the
existing problems and their ethical nature (chapter 3), and the discussed cases (chapter 4),
and the discussions on the theoretical backgrounds provided above in this chapter, this
part of this chapter provides a framework that looks to be both comprehensive and
systematic.
In addition, the existence of different and sometimes conflicting schools or morality
that in some cases are embodied in the various ways of life, is another important point in
developing an ethical framework at the global level. The final framework has to show
respect for cultural diversity and adherence to global ethical mandates (fundamental
human rights and freedoms) at the same time. For this purpose, considering the global
norms as the common heritage of humanity (rather than the impositions of ethical
colonialism) can be illuminating and helpful.523
As described above, the power imbalances among the different parties involved in the
global research enterprise raise serious concerns about safeguarding the rights and
benefits of the vulnerable people or communities as an ethical mandate. Each ethical
framework has to be attentive to this important imbalance in power and its resulted
ethical concerns and problems and this truth that one of the most crucial goals of such an
ethical framework is dealing with this power imbalance in a way to maximize the benefit
and minimize the harm for the most vulnerable parties. In sum, this part of this chapter
provides a systematic, comprehensive, and appropriate ethical framework for Global
Governance for Health Research.
The Criteria of Appropriateness: The aim of this chapter is providing the “most
appropriate” ethical framework for global governance for health research. For this
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purpose, this study needs to delineate a set of criteria for appropriateness. The following
points are among the ones that should be taken into consideration as the “criteria of
appropriateness” for the proposed framework:
1. The suggested framework should be based on and justified by the universal moral
values and principles that can be considered part of the common intellectual heritage of
mankind. In other words, this framework should observe and include fundamental
human rights and freedoms and other cross-cultural norms and values as formulated in
international and universal declarations. At the same time, this framework should be
cultural sensitive. This means that this framework should make room for respect for
pluralism and cultural diversity. One of the main challenges in formulation this network
is finding the most appropriate framework for fulfilling both functions (observe
universal norms and respect for cultural diversity) without any conflicts or
contradictions.
2. This framework is to promote the substitution of governance/globalization from
above with the governance from below.524 The sustainability of global governance and
the international research enterprise depends on the extent of its success in this
substitution as an ethical mandate or priority.
3. Although no specific government is in charge of global governance, this field is
not free of leadership. The ethical framework has to take this important component into
consideration. For this purpose, this ethical framework has to promote the network
model of leadership and formulate its ethical mandates such as transparency,
accountability, representation, and participation.525
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4. The ethical framework has to cover all the broad range of role-players in the
global governance for research. Only a broad and all-encompassing model can solve the
complex and complicated problems of global health research. Being inclusive is one of
the most important features of an effective model.
5. For refraining unilateral interventions, and providing the best possible cost-utility
justification for global heath interventions – including the ones related to heath research
– this is suggestible to strengthen the role of WHO as the leader of global heath
governance.
6. Human health is inseparable from the health of animals and the ecosystem. The
recent experiences of zoonotic pandemics clearly showed that global heath governance
for people is in close relation with and dependence on the global health governance for
animals, and the nature at all. Global warming and its disastrous impacts on global
health is another revealing example. Therefore, having an integrated perspective toward
the health of human beings, animals, and the nature as a whole, is crucial for an effective
governance for every aspect of health, including health research, in the future.
The framework provided below for Global Governance for Health Research has three
main components: (1) the normative cornerstones that appeal to the central concept of
human rights as a part of common intellectual heritage of mankind. (2) The
systematic approach that appeals to the NIH Framework to implement the principles
of universal declarations to the global research enterprise. (3) The situation-based
practical approach that incorporates situation ethics into the framework by describing
the crucial role of the existing networks especially Research Ethics Committees
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consisted of well-trained, culturally informed, and ethically aware members from the
participating and hosting communities.
The Normative Cornerstones: Inspired by the Nuremburg Code, the Universal
Declaration of Human Rights was adopted by the United Nations in 1948. This
declaration later shaper the foundation of various ethical and legal declarations,
guidelines, conventions, and treaties. Embodied in almost all consensual international
and global agreements in the past seven decades, the Universal Declaration of Human
Rights is a noteworthy and radiant part of the common intellectual heritage of mankind.
According to Henk ten Have, this declaration owes this status to its universality and
emancipatory force.526
Because of the fundamental and globally consensual nature of the articles of
Universal Declaration of Human Rights the ethical framework for Global Governance
for Health Research should adopt them as its normative and moral cornerstone. This
declaration has been embodied in the field of global ethics by the UNESCO Universal
Declaration on Bioethics and Human Rights. he UNESCO declaration provides an
unbiased and globally consensual interpretation and expansion of the Universal
Declaration of Human Rights in the field of global bioethics. Therefore, is applicable
and relevant in shaping an ethical framework for Global Governance for Health
Research. Therefore, the second step of the normative cornerstone of the ethical
framework for Global Governance for Health Research is the UNESCO Universal
Declaration on Bioethics and Human Rights.
The ethical principle of Non-Exploitation and the ethical virtue of Compassion are
also the cornerstones of the ethical framework for Global Governance for Health
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Research. The most fundamental ethical concern in health research activities is
exploitation. In addition, although relying on the personal virtues of researchers has been
supplemented and complemented with other reassuring provisions such as independent
review, it does not mean that there is no place for virtues in ethical frameworks. On the
contrary, still the most important fundament of ethical behavior is personal commitment
of people, especially the ones who are at the more powerful sides of relations and
transactions. Therefore, compassion as a personal virtue relevant to the golds of
healthcare and health research is one of the cornerstones of Global Governance for
Health Research.
Table 5.1. The principles of the NIH framework with their corresponding principles in
the UNESCO declaration of Bioethics and Human Rights and their implications on the
Ethical Framework for Global Governance for Health Research (GGHR).
The NIH Framework
Collaborative Partnership

Social Value

The UNESCO
Principles
 Human Dignity and
Human Rights
 Benefit and Harm
 Respect for Human
Vulnerability and
Personal Integrity
 Equality, Justice, and
Equity
 Non-Discrimination
and Non-Stigmatization
 Respect for Cultural
Diversity and Pluralism
 Solidarity and
Cooperation
 Social Responsibility
and Health
 Sharing of Benefits
 Protecting Future
Generations
 Benefit and Harm
 Equality, Justice,
and Equity

235

Ethical Framework for
GGHR
 Respect for the Role and
Participation of Host
Communities; Only Limited
by Human Dignity and
Human Rights
 Prevents unethical
behaviors such as helicopter
research and double
standards
 Assures the fair benefits of
hosting communities

 Consistency between
research questions/aims and
the health needs of host
societies

Scientific Validity

Fair Participant Selection

Favorable Risk-Benefit
Ration

 Respect for Cultural
Diversity and Pluralism
 Solidarity and
Cooperation
 Social Responsibility
and Heath
 Sharing of Benefits
 Protecting Future
Generations
 Benefit and Harm
 Equality, Justice,
and Equity
 Social Responsibility
and Health

 Human Dignity and
Human Rights
 Benefit and Harm
 Respect for Human
Vulnerability and Personal
Integrity
 Equality, Justice, and
Equity
 Non-Discrimination and
Non-Stigmatization
 Solidarity and
Cooperation
 Social Responsibility
and Health
 Risk and Benefit
 Sharing of Benefits
 Social Responsibility
and Health
 Protecting the
Environment
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 Data sharing
Considering the burden of
research on health
infrastructures of host
communities/countries


The importance of
inclusion of scientific validity
as a principle in the soft law

Avoiding unwanted
promoting pseudoscience
and superstitions through
invalid and poorly designed
research
 Preventing double
standards in international and
multi-central research
projects
 Considering the potential
of exploitation of vulnerable
populations

 Considering the importance
of fair and systematic riskbenefit ratios in developing
countries and populations
that lack the expertise or
democratically selected
representatives to do so.
 The importance of training
local experts for risk-benefit
analysis
 The issue of ethical
imperialism and colonialism
in research ethics training
and the importance of
considering local culture and
value systems

Independent Review

Informed Consent

 Benefit and Harms
 Respect for Human
Vulnerability and
Personal Integrity
 Equality, Justice, and
Equity
 Respect for Cultural
Diversity and Pluralism
 Sharing of Benefits
 Protecting Future
Generations
 Human Dignity and
Human Rights
 Consent
 Autonomy and
Individual Responsibility
 Persons without the
Capacity to Consent
 Respect for Human
Vulnerability and Personal
Integrity
 Non-Discrimination and
Non-Stigmatization
 Respect for Cultural
Diversity and Pluralism
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 The importance of inclusion
of independent research
review in the laws and
regulations
 The importance of providing
research oversight training for
LMICs
 The issues of ethical
imperialism and respect for
cultural diversity
 Informed and voluntary
consent as a right of each
competent research
participant
 Consistency of informed
consent with the cultural and
political contexts
 The need to additional
informed consent from the
local authorities does not
override the obligation of
taking consent from each
individual research participant

Respect for Participants

 Human Dignity and
Human Rights
 Benefit and Harm
 Autonomy and
Individual Responsibility
 Consent
 Persons without
Capacity to Consent
 Respect for Human
Vulnerability and Personal
Integrity
 Privacy and
Confidentiality
 Non-Discrimination and
Non-Stigmatization
 Respect for Cultural
Diversity and Pluralism
 Solidarity and
Cooperation
 Social Responsibility
and Health
 Sharing of Benefits.

Conclusions
The ethical framework suggested by this chapter is an interactive combination of
three main elements (see Table 5.2):
The first element that shapes the subjective and personal background and support of
this framework is adopted from virtue ethics. The merging point of two accounts of
virtue ethics: the classic, Aristotelian virtue ethics relying on a set of Masculine ethics
and the modern feminist account of virtue ethics adopted by the Ethics of Care. This
chapter holds that this merging point in the realm of medicine and health research is
embodied in empathy, compassion and care. These virtues (or ethical
attitudes/Attributes) are the basis and background of abidance to this – and any otherethical framework by physicians, healthcare providers, and health researchers.
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The second element is consisted of a certain group of principles originated in the
concepts of human dignity, human rights, and non-exploitation (as the deeper and
fundamental level of principles). These principles are formulated (in the form of an
expanded and detailed framework) and adopted by UNESCO through the UNESCO
Declaration of Bioethics and Human Rights. These principles, because of their
consensual, universal, and cultural-sensitive nature can be considered a part of common
heritage of mankind. For ensuring their best compatibility with the realm of health
research, they are combined with a set of principles provided through the NIH
framework in a systematic manner for research, especially for global research.
The third element of this framework is inspired and informed by the schools of
situation ethics. The virtues and principles should be applied and implemented into
specific situations with innumerable details and characteristics that cannot be
summarized or categorized under specific virtues or principles. A group of ethically
trained and culturally informed and aware persons are needed to deliberate on each case
and appeal and infer to various virtues and principles to formulate the best and most
ethical and culturally acceptable way to apply and implement those abstract notions to
practical situations. This is the share of situation ethics. This mission is being done by
RECs and IRBs all over the world. Without competent and independent IRBs and
RECs, no ethical framework can be useful and applicable to solve the challenges,
issues, and cases ahead of Global Governance for Health Research.
This framework is not free of limitations. In addition, the current trends in politics
show that numerous challenges threaten the integrity of Global Governance for Health
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Research. A brief discussion of these challenges is provided in the next chapter of this
dissertation.
Table 5.2. A scheme of the elements of the ethical framework for Global Governance
for Health Research and their levels and components
Elements
Situation
Ethics

Principles

Virtues

Component
The global network of Research Ethics Committees (RECs) and
Institutional Review Boards (IRBs)
Collaborative Partnership, Social Value,
Scientific Validity, Fair Participant Selection,
Systematic
Favorable Risk-/Benefit Ration, Independent
Approach
Review, Informed Consent, Respect for
Participants
Benefit and Harm; Autonomy and Individual
Responsibility; Consent and Persons Without
Capacity of Consent; Respect for Human
Vulnerability and Personal Integrity; Privacy and
Confidentiality; Equality, Equity, and Justice;
Expanded Level
Non-Discrimination and Non-Stigmatization;
Respect for Cultural Diversity and Pluralism;
Solidarity and Cooperation; Social
Responsibility and Health; Sharing of Benefits;
Protecting Future Generations; Protection of the
Environment
Human Dignity, Human Rights, NonBasic Level
Exploitation
Empathy, Compassion, Care
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Chapter Six: Futurology and Conclusions
In this final chapter, a conclusive picture/analysis of the suggested ethical framework
for Global Governance for Health Research is provided and its trends and possible
developments in the future along with the existing and potential threats and promises are
examined and predicted. In addition, some practical and research recommendations are
suggested for the future.
Global Governance for Health Research and its ethical norms, principles, and
challenges have not been examined sufficiently in the current scholarly literature.
Although both the research ethics and the Global Health Governance have been subjects
of amazing scholarly works, the interface of these two fields, that is the ethics and ethical
framework of Global Governance for Health Research has not been explored by an
enough number of scholarly works in the past decades. This study has been an attempt to
fill this gap in the current literature.
This part of this chapter, after providing a summary of the content of the previous
chapters and some conclusive remarks, tries to depict the predictable future trends of
Global Governance for Health Research, provide a number of practical recommendations,
and finally, suggest further studies that can be the next scholarly steps in exploring and
analyzing this relatively new field of study and research.
i. A Brief Summary and Conclusive Remarks
As described in chapters 1 and 2, Global Governance is composed of sophisticated
and crowded networks of role players that govern various affairs of human social life at
the global scale. Global Health Governance is a branch of Global Governance that
governs the health-related affairs. Although numerous scholarly works have been
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published concerning Global Health Governance, an important branch of this gigantic
complex of networks has not been analyzed sufficiently yet. This insufficiently examined
and analyzed part is global health research enterprise. Global health research, although it
is a part of global health affairs, has its own characteristics and situations that bring about
its specific issues and challenges at the global scale. Therefore, Global Governance for
Health Research, although is generally a part of Global Health Governance, has major
differences (along with similarities and overlaps) with it is different aspect, including the
major role-players, and main issues and challenges.
The major role-players of Global Health Governance are the WHO, the World Bank,
and UNESCO, along with numerous other ones such as UNAIDS and the private and
civil society role-players. The WHO and the World Bank, although important in the
realm of global research, have not been the most influential role-payers in Global
Governance for Health Research. Since the Global Governance for Health Research has
mainly been materialized through internationally recognized frameworks and guidelines,
the organizations that created, adopted, and promulgated these instruments have been the
most influential role-players in the realm of Global Governance for Health Research,
among them being the UNESCO, WMA, and CIOMS.
Global Governance for Health Research has its own challenges that are discussed in
chapter 3 and studied through cases in chapter 4 of this dissertation. Challenges such as
exploitation and helicopter research, double standards, bilateralism, and the impact of
bio-politics. The framework of gaps introduced by Weiss is also relevant to this field and
the knowledge, normative, policy, institutional, and compliance gaps show themselves in
Global Governance for Health Research. The analysis of the challenges in chapter 3
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along with detailed case studies in chapter 4 revealed the ethical nature of the existing
challenges and shortcomings of this field and the need to a comprehensive and systematic
ethical framework. This framework is developed and presented in chapter 5.
The suggested framework for Global Governance for Health Research is composed of
three elements. A virtue-based element/layer that encompasses the most basic moral
attributes of physicians/health researchers and underlie their ethical behavior and their
compliance to the principles. A two-layered principle-based element that encompasses a
layer of fundamental principles, i.e. Human Dignity, Human Rights, and NonExploitation and a layer of more specific or practical principles that mostly adopted from
the UNESCO Declaration of Bioethics and Human Rights to have a comprehensive and
universal approach and from the NIH framework to have a research-oriented systematic
approach. And the last element of the suggested framework is inspired by particularism
or situation ethics that demands establishing, empowering, and strengthening networks of
oversight and review committees/boards to guarantee the continual and comprehensive
case-by-case ethical review and oversight and monitoring all over the gigantic networks
involved in global health research enterprise.
Despite the challenges partly explained below in this chapter, it seems that the
suggested framework can be helpful in shedding ethical light on the challenges of Global
Governance for Health Research and in filling its various gaps. This study is a small step
in filling the knowledge gap. The suggested framework can fill part of the normative gap,
this framework can be an ethical basis for policies that may fill the policy gap, the
situation-ethics element of the framework is concerning the necessity and the ethical way
for filling the institutional gap and finally, removing or alleviating the moral barriers is
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one of the ways for filling the compliance gap. By the way, this should be reminded that
filling these gaps is not a one-time mission, instead, the process of developing and filling
these gaps is continuous and will continue as long as the Global Governance for Health
research is a reality on the global scene.
ii. The future of Global Governance and International Research
This part of this chapter consists of two segments. First, the current trends in the
realm of politics and economics is discussed. Some threats for implementation and an
ethical framework for Global Governance for Health Research are discussed. In
developed countries, the trends of neoliberalism and the recent rise of the wave of
isolationism and protectionism and in developing countries, the local cultures and
authorities that resist against the universality of values such as human rights are discussed
as the existing threats against ethical frameworks for global governance, including Global
Governance for Health Research.
In the next segment of this part, it is explained and predicted that with implementing
the suggested ethical frameworks, what changes would occur in the future of
international research and its global governance. Among the items that are discussed in
this part are strengthening the role of WHO as the leading organization in global heath
governance and adopting an integrated approach to health that include humans, animals,
and nature (ecosystems, climate, etc.) and take into consideration the social and political
determinants of health, e.g. in setting research priorities.
The challenge of neoliberalism, Populistic Isolationism, and Protectionism in
Developed Countries: Donald J. Trump, although is not a classical neoliberalist, is a sort
of embodiment of the figure of ground-breaking and rebellious millionaire that was
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praised and admired by the prophetic figure of neoliberalism, Friedrich Hayek (18991992).527 His winning the 2016 US presidential election, along with the vote to Brexit
(UK’s leaving the European Union) in the UK in the same year, and the rise of popularity
of populist politicians in the other powerful European countries that have always acted as
the engines of globalization, are warning signs for ethical governance of global affairs in
all areas, including the global research enterprise.
Neoliberalism: Neoliberalism is a political and economic theory that centers around
promoting – or creating – free markets in all areas of human affairs, from ordinary goods
and services to the ones that ordinarily are not covered by free market such as healthcare,
basic research, and education. This theory regards individual-centered competition as the
most ethically (fairly) reliable force for governing human social affairs at both domestic
and global levels.528 Neoliberal attitudes and practices have caused most of challenges for
Global Governance for Health Research discussed in chapters 3 and 4 of this dissertation.
Focusing on maximizing the material benefit and minimizing the costs even at the
expense of harming the community and humanity (the attitude that Donald Trump
claimed that makes him ‘smart’ in one of the US presidential election debates in 2016529)
has been the direct cause of various kinds of exploitation occurred in the arena of global
research, from the exploitation and helicopter research in the cases of HIV/AIDS research
in Africa, to having double standards, bilateralism, undue and adverse influence of biopolitics, the problem of bio-piracy, and countless other ethical challenges and cases and
scandals.
All the elements of the suggested ethical framework for Global Governance for
Health Research imply that the health sector and health research cannot be left in the
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hidden hands of free market. The personal virtues that shape the basic layer of this ethical
framework implies that the health professionals and health researchers need to put the
interests of their patients/subjects/communities ahead of their own interests. Compassion
implies sensitivity toward humans’ suffering. This sensitivity, when becomes actualized
in practice, may limit unleashed greed to maximize the material benefits. Furthermore,
the principal-based element of framework encompasses principles such as social
responsibility, solidarity, and collaborative partnership that are also in contrast with
seeking maximized benefits as might be exemplified by the practice of some
pharmaceutical companies. Finally, the situation ethics-based layer/element of the
framework insets in empowering local communities in establishing review and oversight
bodies that protect the interests of local research participants and their communities. This
element also limits profit-seeking in favor of humanity and morality. This is not what can
be considered or called “smart” by President Trump or any other greedy entrepreneur in
the world.
In his inauguration address, President Trump repeated his slogan: “America First!”530
This slogan is the gist of the isolationist and protectionist and xenophobic spirit the flies
over the Western world and has already embodied in Trump’s presidency, the Brexit, and
popularity of the National Front in France and Freedom Party in the Netherlands.
Isolationism through closed borders and reduced moral and human rights related
interventions in the world along with protectionism through putting higher taxes on
imported goods and tougher immigration regulations will act as the reverse engines for
globalization. Their adverse effect in the realm of Global Governance for Health
Research will be (1) less contribution of the Western powers in establishing and
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strengthening the ethical frameworks through contribution in setting standards and
founding and empowering oversight bodies in developing countries; (2) dominance of
neoliberal approach to market and considering health and health research as a part of this
wild global market left in the hands of greedy companies and selfish authorities; (3) rise
of new globally influential powers such as China and India to use their economic power
as a leverage to fill the vacuum of power and governance in the global affairs including
healthcare and health research. Some of these rising powers, especially China, have has a
history of ambiguous and controversial approach to the fundamental principles of the
ethical framework of Global Governance for Health Research, such and human dignity
and human rights and even non-exploitation (considering the exploitative nature of some
parts of labor market in China and the history of exploitation on other areas such ad organ
transplantation). Therefore, the effect of their leadership in global affairs (along with the
relative absence of Western powers) on the ethical aspects of global health research
enterprise should be expected and monitored cautiously.
The Problem of Universality of Human Right in Developing Countries: It has
been claimed that a certain group of concepts are consensual and universal in nature and
belong to the common heritage of mankind. These concepts include respect for human
dignity and human rights and fundamental freedoms. This universal and consensual
nature as asserted in some universal declarations has been one of the theoretical bases of
the framework suggested in the previous chapter of this dissertation for Global
Governance for Health Research. This universality, however, has not been realized in the
real world. Some local cultures do not believe in human rights as they are presented in
the Universal Declaration of Human Rights. In contrary, they argue that their believed
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schools of thoughts (or religions) provide them with different systems and interpretations
of human dignity and human rights that is different and sometimes in contrast with the
concepts presented in the declarations adopted by the UN or UNESCO. They claim that
the concepts of human rights adopted by these international organizations are not
universal, but they are rooted in the Western secular and Judo-Christian cultural
traditions.
It can be argued that although the values of human dignity and human rights are not
absolutely consensual, they are enough consensual to shape the value-based fundaments
of ethical frameworks for Global Governance for health Research. When it comes to the
health research sector, these values become more agreeable by all the parties. Even
countries that have some reservations in adopting conventions on children’s right and
other sensitive topics, have readily adopted the principles of human dignity and human
rights through the declarations on health and health research. Iran, as an example,
regardless of domestic controversies and criticized behaviors in the areas of women’s
rights and freedom of speech, has adopted a series of domestic guidelines for research
ethics that are in extreme consistence with international ones.531 Some other regional
authorities that deny human rights, do not have health research sector within their
territories.
In sum, it seems that all the countries and jurisdictions that have a sort of health
research sector within their boundaries have accepted the fundamental principles of the
principle-based element of the ethical framework suggested in this dissertation.
Therefore, this dissertation argues that the principles adopted in this framework are
globally “enough” consensual and universal.
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An Ethical Framework and a Realistic Place for Optimism: Some practical
recommendations provided in the following part of this chapter can be helpful in
promoting ethical governance in the realm of global health research, including supporting
the key and central role of international organizations as the leading institutions in Global
Governance for Health Research; embracing integrated approaches to health that not only
include humans without any discrimination, but also encompass animals, and the mother
nature; and the last but not the least, taking this fact into consideration that social and
political determinants of health are important determinants of the health all over the
world and they should be included among the global research priorities.
In sum, despite the irregularities, the global trend in the past decades has been toward
establishing more ethical and cross-cultural global governance for health research. There
have been numerous great achievements, partly described in chapter 2 of this dissertation,
including the international declarations and guidelines, consensual adoption of universal
values as parts of common heritage of mankind, establishment of international and crosscultural organizations along with the unprecedented role-playing in the civil society, and
the ethics training programs that have empowered local communities to take part in
ethical review and oversight for research. The above-mentioned trend and achievements
are promising for a future of continual ethical improvements in Global Governance for
Health Research.
iii. Practical and Ethical Recommendations
The ethical framework suggested in chapter 5 for Global Governance for Health
Research encompasses the normative guidance of three major philosophical approaches
to normativity: the virtue-based approach encompassing both classic/masculine and
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feminine virtues, the principle-based approach that includes a layer of more fundamental
and a layer of more detailed principles, and the particularistic or situation ethics
approach. This dissertation argues that implementing this comprehensive model will
solve the existing challenges and problems of Global Governance for Health Research
(described in chapters 3 and 4 of this dissertation) in a multilateral and comprehensive
way. Each virtue and principle included in this framework has its own practical
implications. Explaining the practical implications of each component of this framework
is beyond the scope of this chapter. However, some general recommendations are
provided below to depict how this ethical framework actualize itself in the realm of
Global Governance for Health Research:
1- Establishing a governance system from below (instead of the current top-down
governance) is one of the most fundamental recommendations concluded from the
suggested framework. The appearance of the term of global governance in the political
sciences discourse was due to the newly emerged abundance or non-state rope-players in
the previous decades that take part in governance of global affairs (see chapter 2). The
states, although sovereign and powerful, are limited and sometimes overwhelmed by the
political interests of powerful parties and role-players. Therefore, they may not act
optimally in dealing with challenges of global governance and protecting the interests of
the powerless. The non-state actors are to be the “voice of the voiceless”. As described in
chapter 2, many non-state and civil-society role payers act influentially on the sense of
Global Governance for Health Research. A major part of the existing body of related soft
law (as the main way through which Global Governance for Health Research is embodied
and actualized) is created and adopted and promulgated by international civil society role
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players, the most prominent example being the Declaration of Helsinki adopted by the
WMA. For implementing the suggested ethical framework for Global Governance for
Health Research, empowering and encouraging the governance from below by grass root
institutions and civil society role players seems to be an imperative of utmost importance.
For this purpose, in addition of strengthening civil society, establishing training courses
for local people is a major step. Because the ethically knowledgeable and aware people
are the only ones who can take the lead in establishing and promoting “from below”
governance.
2- Promoting respect for cultural diversity and fundamental human rights as the
common heritage of mankind. Actualization of the principle of “Respect for Cultural
Diversity” is the best practical way to make disappear ethical Imperialism and
Colonialism, and bilateralism. This recommendation combined with establishing a
governance system from below will protect the global research enterprise from some
major challenges such as helicopter research, exploiting poor countries/communities,
double standards, bio-piracy, undue influence of bio-politics at the global scale, and
ethical colonialism. The principle of respect for cultural diversity, as explained in chapter
5, is limited with the principles of “Human Dignity and Human Rights”. Respect for
cultural diversity should be observed to protect the benefits and interests of all the parties
involved in or influenced by research, however should not be appealed to justify any
violation to the fundamental human rights and freedoms by local authorities.
3- Strengthening the role of the leading organizations in Global Governance for
Health Research. The challenge of bilateralism is discussed in chapter 3. The only way
for implementing the ethical framework for Global Governance for Health Research is
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strengthening multilateralism. This means that international organizations, such as WHO
and UNESCO should take the lead in promoting and implementing an ethical framework.
Some organizations cannot play this role because of their belonging to just one party of
interactions. For example, the WMA, although created the most influential international
ethical guideline for research, the Declaration of Helsinki, mostly belongs to physicians.
Therefore, it seems that the WHO or UNESCO are the best suited organizations to take
this role because of their inclusiveness and their relations with states that have the power
and authority needed for implementation and enforcement of ethical guidelines at the
domestic and global levels. For instance, the UNESCO Declaration of Bioethics and
Human Rights mainly addresses the member states of UNESCO.532
4- Adopting an integrated approach to health that includes humans, animals, and
nature (ecosystems, climate, etc.). This element is actualized when a comprehensive
approach is taken and the local role-players are empowered and involved. The planet
Earth is the common habitat of all living organisms. Imposing imbalance and pollution
will have backlashes for the health of human beings. Sustainability is a crucial
precondition of each governance system. Sustainability that safeguards the harmonic and
balanced cohabitation of all the creatures, including the human being. Otherwise, no
governance system or developing program will be lasting and sustainable. The Global
governance for Health Research is no exception for this rule.
5- Taking into consideration the social and political determinants of health, e.g. in
setting research priorities. In every global health crisis (such as the HIV/AIDS pandemic)
this question pops up that what the best way for dealing with the health problems is. Is
this only a technical and biomedical health problem or other factors such as social and
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political structures should also be considered and repaired to achieve satisfactory
results?533 Implementing the ethical framework suggested in chapter 5 necessitates a
comprehensive model. In the realm of research ethics, having independent oversight,
review, and monitoring bodies is a crucial ethical imperative. Having independent
oversight bodies is not possible in the absence of a well-established civil society. The
oversight bodies in the absence of civil society will be dominated by powerful
authorities.534 Therefore, implementing this framework is only possible when all aspects
of collective human life are considered as relevant to health, including the political power
relations and the strength of civil society.
iv. Suggestions for Future Research
Studying Global Governance for Health Research and its ethical challenges and
frameworks is just at its beginning steps and has a long road ahead. Both
theoretical/normative and empirical studies are needed to fill the knowledge, normative,
and policy gaps in this field (see chapter 3). The current threatening and promising trends
that are discussed in this chapter also need to be more clarified via further studies. The
institutional and compliance gaps also necessitate more research and studies to find the
best ways to fill them. The dynamic nature of this field and its gaps continually creates
new gaps and new knowledge to fill them.
In the near future, the following topics need to be studied to shed light on the next
steps of Global Governance for Health Research and its challenges and ethical
frameworks:
1- The current trend of populism along with isolationism and protectionism in the
Western countries is a demanding subject of studies. Is this a real and long-lasting trend
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with continuous impacts on different aspect of globalization and Global Governance,
including Global Governance for Health Research? Or it is just a reactionary period that
will end soon and won’t have lasting impacts on global affairs? If the former prediction
proves right, will there be rising powers among other countries, such as China or India,
which try to replace the US and Western countries as the leading powers in Global
Governance? What will be the impacts of more involvement of these rising powers in
global health research? These questions are to be answered by new studies and research
in the coming years and their answer will have definite impacts on the ethical frameworks
that Global Governance for Health Research will adopt and comply with in the real world
and in practice.
2- The principle-based element of the ethical framework for Global Governance for
Health Research will also be a subject of further theoretical studies and debates. What
principles can be added to or excluded from the existing sets? Are the principles included
in the suggested ethical framework of real universal and consensual nature? Which one of
them has been influenced by ethical colonialism and imperialism? What new principles
can be added to the framework and considered as a part of common intellectual
framework of mankind? The historical course of creation and development of the sets of
principles for global research, from the three principles of the Belmont Report to the four
principles of biomedical ethics formulated by Beauchamp and Childress, to the UNESCO
Universal Declaration of Bioethics and Human Rights, and the NIH Framework, show
that over the past decades, many new principles have been added to the existing
frameworks. The suggested framework in this dissertation have tried to be a
comprehensive one and encompass the previous ones. However, this does not mean that a
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final framework is achieved or is achievable. The process of development and evolution
of ethical frameworks for Global Governance for Health Research is a never-ending and
continuous process fed by incessant chains of studies and research projects on the
previous and new principles.
3- As explained above, the framework of gaps in Global Governance and Global

Governance for Health Research (see chapter 3) is a dynamic framework. It means that
the new gaps continuously appear and are filled with new knowledge and practice that are
rooted in research. Evidence based knowledge created by research is the most
fundamental need when it comes to filling the gaps in Global Governance. Filling the
knowledge gap obviously needs new knowledge. The normative gap demands new
normative and ethical research. The policy gap needs evidence-based knowledge to
support new policies. The institutional gap needs new research on the situation and
weaknesses and strengths of the existing institutions, and compliance gap also needs
research-based information and awareness to be filled. Therefore, as a conclusive remark
on future research, this chapter holds that the next research projects in this area are
needed and should be directed to create evidence-based and normative knowledge to fill
the fivefold gaps of Global governance for Health Research.
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